Clinical Development
PDR001
Protocol CPDR001X2101 / [STUDY_ID_REMOVED]
Open label multicenter Phase I/II study of the safety and 
efficac y of PDR001 administered to patients w ith adv anced 
malignancies
Document type Amended Protocol Version
EUDRACT number 2014 -003929 -17
Version number 08 (Clean )
Development phase I/II
Document status Final
Release date 24-May-2019
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
Template version 02 -Dec-2013

[COMPANY_001] Confidential Page 2
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Table of contents
Table of contents ..................................................................................................................................... [ADDRESS_1162170] of abbreviations ............................................................................................................................... 8
Glossary of terms .................................................................................................................................. 10
Protocol summary: ................................................................................................................................ 11
Amendment 08 (24 -May-2019) ............................................................................................................ 13
Amendment 07 (16 -Jul-2018)............................................................................................................... 14
Amendment 06 (27 -Jul-2017)............................................................................................................... 16
Amendment 05 (30 -Sep-2016) ............................................................................................................. 19
Amendment 04 (13-May-2016) ............................................................................................................ 22
Amendment 03 ...................................................................................................................................... 28
Amendment 02 ...................................................................................................................................... 31
Amendment 01 ...................................................................................................................................... 34
1 Background ........................................................................................................................................... 35
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_013] ................................ 35
1.2 Introduction to the investigational treatment ........................................................................... 36
1.2.1 Overview of PDR001 ........................................................................................... 36
2 Rationale ............................................................................................................................................... 37
2.1 Study rationale and purpose .................................................................................................... 37
2.2 Rationale for the study design ................................................................................................. 38
2.3 Rationale for dose and regimen selection ................................................................................ 39
3 Objectives and endpoints ...................................................................................................................... 39
4 Study design .......................................................................................................................................... 42
4.1 Description of study design ..................................................................................................... 42
4.2 Timing of interim analyses and design adaptations ................................................................. 45
4.3 Definition of end of the study .................................................................................................. 45
4.4 Early study termination ........................................................................................................... 46
5 Population ............................................................................................................................................. 46
5.1 Patient population .................................................................................................................... 46
5.2 Inclusion criteria ...................................................................................................................... 46
5.3 Exclusion criteria ..................................................................................................................... 47
6 Treatment .............................................................................................................................................. 50
6.1 Study treatment ........................................................................................................................ 50
6.1.1 Dosing regimen ..................................................................................................... 50
6.1.2 Ancillary treatments ............................................................................................. 50
6.1.3 Treatment duration ............................................................................................... 51
6.2 Dose escalation guidelines ...................................................................................................... 51

[COMPANY_001] Confidential Page 3
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
6.2.1 Starting dose rationale .......................................................................................... 51
6.2.2 Provisional dose levels ......................................................................................... 52
6.2.3 Guidelines for dose escalation and determination of MTD or RP2D ................... 52
6.2.4 Definitions of dose limiting toxiciti es (DLTs) ..................................................... 55
6.3 Dose modifications .................................................................................................................. 56
6.3.1 Dose modification and dose delay ........................................................................ 56
6.3.2 Follow-up for toxicities ........................................................................................ 56
6.3.3 Anticipated risks and safet y concerns of the study drug ....................................... 61
6.4 Concomitant medications ........................................................................................................ 61
6.4.1 Permitted concomitant therapy ............................................................................. 61
6.4.2 Permitted concomitant therapy requiring caution and/or action ........................... [ADDRESS_1162171] abnormalities ............................................................................... 86
8.2 Serious adverse events ............................................................................................................. 87
8.2.1 Definitions ............................................................................................................ 87

[COMPANY_001] Confidential Page 4
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
8.2.2 Reporting .............................................................................................................. 87
8.3 Pregnancies .............................................................................................................................. 89
8.4 Warnings and precautions ....................................................................................................... 89
8.5 Data Monitoring Committee .................................................................................................... 89
9 Data collection and management .......................................................................................................... 90
9.1 Data confidentiality ................................................................................................................. 90
9.2 Site monitoring ........................................................................................................................ 90
9.3 Data collection ................................
......................................................................................... 91
9.4 Database management and quality control .............................................................................. 91
10 Statistical methods and data analysis .................................................................................................... 92
10.1 Analysis sets ............................................................................................................................ 93
10.1.1 Full Analy sis Set ................................................................................................... 93
10.1.2 Safety  Set.............................................................................................................. 93
10.1.3 Per-Protocol Set .................................................................................................... 93
10.1.4 Dose -determining safety set ................................................................................. 93
10.1.5 Dose -determining pharmacokinetic set ................................................................ 94
10.1.6 Pharmacokinetic analysis set ................................................................................ 94
10.2 Patient demographics/other baseline characteristics ............................................................... 94
10.3 Treatments (study treatment, concomitant therapi[INVESTIGATOR_014], compliance) ......................................... 94
10.4 Primary objective .................................................................................................................... 95
10.4.1 Variable ................................................................................................................ 95
10.4.2 Statistical hypothesis, model, and method of analysis .......................................... 95
10.4.3 Handling of missing values/censoring/discontinuations ....................................... 98
10.4.4 Supportive analyses .............................................................................................. 98
10.5 Secondary objectives ............................................................................................................... 98
10.5.1 Key secondary objective(s) ................................................................................... 98
10.5.2 Other secondary efficacy objectives ..................................................................... 98
10.5.3 Safety  objectives ................................................................................................... 99
10.5.4 Pharmacokinetics ................................................................................................ 101
102
102
102
103
10.7 Interim analysis ..................................................................................................................... 103
10.8 Sample size calculation ......................................................................................................... 104
10.9 Power for analysis of key secondary variables ...................................................................... 105
11 Ethical considerations and administrative proc edures ........................................................................ 106
11.1 Regulatory and ethical compliance ........................................................................................ 106
11.2 Responsibilities of the investigator and IRB/IEC/REB ......................................................... 106
11.3 Informed consent procedures ................................................................................................ 106

[COMPANY_001] Confidential Page 5
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
11.[ADDRESS_1162172] keepi[INVESTIGATOR_5304] ....................................... 107
11.7 Confidentiality of study documents and patient records ....................................................... 108
11.8 Audits and inspections ........................................................................................................... 108
11.9 Financial disclosures ............................................................................................................. 108
12 Protocol adherence .............................................................................................................................. 109
12.1 Amendments to the protocol ................................................................................................. 109
13 References (available upon request) ................................................................................................... 110
14 Appendices .......................................................................................................................................... 114
14.1 Appendix 1: Guidelines for Response, Duration of Overall Response, TTF, TTP, 
Progression -Free Survival  (based on RECIST 1.1) ............................. 114
14.1.1 Introduction ........................................................................................................ 115
14.1.2 Efficacy assessments .......................................................................................... 115
14.1.3 Efficacy definitions ............................................................................................. 123
14.1.4 Data handling and programming rules ................................................................ 132
14.1.5 References (available upon request) ................................................................... 135
14.2 Appendix 2: Guidelines for immune -related Response Criteria (irRC) using one -
dimensional measurements (simulating RECIST 1.1) ........................................................... 137
14.2.1 Introduction ........................................................................................................ 137
14.2.2 New lesions and non- target lesions .................................................................... 137
14.2.3 Follow-up evaluation of target and non -target lesions ....................................... 137
14.2.4 Definitions of response categories and evaluation of overall lesion response ....138
14.2.5 Only non -measurable disease at baseline ........................................................... 139
14.2.6 References (available upon request) ................................................................... 139
14.3 Appendix 3: Statistical details of Bayesian regression models, priors, design operating 
characteristics and hypothetical dose escalation scenarios .................................................... 140
14.3.1 Bayesian linear regression model ....................................................................... 140
14.3.2 Bayesian logistic regression model (BLRM) ...................................................... 147
14.3.3 References (available upon request) ................................................................... [ADDRESS_1162173] of appendices
Appendix 1 : Guidelines for Response, Duration of Overall Response, TTF, TTP, Progression -
Free Survival  (based on RECIST 1.1)
Appendix 2: Guidelines for immune- related Response Criteria (irRC) using one -dimensional 
measurements (simulating RECI ST 1.1)
Appendix 3 : Statistical details of Bay
esian regression models, priors, design operati ng 
characteristics and h ypothetical dose escalation scenarios

[COMPANY_001] Confidential Page 6
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
List of figures
Figure 2 -1 Blockade of PD -1/PD -L1 interaction b y PDR001 ................................ [ADDRESS_1162174] of tables
Table 3
-1 Objectives and related endpoints .......................................................... 40
Table 6
-1 Dose and treatment schedule................................................................. 50
Table 6
-2 Provisional dose levels .......................................................................... 52
Table 6
-3 Criteria for defining dose limiting toxicities ......................................... 55
Table 6
-4 Follow -up evaluatio ns for selected toxicities ........................................ 57
Table 7
-1 Visit evaluation schedule (applicable for all treatment regimens, 
duration of cy cle is adapted accordingly ) ............................................. 65
Table 7
-2 Disease assessment collection plan....................................................... 74
Table 7
-3 ECOG performance status ..................................................................... 75
Table 7
-4 Local clinical laboratory  parameters collection pla n ............................ 76
Table 7-5 12 lead ECG collection plan ................................................................. 77
Table 7
-6 Pharmacokinet ic blood collection log [Dose escalation (all 
patients) and phase II part (5 per disease group (1a, 2, 3 and 4) and 
15 patients in group 1b)] ................................ ................................ .......79
Table 7-7 Abbrevi ated pharmacokinetic blood collection log [phase II part 
(all other patients)] ................................................................................ 80
Table 7
-8 Biomarker sample collection plan ......................................................... 81
Table 10
-1 Noncompartmental pharmacokinetic parameters ................................ 101
Table 10-2 Operating characteristics of the design (probability to declare 
efficacy )............................................................................................... 105
Table 10
-3 Observed ORR and 90% Credible Interval......................................... 105
Table 14-1 Response criteria for target lesions ..................................................... 120
Table 14
-2 Response criteria for non -target lesions .............................................. 122
Table 14
-3 Overall lesion response at each assessment ........................................ 123
Table 14
-4 Overall lesion response at each assessment: patients with non -
target disease onl y............................................................................... 130
Table 14
-5 Options for event dates used in PFS, TTP, duration of response ........ 131
Table 14-6 Overall response at each assessment ................................................... 139

[COMPANY_001] Confidential Page 7
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Table 14-7 Prior distributions of model hy per-parameters (N=Normal, LN= 
Log-Normal) ....................................................................................... 141
Table 14
-8 Geom etric mean (micro gram day /mL) and geometric CV% of 
AUC data from three Nivolumab or Pembrolizumab studies ............. 141
Table 14-9 Prior distribution of (log(Alpha), log(Beta)) and sigma for the new 
trial...................................................................................................... 142
Table 14
-10 Area under the pembrolizumab concentration versus time curve b y 
treatment arm ...................................................................................... 142
Table 14
-11 Area under the pembrolizumab concentration versus time curve at 
steady  state by  [CONTACT_2939] ................................ .............................. 143
Table 14
-12 Area under the nivolumab concentration versus time curve b y dose 
level ..................................................................................................... 143
Table 14
-13 Hypothetical profiles of dose -exposure relation ship used in 
simulations .......................................................................................... 144
Table 14
-14 Summary  of recommendation rate for all profiles and sample sets 
at various doses based on the dose recommendation criteria (1) and 
(2)................................ ................................ ................................ ........ 146
Table 14
-15 Summary  of recommendation rate for all profiles and samples set 
at various doses based on the dose recommendation criteria (1 ), 
(2), and (3) ........................................................................................... 147
Table 14
-16 Prior distribution of model parameters ............................................... 149
Table 14
-17 Summary  of prior distribution of DL T rates (derived from the 
mixture prior in Table 14 -16).............................................................. 149
Table 14
-18 Summary  of prior distribution of DL T rates (derived from the 
Component 1 prior in Table 14 -16) .................................................... 149
Table 14
-19 Summary  of prior distribution of DL T rates (derived from the 
Component 2 prior in Table 14 -16) .................................................... 150
Table 14
-20 Hypothetical dose escalation scenarios for on- study  decisions .......... 150

[COMPANY_001] Confidential Page 8
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
List of abbreviations
AE Adverse Event
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT
APC Antigen Presenting Cell
AST Aspartate aminotransferase/glutamic oxaloacetic tr ansaminase/GOT
AUC Area Under the Curve
BLRM Bayesian Logistic Regression Model
BOR Best Overall Response
CMO & PS Chief Medical Office and Patient Safety
CNS Central Nervous System
CRC Colorectal Cancer
CRF Case Report/Record Form; the term CRF can be applied to either EDC or Paper
CRO Contract Research Organization
CSF Colony Stimulating Growth Factor
CSR Clinical study report
CTCAE Common Terminology Criteria for Adverse Events
DCR Disease Control Rate
DDP Dose Determin ing Pharmacokinetic Set
DDS Dose -Determining Safety Set
DLT Dose Limiting Toxicity
DOR Duration of Response
EBV Epstein Barr Virus
ECG Electrocardiogram
EDC Electronic Data Capture
EOT End of Treatment
ER Estrogen Receptor
EWOC Escalation W ith Overdose Control
FAS Full Analysis Set
FIH First In Human
FU Follow -up
HBV Hepatitis B Virus
HCV Hepatitis C Virus
HER2 Human Epi[INVESTIGATOR_272067] [ADDRESS_1162175] Non -Severely Toxic Dose
i.v. Intravenous(ly)
ICF Informed Consent Form
IEC Independent Ethics Committee
IFN-γ interferon -gamma
IG Immunogenicity
IHC Immunohistochemistry
IL-[ADDRESS_1162176]
irRC immune related Response Criteria

[COMPANY_001] Confidential Page 9
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
mAb(s) monoclonal Antibody(ies)
MHC Major Histocompatibility Complex
MSI-High (MSI -H) Microsatellite instability high
MTD Maximum Tolerated Dose
NSCLC Non-Small Cell Lung Carcinoma
NYHA [LOCATION_001] Heart Association
ORR Overall Response Rate
PAS Pharmacokinetic Analysis Set
PD Pharmacodynamics
PD-[ADDRESS_1162177] Response Evaluation Criteria In Solid Tumors
RP2D Recommended phase 2 dose
SAE(s) Serious Adverse Event(s)
SEB Staphylococcal Enterotoxin B
SEC Safety Event Categories
SJS Stevens Johnson Syndrome
TCR T Cell Receptor
TEN Toxic Epi[INVESTIGATOR_837209] 10
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_837233] A biological specimen including, for example, blood (plasma, serum), saliva, tissue, 
urine, stool, etc. taken from a study subject or study patient
Cohort A group of newly enrolled patients treated at a specific dose and regimen (i.e. treatment 
group) at the same time
Cycles Number and timing or recommended repetitions of therapy are usually expressed as 
number of days (e.g.: q28 days)
Dose level The dose of drug given to the patie nt (total daily or weekly etc.)
Enrollment Point/time of patient entry into the study; the point at which informed consent must be 
obtained (i.e. prior to starting any of the procedures described in the protocol)
Investigational drug The study treatment whose properties are being tested in the study; this definition is 
consistent with US CFR 21 Section 312.3 and is synonymous with “investigational new 
drug.”
Investigationa l 
treatmentDrug whose properties are being tested in the study as well as their associated placebo 
and active treatment controls (when applicable). This also includes approved drugs 
used outside of their indication/approved dosage, or that are tested in a fixed 
combination. Investigational treatment generally does not include other study 
treatments administered as concomitant background therapy required or allowed by [CONTACT_348404]/dosage
Patient Number 
(Patient No.)A unique identifying number assigned to each patient who enrolls in the study
Personal data Subject information collected by [CONTACT_656994]. This data includes subject identifier info rmation, study 
information and biological samples
Premature patient 
withdrawalPoint/time when the patient exits from the study prior to the planned completion of all 
study treatment administration and/or assessments; at this time all study treatment 
administration is discontinued and no further assessments are planned, unless the 
patient will be followed for progression and/or survival
Stage in cancer The extent of a cancer in the body. Staging is usually based on the size of the tumor, 
whether lymph nodes contain cancer, and whether the cancer has spread from the 
original site to other parts of the body
Stop study participation Point/time at which the patient came in for a final evaluation visit or when study 
treatment was discontinued whichever is later
Study treatment Includes any drug or combination of drugs in any study arm administered to the patient 
as part of the required study procedures, including placebo and active drug run -ins.
In specific examples, it is important to judge investigationa l treatment component 
relationship relative to a study treatment combination; study treatment in this case 
refers to the investigational and non -investigational treatments in combination.
Study treatment 
discontinuationPoint/time when a patient permanently discontinues study treatment for any reason
Treatment group A treatment group defines the dose and regimen or the combination, and may consist 
of 1 or more cohorts. Cohorts are not expanded, new cohorts are enrolled.
Variable Identifier used in the data analysis; derived directly or indirectly from data collected 
using specified assessments at specified timepoints
Withdrawal of Consent Withdrawal of consent from the study occurs only when a subject does not want to 
participate in the study any longe r, and does not allow any further collection of personal 
data

[COMPANY_001] Confidential Page 11
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Protocol summary :
Protocol number CPDR001X2101
Title Open label multicenter Phase I/II study of the safety and efficacy of PDR001 
administered to patients with advanced malignancies.
Brief title Phase I/II study of PDR001 in patients with advanced malignancies.
Sponsor and Clinical 
Phase[COMPANY_001] Phase I/II
Investigation type Drug
Study type Interventional
Purpose and rationale The purpose of this “first -in-human” study of PDR001 is to c haracterize the safety, 
tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of 
PDR001 administered i.v. as a single agent to adult patients with solid tumors
By [CONTACT_632734]-1 and its ligands, PD -L1 and PD-L2, PDR001 
inhibits the PD -1 immune checkpoint, resulting in activation of an antitumor immune 
response by [CONTACT_632735] T-cells and inhibiting regulatory T-cells.
Primary Objective(s) Phase I: To estimate the RP2D and/or the MTD for PDR001
Phase II: To estimate the anti- tumor activity of PDR001
Secondary Objectives ● To characterize the safety and tolerability of PDR001
● To characterize the pharmacokinetic profile of PDR001
● To further investigate the anti -tumor activity of PDR001
Study design This study has been designed as a phase I/II, multi-center, open -label study starting 
with a phase I dose escalation part followed by a phase II part.
PDR001 will be administered every 2 weeks (or every 3 or 4 weeks) until patient 
experiences unacceptable toxicity, progressive disease per immune related Response 
Criteria (irRC) and/or treatment is discontinued at the discretion of t he investigator or 
the patient.
Population The phase I part of the study will be conducted in adult patients with advanced solid 
tumors.
The phase II part of the study will be conducted in adult patients enrolled in four distinct 
diseases (melanoma, NSCLC, TNBC and anaplastic thyroid cancer)
Inclusion criteria 1. Written informed consent must be obtained prior to an y screening procedures
2. Patient (male or female) ≥ 18 years of age
3. Phase I part: Patients with advanced/metastatic solid tumors, with measurable or 
non-measurable disease as determined by [CONTACT_44993] 1.1 (refer to Appendix 1 ), 
who have progressed despi[INVESTIGATOR_217892], or 
for whom no standard therapy exists.
4. Phase II part: Patients with advanced/metastatic solid tumors, with at least one 
measurable lesio n as determined by [CONTACT_44993] 1.1, who have progressed 
following their last prior therapy, and fit into one of the following groups:
● Groups 1a and 1b: NSCLC
● Patients with NSCLC must have had disease recurrence or progression 
during or after no m ore than one prior systemic chemotherapy regimen (platinum 
doublet -based) for advanced or metastatic disease. Prior maintenance therapy is 
allowed (e.g. pemetrexed, erlotinib, bevacizumab).
● Only patients with EGFR mutation-negative tumor are eligible ( defined as 
negative for exon 19 deletions and for the L858R mutation in EGFR at a minimum; 
however, if more extensive EGFR mutation testing has been performed, the tumor must 
not harbor any known activating EGFR mutations in Exons 18-21 in order to be 
considered EGFR mutation -negative). All patients must be tested for EGFR mutational 
status and, for ALK translocation status if no mutation is detected in EGFR. Patients 
with ALK translocation -positive NSCLC must have had disease progression following 
treatmen t with a corresponding inhibitor and no more than one systemic chemotherapy 
regimen (platinum doublet -based) , in any sequence.
● Group 2: Melanoma
● All patients must have been tested for BRAF mutations. Patients with BRAF 
V600 mutation positive melanom a must have clinical or radiological evidence of 

[COMPANY_001] Confidential Page 12
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
disease progression during or after Treatment with a BRAF inhibitor (alone or in 
combination with other agents). Patients without BRAF mutation are not required to 
have received a prior therapy.
● Group 3: Triple negative breast cancer
● Group 4: Anaplastic thyroid cancer
● Patients are not required to have received or progressed on a prior therapy.
● Patients in this indication must not be at short term risk for life threatening 
complications (such as airway compromise or bleeding from locoregional or metastatic 
disease ).
● Chemoradiation and/or surgery should be considered prior to study entry for 
those patients with locally advanced disease if those therapi[INVESTIGATOR_837210] t of the patient .
5. ECOG Performance Status ≤ 1.
6. Patients must have a site of disease amenable to biopsy, and be a candidate for 
tumor biopsy. Patient must be willing to undergo a new tumor biopsy at baseline or at 
molecular pre -screening if applicable , and during therapy on this study. For patients in 
the phase II part of the study, exceptions may be granted after documented discussion 
with [COMPANY_001]. After a sufficient number of paired biopsies are collected, the decision 
may be taken to stop the colle ction of biopsies.
Exclusion criteria 
(selected)1. History of severe hypersensitivity reactions to other mAbs
2. Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, 
type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only 
requiring hormone replacement, psoriasis not requiring systemic treatment, or 
conditions not expected to recur in the absence of an external trigger are permitted to 
enroll.
3. History of drug-induced pneumonitis or current pneumonitis.
4. Active infection requiring systemic antibiotic therapy.
5. HIV infection.
6. Active HBV or HCV infection.
7. Patients with ocular melanoma.
8. Systemic anti -cancer therapy within [ADDRESS_1162178] major delayed toxicity, e.g. mitomycin C and nitrosoureas, 4 
weeks washout period. For patients receiving anticancer immunotherapi[INVESTIGATOR_837211] -4 antagonists, 6 weeks is indicated as the washout period.
9. Prior PD -1-or PD -L1-directed therapy .
10. Patients requiring chronic treatment with systemic steroid therapy, other than 
replacement -dose steroids in the setting of adrenal insufficiency. Topi[INVESTIGATOR_2855], inhaled, nasal 
and ophthalmic steroids are not prohibited.
11. Patients receiving systemic treatment with any immunosuppressive medication 
(other than steroids as described above).
12. Use of any live vaccines within 4 weeks of initiation of study treatment.
13. Presence of ≥ CTCAE grade 2 toxicity (except alopecia, peripheral neuropathy and 
ototoxi city, which are excluded if ≥ CTCAE grade 3) due to prior cancer therapy.
Investigational and 
reference therapyPDR001
Efficacy assessments Tumor assessment per RECIST v1.[ADDRESS_1162179] -treatment newly obtained tumor 
samples, plasma .
Data analysi s The study data will be analyzed and reported based on all patients’ data of the Phase I 
and Phase II parts up to the time when all patients have completed at least six cycles of 
treatment or discontinued the study.
Key words Phase I/II, PDR001, Checkpoi nt inhibitor, PD -1, PD -L1.

[COMPANY_001] Confidential Page 13
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Amendment 08 (24- May-2019 )
Amendment rationale 
This protocol amendment revises the definition of end of study  to include the option for patients 
still on study  treatment and who,in the opi[INVESTIGATOR_871] ,are still deriving clinical 
benefit atthe time of end of study , to transfer to another study  or to an alternative treatment 
option to continue providing stud y treatment to these patients.
Study Status
The CPDR001X2101 study  started enrollment on 27- Apr- 2015. The last patient was enrolled 
on 22- Mar- 2018. A total of [ADDRESS_1162180] been treated : 58 patients in the dose escalation 
part and 261 patients in Phase II part of study  (118 in NSCL C groups, 61 in melanoma group, 
40 in TNBC group and 42 in anaplastic th yroid cancer group). As of 06 -May-2019, 25 patients 
were still on treatment.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
Section 4.3: Definition of end of study :
Addition of language to acc ount for patients who would transfer into another study  or an 
alternative treatment option to continue provision of study treatment.
Section 7.1.4: Discontinuation of study treatment:
Addition of language to specify  that patients who transfer to another st udy or an 
alternative treatment option to continue provision of study  treatment will complete end of 
treatment procedures.
Section 7.1.6: Follow up period:
Addition of language to specify  that patients who transfer into another study  or an 
alternative treatment option to continue provision of study  treatment will not complete the 
safet y, disease progression and survival follow up.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 14
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Amendment 07 (16- Jul-2018 )
Amendment rationale 
The primary  purpose of this amendment is to incorporate health authorit y-requested language 
requiring study  treatment discontinuation inthe event of Stevens Johnson Syndrome (SJS)/toxic 
epi[INVESTIGATOR_23936] (TEN).
After the occurrence of a case of Stevens Johnson Syndrome in a study  with PDR001 in 
combination with another investigational agent , the dose modification guidelines for protoco ls 
using PDR001 were updated to mandate permanent discontinuation of study  treatment for 
patients who experience SJS or Lyell syndrome/toxic epi[INVESTIGATOR_194] (TEN). This change 
has alread y been implemented as part of an urgent safet y measure released on [ADDRESS_1162181] recent guidelines, reference to the events meeting the definition of a DLT 
after the DLT period and how to handle them has been removed.
Other changes to the protocol include:
The exclusion criteria has been amended to remove the use of condom for male study  
participants receiving PDR001. Because monoclonal antibodies are not genotoxic due to 
their high molecular weight, and are not expected to interact with DNA. In addition, they 
have a low distribution to the semen,
a relativel y small volume of semen delivered to the 
partner, and very  low absorption. Fetal harm from semen delivery  is therefore biologically  
implausible and the amount of monoclonal antibodies able to gain access to the partner’s 
systemic circulation via trans -epi[INVESTIGATOR_837212]. 
 
Update of language for irRC assessment to clarify criteria for new measurable lesions and 
irRC response in case of only non-measurable disease at baseline.
The removal of t he reporting of total dose per cy cle from statistical section
,given dose 
intensity  and relative dose intensity  alread y serve as metrics of stud y treatment. More 
details and clarifications were also added for reporting other secondary  efficacy  
objectives. Moreover modification have been made to follow [COMPANY_001] analy sis standards 
safet y.
The w ithdrawal of consent language has been revised to differentiate sample use after a 
patient withdraws consent based on the different regulations/laws around the world.
Further minor changes have been made to correct inconsistencies .

[COMPANY_001] Confidential Page 15
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Study status
The CPDR001X2101 study  started enrollment on 27- Apr- 2015. The last patient was enrolled 
on 22- Mar-2018. Atotal of [ADDRESS_1162182] been treated 
in the dose escalation part and 261 patients ha vebeen treated in Phase II part of the stud y (118 
in NSCL C groups, 61 in melanoma group, 40 in TNBC group and 42 in anaplastic thyroid 
cancer group).
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
Section 3: Objectives and endpoints
Clarification that ORR in Phase I and PFS, DOR and DCR in Phase I  and Phase II part are 
per both RECI ST 1.1 and irRC was made in Ta ble 3 -1
Section 5.3: Exclusion criteria
The exclusion criteri on [ADDRESS_1162183] thatuse of a condom is no longer
required. Consequently  pregnancy  outcomes collection for the female partners of any  
males who took treatment in the study  is not required any more and has been removed in 
Section 8.3
Section 6.3.1: Dose modification and dose delay
Instruction for dose mod ification was updated and Table 6- [ADDRESS_1162184] 
of abbreviations was updated to add SJS and TEN
Section [IP_ADDRESS]: Replacement policy
Inconsistency  in writing DDS across sections has been corrected.
Section 7.1.5: Withdrawal of consent
With drawal of consent language was revised and changes regarding the use of samples 
after consent is withdrawn were implemented. Update was also implemented on Glossary
Section 7.2: Assessment ty pes
 
Clarification that collection of central ECG (S ection [IP_ADDRESS]) and PK and IG samples 
(Section 7.2.3) will stop after the firstprimary  CSR data cut- offas it was previously  
indicated as primary  CSR only
Section 8.2: Serious adverse events
Drug Safet y and Epi[INVESTIGATOR_623] (DS&E) has been replaced b y Chief Medical Office and 
Patient Safety  (CMO & PS) in Section 8.2.2. Change has also been made in Section 8.[ADDRESS_1162185] of abbreviations
Section 8.3: Pregnancies
Follow -up of newborn has been extended from 3 months to 12 months
Section 10.1.5: Dose-determining pharmacokinetic set

[COMPANY_001] Confidential Page 16
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Clarification provided that DDP is on Phase I dose escalation part
Section 10.3: Treatments (study  treatment, concomitant therapi[INVESTIGATOR_014], compliance)
Total dose per cy clesummary hasbeen deleted as already  covered by  [CONTACT_837234] .
Section 10.4.2: Statistical hy pothesis, model, and method of anal ysis
Paragr aph on groups sample size has been updated to correct inconsistencies with other 
sections.
Section 10.5: Secondary  objectives
Update has been made to clarify  data reporting for secondary  efficacy  objectives (Section 
10.5.2) and safet y object ives (S ection 1 [IP_ADDRESS]). 
New references have been added to 
Section 13 (References).
Removal or urinary  test and frequency table for newly  occurring on –treatment grades [ADDRESS_1162186] (Section [IP_ADDRESS]) .
Description of analy sis of Time To Response has been removed to align text with Table [ADDRESS_1162187] of abbreviations.
Section 14.2: Appendix 2: Guidelines for immune -related Response Criteria (irRC) using one -
dimensional measurements (simulating RECI ST 1.1)
Wording has been updated to provide further clarifications on irRC assessment and Table 
14-6 updated accordingl y
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review 
Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The change s in this amendment identified above as being related to the USM have alread y been 
implemented by a USM letter issued on 15 June 2018. These changes are required for patient 
safet y (i.e. necessary  to eliminate immediate hazards to the trial subjects ICH GC P 3.3.8). 
Therefore they were required to have been implemented prior to IRB/IEC approval of this 
amendment. 
All other changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consents. Sites are required to update and submit for 
approval revised Informed Consents that take into account the changes described in this 
protocol amendment.
Amendment 06 (27- Jul-2017)
Amendment rationale
The main purpose of this amendment is to remove therequirement for progression on prior 
therap y for patients with anaplastic thyroid cancer ; patients are no longer required to have 
received therap y prior to being eligible for treatment with PDR001 . Outcomes for patients with 
this disease are dismal with amedian life expectancy  after diagnosis of less than six months 

[COMPANY_001] Confidential Page 17
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
(Neff et al2008 ). Given the poor outcome after standard therap y current NCCN treatment 
guidelines recommend that all patients be considered for clinical trials (Neff et al. 2008; NCCN 
Guidelines (version 2.2017): Thy roid Carcinoma).
Some data suggest that this disease may be sensitive to PD-
1 blockade. In published data, six 
of eight tumors from patients with anaplastic thyroid cancer expressed high levels of PD -L1 on 
tumor cells and were infiltrated by [CONTACT_837235] (Bastman et al, 2016 ). In preliminary  data from 
the first 12 anaplastic thyroid cancer patients treated and evaluable for efficacy  in the phase II 
part of this ongoing study  (CPDR001X2101), one patient has a confirmed partial res ponse (~ -
52% by [CONTACT_13407]) and an additional patient has a confirmed reduction in their disease 
burden (~ -14% by [CONTACT_13407]). However, because of the aggressive nature of the disease, 
most anaplastic thy roid cancer patients on the trial to dat e have developed progressive disease 
or died prior to the first scheduled imaging evaluation (at eight weeks), allowing little time for 
immunotherapy  to provide benefit. The inclusion criteria are therefore revised in this 
amendment to allow treatment earl ier in the disease course .
Specific changes to inclusion criterion #4 for patients with anaplastic thy roid cancer include:
1.Patients are not required to have received or progressed on a prior therap y.
2. Patients must not be at short term risk for life threatening complications ( such as airway  
compromise or bleeding from locoregional or metastatic disease ).
3.Chemoradiation and/or surgery  should be considered prior to study  entry  for those patients 
with loca lly advanced disease if those therapi[INVESTIGATOR_837213].
Other changes to this protocol include:
Mutations affecting BRAF occur in approximately  11% -27% of patients with anaplastic 
thyroidcancer (Tiedje et al 201 7; Guerra et al 2013 ; Kunstman et al 2015 ). To facilitate a more 
complete understanding of the patient population benefiting from treatment with PDR001, 
tumor samples will be tested to determine BRAF V600 mutational status. Knowledge of the 
BRAF mutation 
status is not required for study  entry .
The available preclinical data and analysis of triplicate, centrall y reviewed ECGs collected 
during the study  indicate that PDR001 does not have a risk of QTc prolongation (PDR001 
Investigator’s Brochure Edition 6). This amendment will therefore require ECG collection only 
at Screening and as clinically  indicated.
Prohibited concomitant therapy  has been modified to better align with medical practice in 
immuno -oncology . Specifically , patients who experience RECI ST prog ression in one location 
(such as in the brain) may nonetheless continue to receive clinical benefit from PDR001 
treatment provided selective treatment of a site of metastasis was allowed (such as irradiation 
of brain metastases). Therefore, in the setting of RECI ST progression, but where the 
investigator is of the opi[INVESTIGATOR_837214], the amended 
protocol will allow radiotherap y and surgery .
The low prevalence of the anaplastic thyroid cancer may lead to uneven speed inrecruitment 
across indications in phase II part. Therefore the data in different indications may mature at 
different times. Separate primary  analyses and indication -specific complete clinical study  

[COMPANY_001] Confidential Page 18
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
reports may be provided for this study . Therefore, t he protocol has been amended to allow 
separate primary  anal yses.
To align with the EMA standard term list, the PDR001 pharmaceutical form has been updated 
to “Powder for solution for infusion”.
 
 
Minor inconsistencies we re corrected and clarifications made throughout the document.
Study status
The CPDR001X2101 study  started enrollment on 27- Apr- 2015. As of 29-Jun- 2017, a total of 
286 patients had been treated. Fifty -eight patients had been treated in the dose escalation part 
and 228 patients had been treated in Phase II part of the study  (114in NSCL C group s , 61 in 
melanoma group, 40 in TNBC group and 1 3in anaplastic thy roid cancer group). Enrollment to 
the anaplastic th yroid cancer group in the Phase II part is ongoing .
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
Section 4.1: Description of study  design
Replacement o f description of data reporting with reference to section 10 where data 
reporting is described.
Section 5.2: I nclusion criteria regarding Group 4 (anaplastic thy roid cancer)
Removal of the requirement of progression on prior therap y.
Patients must not be a t short term risk for life threatening complications (such a s airway  
compromise or bleeding from locoregional or metastatic disease).
Chemoradiation and/or surgery  should be considered prior to study  entry  for those patients 
with locally  advanced disease if those therapi[INVESTIGATOR_837213] .
Section 6.4.3: Prohibited concomitant therap y
Addition that r adiotherapy and surgery  oflesions after progression based on RECI ST may  
be allowed after documented discussion and approval by  [CONTACT_5343].
Section 6.6: Study  drug preparation and dispensation
To align with the EMA standard term list, the PDR001 pharmaceutical form has been 
updated to “Powder for solution for infusion”. Change is made in Table 6 -
1.
Section [IP_ADDRESS]: Pa tient demographics and other baseline characteristics
Addition of BRAF V600 molecular status testing in tumor samples for patients in the 
anaplastic th yroid cancer group. Change is made in Table 7 -8. Knowledge of the BRAF 
mutation status is not required fo r study  entry .

[COMPANY_001] Confidential Page 19
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Section 7.1.6: Follow up period
Clarification on the description of the safet y evaluations
Section [IP_ADDRESS] Cardiac assessment
Change of ECG schedule from Screening, C1D1, C3D1, C6D1, and EoT to Screening and 
as clinically indicated . Change i s made in Table 7- 1 and Table 7 -5
Section 7.2.3: Pharmacokinetic and immunogenicity  assessments
 
Section 10: Statistical methods and data anal ysis
Addition that several primary  CSRs might be prepared which may  include more than one 
indication.
Section 10.4.2: Statistical hy pothesis, model, and method of anal ysis
Removal of repeating information on primary  analy sis already  detailed in section 10.
Section [IP_ADDRESS] and [IP_ADDRESS]: Analy sis set and groupi[INVESTIGATOR_837215]
Change of last day  to On- treatment period definition from [ADDRESS_1162188] 
dose of study  medication (all patients will continue to be followed for [ADDRESS_1162189] 
dose)
Change of Start date of post -treatment period from [ADDRESS_1162190] dose of 
study  medication
Addition of safet y summaries description
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review 
Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.
Amendment 05 (30- Sep-2016 )
Amendment rationale
The protocol is amended to increase the duration of contraception and safety follow -up periods 
post PDR001 treatment from 90 day s to 150 day s, using five times the upper limit of the half -
life of 23 days and an added safet y margin. These changes are related to an Urgent Safet y 
Measure communicated on 08- Jun- 2016 to all investigators.  
 
 
 

[COMPANY_001] Confidential Page 20
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Therefore, after the start of a new antineoplastic therap y during the safet y follow -up, only  AEs 
and SAEs suspected to be related to PDR001 will be collected in order to focus on the collection 
of information relevant to PDR001; and conc omitant medications will be recorded until the [ADDRESS_1162191].
 
 
 
 
 
 
Language relatin g to bone scans and other radiologic exams for evaluation of bone metastases 
is clarified.
Study status
The CPDR001X2101 study  started enrollment on 27-Apr-2015. As of 27 -Mar-2016, a total of 
88 
patients had been treated. 58 patients had been treated in the dose escalation part and 30 
patients had been enrolled in Phase II part of the study  (5 in NSCL C group, 12 in melanoma 
group and 13 in TNBC group). Enrollment to all cohorts in Phase II part is ongoing.
Changes to the protocol
Changes to specific section s of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
 
 
Section 4.1: Study  design
For consistency  across document reference to 3 and 4 weeks schedule has been added in 
description of study  design
Change of safet y follow- up period from 90 day s to 150 day s. The extension of safet y 
follow -up period to 150 day s including safet y assessments is reflected in Section 4.3, 
Section 6.3.2, Table 7 -1, Section 7.1.6, Section 8.1.1, Section 8.2.2
Section 5.3: Exclusion criteria
Change of period of use of contraception for female participant (exclusion criteria 24) and 
use of condom for sexually  active males (exclusion criteria 25) from [ADDRESS_1162192] dose is 
reflected throughout the d ocument. Change is made in Table 7 -1 and Section 7.2.2.

[COMPANY_001] Confidential Page 21
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Table 7- 1: Visit evaluation schedule
Addition of plasma collection for cy tokines
Addition that after initiation of new antineoplastic therap y, onl y AEs/SAEs suspected to 
be related to stud y treatment will be collected
Addition that concomitant medications and non -drug procedures are reported until the [ADDRESS_1162193]. 
Change is made in Section 7.1.6
Section 7.1.6: Follow- up per iod
Addition that PD and PK data collected during the follow -up period should be recorded on 
Biomarker blood sample CRF
Addition of safet y follow -up phone call or visit at 30, 90, and 150 day s is reflected in 
Table 7-1, Section 7.1.6
Table 7-2: Disease assessment collection plan
Clarification that bone scan is on whole bod y
Addition that localized bone CT, MRI  or x-ray are acceptable procedures for evaluating 
bone lesions
Section 7.2.3: Pharmacokinetics and immunogenicity  assessments
For consistency  text an d Table 7- 6 were updated.
Table 7-6 Pharmacokinetic blood collection log and Table 7-7 Abbreviated pharmacokinetic 
blood collection log
Addition of PK  sample collections at [ADDRESS_1162194] dose
Section 8.1: Adverse events
Addition that after initiation of new post -treatment antineoplastic therapy , only  AEs 
suspected to be related to study  treatment will be reported. Change is made in Section 8.2
Section 10.4.2: Statistical hy pothesis, model, and method of anal ysis
Addition of indications to the group numbers
Section 10.5.3: Safety  objectives
Change of last day  to On- treatment period definition from [ADDRESS_1162195] 
dose of study  medication
Change of Start date of post -treatment period from [ADDRESS_1162196] dose of 
study  medication
Section 10.5.4 PharmacokineticsLanguage has been changed to simplify  analy sis of IG 
data
 

[COMPANY_001] Confidential Page 22
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Section 11.5: Publ ication of study protocol and results
Language was updated to align with new clinical trial protocol template
Section 13 (References)
New reference cited in Section 7.2.4 was added
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation with exception of contraception and safety  follow -up period to 150 days related
to an Urgent Safety  Measure already  implemented and that don’t require IRB/EC approval.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.
Amendment 04 (13- May-2016)
Amendment rationale
In order to support the choice of the treatment dose and regimen for further development of 
PDR001, this amendment adds a group of patients with NSCL C treated with the alternative 
treatment regimen of [ADDRESS_1162197] these patients receive limited benefit from treatment with single agent 
PD-1 inhibitors (Borghaei 2015). Patients with ALK translocation -positive NSCL C are eligible, 
as the currently  available published dataset for these patients treated with PD-
1 inhibitors is 
limited and therefore ALK translocation -positive patients will be included.
Language was updated to clarify  when patients from the dose escalation part may switch to the 
RP2D.

[COMPANY_001] Confidential Page 23
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
This amendment adds a group of patients with anaplastic thyroid cancer in the phase II part. 
This is an exploratory  group for a type of cancer without effective treatment optio ns, but with 
evidence of clinical activity  in one patient treated during the dose escalation phase of this study. 
The addition of these patients will allow an assessment of whether PDR001 may be active in 
this aggressive disease. For this group of patients only, focal irradiation is allowed to a target 
lesion if it is life-threatening, provided that other measurable disease remains. This exception 
is allowed to provide sufficient time for immunotherapy  to act in patients with rapi[INVESTIGATOR_2478] y 
progressing disease. For patients with anaplastic thyroid cancer only, the archival diagnostic 
specimen or a new biopsy  at study  entry  will be reviewed to confirm the diagnosis.
As different treatment regimens are used in this study , additional language was provided to 
clarify  in which context it may  or may  not be allowed to switch from one regimen to another.
To further pursue the goal of allowing a preliminary  assessment of efficacy  relative to published 
data for similar patients being treated with other PD-1 checkpoint inhibit ors, the exclusion 
criteria were updated to exclude patients with electrolyte abnormalities > CTCAE grade 2. The 
exclusion criteria were also updated to clarify that a washout period of 4 weeks is required only 
for live vaccines and to exclude patients who may not comply  with the study  for non-medical 
reasons. The ECOG performance inclusion criterion was also changed to ≤1.
In order to provide more flexibility  in the treatment of symptoms caused by [CONTACT_837236], the prohibited concomitant therapy  section 
was updated to allow localized radiotherap y for non -target lesions.
The inclusion criteria of the phase II part of the study require that the status is known for EGFR 
(and ALK if EGFR mutation -negat ive) for patients with NSCL C, and for BRAF V600 for 
patients with melanoma. Because the determination of EGFR, ALK, or BRAF V600 mutational 
status is not performed routinely  as part of standard assessment of disease in all countries or 
study  sites, this amendment includes the determination of these molecular parameters at 
molecular pre -screening by  a local laboratory , or by  a [COMPANY_001] -designated laboratory  if a local 
laboratory  test is not feasible, for patients with a tumor of unknown status.
For the monit oring of the thyroid function, the measurement of free T4 is a more 
specific 
parameter as compared to total T4, therefore total T4 is removed and free T4 is added to the 
protocol assessments.
Current data suggest that the response to drugs targeting checkp oint inhibitors depend in part 
on the mutation burden in the tumor (Rizvi et al 2015).  
 
As Japan may  join in the phase II part of the study, language specific for Japan has been added 
in the relevant sections of the protocol. This includes changes made to the exclusion criteria 
requested b ya Health Authority .
The section on the reporting of SAEs has been updated to reflect a new procedure for the 
reporting of SAEs at [COMPANY_001].
Procedures for tumor evaluation were updated to include bone scans to be consistent with the 
methods of evaluation listed in the RECI ST guideline (Section 14.1).

[COMPANY_001] Confidential Page 24
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
In various sections (e.g. Table 3-1, and Section 10), correction was made to clarify  that the 
exposure data used in the Bayesian linear model will be the data collected in cycle 3, not the 
data collected after the first dose.
Minor inconsistencies/clarifications were also made throughout the document.
Study status
The CPDR001X2101 study  started enrollment on 
27 April 2015. As of 17 December 2015, a 
total of 58 patients had been treated in the study  at the dose levels of 1, 3 and 10 mg/kg Q2W 
and 3 and 5 mg/kg Q4W. No patient has experienced any  DLT and the toxicity  profile appears 
to be similar to that of marketed inhibitors of PD-1. The PK data obtained from the dose 
escalation, and modeling of the exposure data, support the use of flat dosing for PDR001 of 400 
mg given every  4 weeks as RP2D. The expected PDR001 Ctrough concentrations are in line 
with observed stead y state mean Ctrough concentrations for pembrolizumab, which is approved 
with substantial efficacy in several cancer types. The data also support the use of 300 mg Q3W 
as an alternative dose regimen if it is more convenient for scheduling purposes, for example in 
combination treatment regimens.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
Section [IP_ADDRESS] Clinical experience:
Update on the status of the currently  ongoing CPDR001X2101 study .
Section 2.1 Study  rationale and purpose:
Addition of rationale for the inclusion of anaplastic thy roid cancer patients.
Section 2.2 Rationale for the study  design:
Addition of rationale for the inclusion of TNBC and anaplastic th yroid cancer patients in 
the phase II part of the study .
Section 2.3 Rationale for dose and regimen selection:
Addition of rationale for the testing of alternative regimens.
Table 3
-1 Objectives and related endpoints:
 
 
Section 4.1 Description of study  design:
Update of the Phase II part to include a group of patients with NSCL C treated with 
PDR001 given on a Q3W schedule and a group of patients with anaplastic thy roid cancer 
treated with PDR001 given on a Q4W schedule. Figure 4 -1 was updated accordingl y.
Update of the treatment cycle duration to include a 21 day cycle if patients are treated on a 
Q3W schedule.

[COMPANY_001] Confidential Page 25
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Clarification that only  one visit 90 day s after the end of treatment is required for safety  
follow -up.
Section 5.1 Patient population:
Language updated to reflect the addition of an anaplastic thy roid ca ncer group and one 
subgroup in the NSCLC group.
Section 5.2 I nclusion criteria:
Inclusion criterion 2: addition of the language specific for Japan
Inclusion criterion 4:
Clarification on prior therapi[INVESTIGATOR_837216]
Additional patients with NSCL C have been added to test a 300 mg Q3W dose 
regimen in addition to the 400 mg Q4W regimen
A group of patients with anaplastic th yroid cancer has been added
The requirement for failure of s ystemic chemotherapy  for patients with melanoma 
prior to being e ligible for this study  has been removed
Only  patients with EGFR mutation- negative NSCLC can be included
Language has been changed to clarify  that patients with NSCL C must have been 
treated with no more than one prior course of s ystemic chemotherap y (platinum -
doublet)
Inclusion criterion 5: modification to include patients with ECOG ≤ 1
Section 5.3 Exclusion criteria:
Exclusion criterion 3: updated to exclude patients with electrol yte abnormality  > CTCAE 
grade 2
Exclusion criterion 6: added to exclude patients with history  or current pneumonitis
Exclusion criterion 10: addition of examples for indolent malignancy
Exclusion criterion 12: updated to exclude patients with any  condition that would prevent 
them from participating appropriatel y in the clinical study.
Exclusion criterion 17: updated to require no live vaccine in the [ADDRESS_1162198] 
dose.
Exclusion criterion 24: clarified the definition of women who are considered post -
menopausal and not of child bearing potential
Section 6.1.1 Dosing regimen
Clarification that if switching the dose of PDR001 to the RP2D results in an increase in 
the dose, then the patient must fulfill the criteria for intrapatient dose escalation as 
outlined in Section [IP_ADDRESS].
Section [IP_ADDRESS] I ntra-Patient dose escalation:
Clarification that intra -patient dose escalation includes also the use of a more frequent 
regimen
Addition of a specification that during the phase II part of the stud y, intra -patient dose 
escalation or ch ange of dosing regimen is not permitted.

[COMPANY_001] Confidential Page 26
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Section 6.4.3 Prohibited concomitant therap y:
Clarification that the use of localized palliative radiotherap y for the treatment of 
symptoms related to non- target lesions may  be allowed after documented discussion wi th 
[COMPANY_001]. Also, patients in the anaplastic th yroid cancer group may be allowed to receive 
limited -field radiotherapy to a target lesion that is life -threatening.
Table 7-1 Visit evaluation schedule:
Update of the title to indicate that this visit evaluation schedule applies to all treatment 
regimens and that the duration of cy cle will be adapted according to the treatment 
regimen.
Addition of molecular pre- screening visit.
Addition of the local or central assessment of EGFR, AL K, BRAF V600.
Clarification that the results of the pregnancy  tests performed during the safety  follow -up 
need to be recorded in the source documentation only .
Clarification of the wording on the tumor assessments to allow keepi[INVESTIGATOR_837217] y from the duration of the cy cle.
 
Clarification that only  one visit 90 day s after the end of treatment is required for safety  
follow -up.
Section 7.1.1 Molecular pre- screening:
Addition of the molecular pre-screening to obtain the mutational status of EGFR (for 
NSCL C indication), ALK (for NSCL C indication if applicable) or BRAF V600 mutation 
(for melanoma indication).
Section [IP_ADDRESS] Patient demographics and other baseline characteristics:
Addition of the possibility  to test locall y, or b y a [COMPANY_001] -designated laboratory  if a local 
laboratory  test is not feasible, for the status of EGFR and ALK mutations for NSCL C and 
BRAF V600 mutation status for melanoma, if the status is unknown at the time of 
enrollment of the patient.
Section 7.1.3 Treatment period:
Clarification on the duration of the cy cle according to the treatment regimen (i.e. 21 day  or 
28 day  cycle).
Section 7.1.6 Follow -up Period
Clarification that only  one visit 90 day s after the end of treatment is required for safety  
follow -
up.
Table 7-2 Disease assessment collection plan
Clarification of the wording on the tumor assessments to allow keepi[INVESTIGATOR_837218]
7.2.1 and in Table 7 -2.
Addition of a bone scan to evaluate patients with bone metastasis.
Table 7- 4 Local clinical laboratory  parameters collection plan:

[COMPANY_001] Confidential Page 27
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Replacement of Tota l T4 by  [CONTACT_181374] T4.
Section [IP_ADDRESS].7 Pregnancy  and assessment of fertility
Clarification that the results of the pregnancy  tests performed during the safety  follow -up 
need to be recorded in the source documentation only .
Section [IP_ADDRESS].1 Electrocardiogram (ECG)
Clarification that unique ECGs are collected onl y for Screening and EoT visits, as it does 
not apply  to unscheduled assessments which can be either unique or multiple at a given 
visit depending on the needs to perform an unplanned ECG.
Table 7-6
Updat e of the title to clarify  the number of patients to whom this table applies, according 
to the group.
Clarification of the timepoint for a Q3W schedule at Cy cle 2Day  1 and C ycle 4Day  1 and 
addition of a 48h time window for this PK and IG sample collection
Table 7-7
Clarification of the timepoint for a Q3W schedule at Cy cle 2Day  1 and C ycle 4Day  1 and 
addition of a 48h time window for this PK and IG sample collection
Section [IP_ADDRESS] PK and immunogenicit y sample handling, labeling, and shippi[INVESTIGATOR_3931]
Update of the sample process description.
Section 7.2.4 Biomarkers
Removal of the example of IFN -gamma, as this parameter might no longer be anal yzed in 
this context.
Table 7-8
Addition of samples to confirm diagnosis for anaplastic thy roid cancer patients.
Section 8 Safety  monitoring and reporting
The following sections were updated to reflect the new procedure for the reporting of 
SAEs at [COMPANY_001]: 8.1.1; 8.2.2
Section 8.2.2 was also updated to include language specific for Japan.
Section 10 Statistical methods and data analy sis
The following sections were updated to reflect the above described changes: 10; 10.4.1; 
10.4.2; 10.5.2; 10.6.1; 10.6.2; 10.8: Table 10 -
3
Section 10.4.4 was updated to include sensitivity  analy ses of ORR where the tumor 
response assessments are censored at the time of radiotherap y if a substantial number of 
patients are treated with palliative radiotherap y.
Section 13 References
New references cited in the amendment 4 rationale and Section 2 were added.

[COMPANY_001] Confidential Page 28
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
IRB/IEC
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.
Amendment [ADDRESS_1162199] one systemic treatment regimen (for those with 
BRAF -wild type disease) or one systemic treatment regimen and a BRAF inhibitor (for those 
with BRAF -mutant disease). No disease -specific limitations are required for patients with triple 
negative breast cancer. As it was alread y the case in the previous version of the protocol, for all 
indications, patients who had previously  received a PD-1 or PD-L1 checkpoint inhibitor are 
excluded from participating; those who had previously  received other anticancer 
immunotherapi[INVESTIGATOR_632708] A-4- directed therapy  are eligible.
This amendment also allows the testing of a fixed/flat dose of PDR001 in the phase II part of 
the study . The use of a fixed/flat dose would reduce the risk of dosing errors and would also
reduce drug product wastage. A decision about whether a fixed dose or a dose based on body 
weight is more appropriate will be made after assessing the PK data collected in the phase I part 
of the study , taking into consideration both PK and safet y data. Patients enrolled in the dose 
escalation part may be given the option of switching to the RP2D (dose and schedule) after 
completing four cy cles of treatment.
The requirement that patients have biopsiable disease and be willing to undergo biopsy  during 
the p hase II part of the study  is adjusted to allow exceptions after documented discussion with 
[COMPANY_001]. This amendment also introduces the possibility  to stop the collection of biopsies, once 
a sufficient number of paired biopsies has been collected. This cha nge may ease the burden of 
biopsies for patients.
The emergence of acquired resistance to therap y is a major problem for patients with cancer, 
and understanding the mechanism of acquired resistance to immunotherapi[INVESTIGATOR_837219]. Under this amendment, language has been added to allow the collection of 

[COMPANY_001] Confidential Page 29
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
tumor tissue upon the development of acquired resistance to treatment. The purpose of this 
sample is to identify  changes in the tumor that may  underlie treatment resistance.
Based on preliminary  pharmacokinetic data and the possibility  of delay ed appearance of 
immune -related adverse events, the safet y follow- up period has been extended to [ADDRESS_1162200] [COMPANY_001] guidelines for the prevention of pregnancies in 
participants in clinical trials and their partners, the exclusion criteria were updated to exclude 
sexually  active male subjects who are not willing to use a condom during the study .
Japan is no longer planni ng to participate in this global study , therefore the language specific 
for Japan was removed from the protocol.
Minor inconsistencies/clarifications were made throughout the document.
Study status
The study started enrollment on [ADDRESS_1162201] been treated in the study  at the dose levels of 1, 3 and 10 mg/kg Q2W and 3 and 5 mg/kg 
Q4W. No patient has experienced any DLT in the completed cohorts. Seven patients have 
discontinued the study , four patients due to progression of disease and 3 patients due to SAEs 
which were not suspected to be related to stud y drug.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through re d font for deletions and red underlined for insertions.
Table 3-1 Objectives and related endpoints:
Section 4 Study  design:
Change in sample size in the phase II part o f the study . Figure 4- 1 was updated 
accordingl y.
Addition of language to introduce the possibility  of treating patients at a flat dose in the 
phase II part of the stud y
The safet y follow -up was increased from 30 to 90 day s. This change was applied 
througho ut the protocol in Sections 4.3; 6.3.2; 7.1.6; 8.1.1; 8.2.2; [IP_ADDRESS].
Section 5.2 I nclusion criteria:
Inclusion criterion 2: deletion of the language specific for Japan
Inclusion criterion 4: addition of more detailed definition of the inclusion criteria for 
NSCL C and melanoma
Inclusion criterion 6: adjusted to allow exceptions for patients in the phase II part of the 
study ; and addition of the possibility  to stop the collection of biopsies, once a sufficient 
number of paired biopsies has been collected.
Section 5.3 Exclusion criteria:
Clarification of exclusion criterion 5

[COMPANY_001] Confidential Page 30
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Addition of ocular melanoma as exclusion criterion 10
Addition of a washout period for immunotherapi[INVESTIGATOR_837220] -4 antagonists in 
criterion 12
Addition of total hy sterectomy  in the definition of female sterilization and update of the 
definition of highl y effective contraception in exclusion criterion 23
Addition of exclusion criterion 24, which excludes sexually  active male subjects who do 
not use a condom during intercourse
Section 6.1 Study  treatment:
Addition of the possibility  to switch to treatment with PDR001 at the RP2D (dose and 
schedule) for patients enrolled in the phase I part of the study .
Section [IP_ADDRESS] Bay
esian dose exposure model:
Clarification that the exposure data used in the model will be the data collected in cy cle 3, 
not the data collected after the first dose.
Section 6.6 Study  drug preparation and dispensation:
Clarification that also dose interruptions must be recorded in the dosage administration 
record CRF.
Section 7.1 Visit flow and visit schedule:
Clarification of the visit window for the pregnancy  test at screening
Table 7-1 Visit evaluation schedule:
Addition of the safet y follow -up at [ADDRESS_1162202] dose of study  
treatment, as well as related assessments.
Addition of the new tumor biopsy sample collection at time of disease progression
Section [IP_ADDRESS] Patient demographics and other baseline characteristics:
Addition of the collection of information regarding the status of EGFR and ALK 
mutations for NSCL C and BRAF V600 mutation status for melanoma in the phase II part 
of the study .
Section 7.1.3 Treatment period:
Deletion of redundant text
Section 7.1.4 Discontinuation of study  treatment:
Deletion of text that does not apply in this prot ocol
Section 7.1.6 Follow- up period:
Addition of the 60 day  and 90 day  safet y follow -up and associated assessments
Clarification that also in case of clinical progression, the patient would not be followed for 
disease progression.
Addition of the reference to the end of post treatment phase disposition CRF.
Table 7-2 Disease assessment collection plan
Addition of wording relating to the disease progression follow- up to align with the text in 
Section 7.2.1.

[COMPANY_001] Confidential Page 31
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Correction of the Table [ADDRESS_1162203]/MRI to align with 
standard clinical practice.
Section [IP_ADDRESS] Height and weight:
Clarification of the units for these parameters
Section [IP_ADDRESS].6 Cy tokines
Clarification that the sample anal ysis will be performed locall y
Section [IP_ADDRESS].7 Pregnancy  and assessment of fertility
Addition of pregnancy  tests during the safet y follow -up period
Table 7
-6
Removal of the dose reference ID which is not required for the stud y sites to understand 
the PK and IG sample collection schedule
Clarif ication of the time point [ADDRESS_1162204] -dose for the Q4W schedule
Section 7.2.4 Biomarkers
Addition of the assessment of mechanisms of resistance to PDR001
Section 10 Statistical methods and data analy sis
The following sections were updated to reflect the above described changes: 10.4.2; 
[IP_ADDRESS]; 10.6.2; 10.7; 10.8
Section 13 References
New references cited in the Section 10.8 were added.
Section 
14.2 Appendix 2: Guidelines for immune -related Response Criteria (irRC) using one-
dimensional measurements (simulating RECI ST 1.1)
The lesion diameter measurements under RECIST 1.1 and irRC are the long axis (or 
longest diameter) for non -nodal lesions and the short axis for the nodal lesions. Sections 
14.2.2, 14.2.[ADDRESS_1162205] 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IE C approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.
Amendment 02
Amendment rationale
The landscape of treatment with immunomodulatory therapy  in oncology  is evolving rapi[INVESTIGATOR_375], 
and particularl y so with antibodies that target the PD-1/PD -L1 interaction. In response to 
emerging publicall y available clinical data this amendm ent changes the disease indications that 

[COMPANY_001] Confidential Page 32
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
will be studied. Specifically , the phase II dose expansion part of the study will now focus on 
patients with NSCL C, melanoma and triple negative breast cancer; the planned expansion 
groups for patients with gastric and esophageal cancer, colorectal cancer and anal cancer have 
been removed. The inclusion criteria affected by [CONTACT_837237] y. 
The total number of patients treated in each group of patients in the Phase II part will remain 
unch anged.
Removal of the gastric/esophageal, colorectal and anal cancer groups also affects the role of the 
PD-L1 biomarker, which was an inclusion criterion for these patients. Published data for PD-
L1 expression and tumor response in multiple diseases sugge sts a positive correlation between 
PD-L1 expression in tumor and response to treatment. Nevertheless, tumor responses have been 
reported in patients with low PD-L1 expression. In addition, the most appropriate assay  and 
criteria for defining “positive” tumors are uncertain and an area of active clinical investigation. 
Therefore, no molecular screening for PD -L1 will be performed to select patients however PD -
L1 expression will be assessed retrospectivel y for all patients.
At the time of RP2D/MTD determinati on, the amount of efficacy  data collected may be limited. 
To provide greater confidence in choosing the most appropriate dose for further development, 
the study  design has been updated to allow testing of two doses of PDR001 in one disease 
indication durin g the phase II part .
Furthermore a few exclusion criteria were clarified:
Patients with active autoimmune disease are excluded.
In order to ensure that all patients with HIV, active HBV or active HCV infection are 
excluded, the wording in the exclusion cri teria was adjusted and the corresponding tests 
were added at Screening.
In addition, collection of a sample for cy tokine assessment (IL -6 and IFN-γ) was added for all 
patients at Screening. This baseline sample will serve as a comparator for those patients who 
need the follow- up assessment of cytokines (i.e. if the patient has an adverse event suspected to 
be a cy tokine release s yndrome) .
In Section 6.4.3 Prohibited concomitant therapy , the wording related to the use of systemic 
steroid therapy  during the c ourse of study  was adjusted in order to provide more flexibility  for 
patients who would need such therap y for treatment of acute conditions.
In order to align the collection and analysis of pharmacod ynamic biomarkers with preclinical 
evidence on the timing of immune response in tumor after therap y with PD-1 blocking 
antibodies, the collection of the on- treatment new tumor biopsy sample was moved from C2D1 
(i.e. between C2D1 and C2D15) to C3D1 (i.e. between C3D1 and C3D15).
Minor inconsistencies/clarificatio ns were made throughout the document.
Study status
The study  started enrollment on [ADDRESS_1162206] cohort at the dose of 1 mg/kg.

[COMPANY_001] Confidential Page 33
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
Section 2.1 Study  rationale and purpose:
Change of the indications in the phase II part.
The groups were changed throu ghout the protocol including Figure 4 -1.
Section 4.1 Description of study  design:
Removal of the molecular screening for PD -L1 expression. Reference to molecular 
screening was removed throughout the protocol.
Addition of the possibility  to test a second dose level in one or more indications during the 
Phase II part.
Section 5.2 I nclusion criteria:
Inclusion criterion [ADDRESS_1162207] the change in the tumor t ypes to be included in 
the phase II part.
Section 5.3 Exclusion criteria:
Change in exclusion criterion 5 to clarify  that patients with active autoimmune disease are 
excluded.
Change in exclusion criterion 7 to clarify  that an y patient with HIV infection is excluded.
Clarification of exclusion criterion 13 excluding patient that require c hronic treatment 
with sy stemic steroids.
Clarification of exclusion criterion 14
Further specification of exclusion criterion 17 in relation to prior radiotherapy  for patients 
enrolled in the Phase II part.
Section 6.4.3 Prohibited concomitant therap y
Upda te of the wording on the use of s ystemic steroid therap y during the course of the 
study .
Section 6.5.1 Patient numbering
Addition of wording to ensure patient number will be unique and unchanged for a patient.
Section [IP_ADDRESS] L aboratory  evaluations
Additio n of HIV, HBV and HCV assessments at Screening.
Addition of the collection of a sample for cy tokine assessment at Screening.
Changes were made to Table 7 -1 and Table 7- 4 accordingl y.
Section [IP_ADDRESS].1 Electrocardiogram (ECG)
Wording clarification on the nu mber of ECGs to be performed at Screening, EoT and 
Unscheduled visits was provided.
Section 7.2.4 Biomarkers
Change of timepoint for new tumor biopsy  sample collection from between C2D1 and 
C2D15 to between C3D1 and C3D15.

[COMPANY_001] Confidential Page 34
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Section 8.2.2 Reporting
removal of wording related to the molecular screening.
removal of the language specific for Japan, as SAEs will be reported in English for this 
study  in Japan.
Section 10 Statistical methods and anal ysis
Sections 10, 10.1.3, 10.4.2, 10.5.2, 10.6.1, 10.6.2, 10.[ADDRESS_1162208] 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. The changes herein affect the Informed Consent. Sites are required to update 
and submit for approval a revised Informed Consent that takes into account the changes 
described in this protocol amendment.
Amendment 01
Amendment rationale
This amendment addresses the following revision requested b ya regulatory authority :
To reduce the starting dose of PDR001 to 1 mg/kg administered once every two weeks, as 
requested b y a regulatory authority .
Additional minor corrections/clarifications were also made. The details are provided in the 
below section C hanges to the protocol.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
Section 6.2.1 Starting dose r ationale:
Change of starting dose to 1 mg/kg.
The starting dose was updated throughout the protocol.
Minor corrections/clarifications in Section 6.3.1 and Table 7 -2.
IRB/IEC/HA  Approval
A copy of this amended protocol will be sent to the Institutional Revi ew Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. The changes herein affect the Informed Consent. Sites are required to update 
and submit for approval a revised Informed Consent that takes into account the changes 
described in this protocol amendment.

[COMPANY_001] Confidential Page 35
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
1 Background
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_837221], 
and that immune -surveillance may be an ongoing process in healthy  people that is important 
for eliminating malignant cells before a cancer can develop. This theory  is borne out by [CONTACT_837238] y increased risk of a variet y of solid and hematological malignancies in 
immunosuppressed patients following solid organ transplantation (Vesely  et al 2011 ). The 
ability  of the immune s ystem to attack and kill an established cancer to a clinically  meaningful 
degree was first demonstrated by [CONTACT_837239] m yeloid leukemia following allogeneic bone marrow transplant ( Kolb et a l 1990 ). The 
activity  of interleukin 2 (IL2) and interferon alpha (IFN -α) in patients with renal cell carcinoma 
and melanoma demonstrated that immunotherap y can be active in solid tumor oncology, albeit 
in a minority  of patients ( Kirkwood 1985
, Creagan 1990 , Fyfe 1996 ).
The activity of c ytotoxic T
-lymphocy tes is the result of both stimulatory  and inhi bitory  signals. 
Besides the activation resulting from the interaction of the antigen presented in the major 
histocompatibility  complex (MHC) on the antigen -presenting cell (APC) with the T-cell 
receptor (TCR), there are inhibitory signals mediated b y checkpoint molecules, such as CTLA-
[ADDRESS_1162209] healthy  tissues from excessive T-lymphocy te activation (Blank 2014). 
PD-
1 is a critical checkpoint receptor that is expressed by T cells upon activa tion (Freeman 
2008). It is also expressed by B cells, NK cells, dendritic cells, and activated monocy tes. The 
ligands for PD-1: Programmed Death -Ligand 1 (PD-L1) and Programmed Death -Ligand 2 (PD-
L2) areexpressed by [CONTACT_179968], monocy tes and dendritic 
cells, and can be induced on 
numerous cell t ypes (T cells, endothelial cells, and tumor cells) during inflammation ( Keir et al 
2008). Engagement of PD- 1by [CONTACT_837240]-L1 and PD-L2 transduces a signal that inhibits 
T-cell proliferation, cytokine production, and cytolytic function (Riley  2009). The PD-[ADDRESS_1162210] primarily  in peripheral tissues to dampen ongoing immune 
responses and/or to prevent autoimmunity .
During tumorigenesis, cancer cells from a wide range of tumor types exploit immune 
checkpoint pathway s, such as PD-1, to avoid detection by [CONTACT_217935] (Murphy  
2011). Blockade of the PD -[ADDRESS_1162211]  has been shown to lead to increased numbers of effector 
T cells through induction or expansion and improved cytolytic activity  towards 
tumors. 
Additionally , PD-1 blockade is associated with accumulation of effector T cells and reduced 
numbers of regulatory  T cells (Tregs) at the tumor 
site. (Wang 2009 , Mangsb o 2010 , 
Mkrtichy an 2011 , Rosenblatt 2011).
Monoclonal antibody  (mAb) inhibitors of immunological checkpoints, including PD-
[ADDRESS_1162212] demonstrated significant single 
agent activit y in melanoma, non-small cell lung carcinoma (NSCL C), triple negative breast 
cancer (TNBC) and other solid tumors ( Topalian 2012, Hamid 2013b , Topalian 2014, Seiwert 
2014 , Powles 2014, Garon 2015, Moreno and Ribas 2015, Robert 2015). In patients with 

[COMPANY_001] Confidential Page 36
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
previously  treated, unresectable melanoma the response rates to pembrolizumab and nivolumab 
were 34% and 31%, respectivel y; and the PFS were 50 weeks and 9.7 months, respectivel y 
(Ribas 2014, Topalian 2014 ). In patients with advanced, previously  untreated non -small cell 
lung cancer the response rates to pembrolizumab and nivolumab were 26% and 30%, (Rizvi 
2014, Gettinger 2014 ).
1.2 Introduction to the investigational treatment
1.2.1 Overview  of PDR001
PDR001 is a high-affinity , ligand -
blocking, humanized anti-PD-1 IgG4 antibody  that blocks 
the binding of PD-L1 and PD-L2 to PD-1. PDR001 recognizes PD-1 in cynomolgus monkeys 
and shows functional activity  in vitro/ex vivo. For further details, please refer to the [PDR001 
Investigator’s Brochure].
[IP_ADDRESS] Non- clinical experience
PDR001 binds specifically and with high affinit y to human PD -1. In Biacore assay s, the KD of 
PDR001 on human PD -1 is 0.827 nM. In ex vivo ly mphocy te stimulation assay s using human 
blood, PDR001 enhances interleukin -2 (IL-2) production by [CONTACT_3450]  2 fold in respons e 
to super antigen stimulation with Staphy lococcal enterotoxin B (SEB). PDR001 does not cross -
react with rodent PD-1, and cannot be evaluated in murine tumor models. It does cross -react 
with cynomolgus monkey  PD-1, and is functionally  active, making cynomo lgus monkey  a 
relevant species for toxicology  studies. The affinity  of PDR001 for cy nomolgus PD -[ADDRESS_1162213] article -related in-life, mortality , organ weight 
changes, or macroscopic findings were noted. There were no PDR001 -related effects seen in 
any of the safet y pharmacology  endpoints assessed (cardiovascular, neurobehavioral, and 
respi[INVESTIGATOR_696] ). Macrophage infiltrates into the spleni c white pulp were observed in animals given 
100 mg/kg/week and mononuclear cell infiltrates, often associated with fibrosis, around the 
injection site blood vessel (saphenous vein) in a few animals given 25mg/kg/week. These 
PDR001 -related microscopic cha nges were fully  reversible after an eight week recovery .
The following changes were noted in main phase and recovery  treated animals as well as control 
recovery  animals. Mostly  low grade changes were noted in several tissues in the form of 
mononuclear infiltrates in the vascular and perivascular space. In general, in most organs, 
vascular/perivascular changes were limited to one or a few blood vessels in each organ and 
sometimes involved a segment of a blood vessel with occasional vessel wall degeneration. No 
evidence of parench ymal damage was associated with the vascular/perivascular changes in an y 
of the organs examined and the changes were not associated with any frank tissue injury . While 
these effects were not exclusive to treated animals, because of their nature and close association 

[COMPANY_001] Confidential Page 37
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
with the expected pharmacology  of PD1 blockade, a potential PDR001 related effect cannot be 
excluded. There were no test article related effects seen in the cardiovascular assessments. All 
other microscopic findings were considered spontaneous or otherwise unrelated to PDR001 
administration.
Dose -dependent exposure to PDR001 in each dose group was confirmed. A pharmacod ynamic 
ex vivo superantigen stimulated whole blood assay  measuring IL-[ADDRESS_1162214] Non-Severel y Toxic Dose (HNSTD) 
dose in this study  was 100 mg/kg. PDR001 has a favorable safety  profile in monkey s that 
supports a projected human starting dose of 1 mg/kg in the first in human study 
CPDR001X2101. For further details, please refer to the [PDR001 I nvestigator’s Brochure].
[IP_ADDRESS] Clinical experience
This study  started enrollment on 27 April 2015. As of 17 December 2015, a total of 58 patients 
had been treated in the study  at the dose level s of 1, 3 and 10 mg/kg Q2W and 3 and 5 mg/kg 
Q4W. No patient has experienced an y DLT and the toxicity  profile appears to be similar to that 
of marketed inhibitors of PD-1 (pembrolizumab US label , nivolumab US label ). The PK data 
obtained from the dose escalation, and modeling of the exposure data, support the use of flat 
dosing for PDR001 of 400 mg given every  4 weeks as RP2D. The expected PDR001 Ctrough 
concentrations are in line with observed steady  state mean Ctrough concentrations for 
pembrolizumab, which is approved with substantial efficacy  in several cancer types 
(pembrolizumab US label ). The data also support the use of 300 mg Q3W as an alternative dose 
regimen if it is more convenient for scheduling purposes, for example in combination treatment 
regimens.
2 Rationale
2.1 Stud y rationale and purpose
This FIH, phase I/II clinical study  of PDR001 will characterize the safet y, tolerability, 
pharmacokinetics (PK), pharmacod ynamics (PD) and antitumor activity  of PDR001 
administered i.v. as a single agent. By [CONTACT_632734]-
1 and its ligands, 
PD-L1 and PD -L2, PDR001 inhibits the PD- 1 immune checkpoint, resulting in activation of an 
antitumor immune response by [CONTACT_632735] T-cells and inhibiting regulatory  T-cells 
(Hamid and Carvejal 2013a ). From ongoing studies with anti-PD-1 antibodies, such as 
nivolumab and pembrolizumab, it is evident that PD-1 checkpoint inhibition results in clinicall y 
important anti- tumor activity  (Topalian 2012 , Hamid 2013b
, Topalian 2014 , Seiwert 2014).

[COMPANY_001] Confidential Page 38
Amended Protocol Version 08 (Clean ) Protocol No. CPDR001X2101
Figure 2-1 Blockade of PD -1/PD -L1 interaction by  [CONTACT_217936]001
APC: Antigen Presenting Cell; MHC: Major Histocompatibility; TCR: T Cell Receptor
This study  is designed both to establish a recommended dose and schedule for the anti PD-1 
antibody , PDR001, and to make a preliminary  assessment of PDR001 antitumor activity  in 
NSCL C, melanoma, anaplastic thyroid cancer and TNBC. This FIH study  is designed to 
establish if PDR001 is tolerable and active, and provide data to support future disease -specific 
development.
2.2 Rationale for the study  design
This is an open -label, non-
randomized phase I/II study  of single -agent PDR001. The phase I 
part of the study  is a PK-and dose limiting toxicity  (DLT) -guided dose escalation. Cohorts of 
patients will receive escalating doses of PDR001 until a dose is reached, which fulfills one of 
the following criteria:
Achieves PDR001 exposure (Area Under the Curve: AUC) comparable to the AUC 
reported for pembrolizumab and nivolumab at the doses being used in the ongoing phase 
III studies
Is the maxi mum tolerated dose (MTD), based on occurrence of dose limiting toxicities 
(DLTs).
During their early development, both nivolumab and pembrolizumab were escalated to high 
doses (10 mg/kg every  2 weeks) without reaching a MTD. Both antibodies have demonstrated 
similar response rates across a wide range of doses and are now being developed at doses of 2 -
3 mg/kg every  2-3 weeks (Topalian 2014
, Robert 2014). PDR001 binds to PD-[ADDRESS_1162215] similar PK and pharmacod ynamic properties as 
pembrolizumab and nivolumab the PK-guided dose escalatio n approach being taken in this 

[COMPANY_001] Confidential Page 39
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
study  is expected to identify  an active dose of PDR001 without the need to escalate to very high 
doses or to evaluate a large number of dose levels. In addition, pharmacody namic parameters 
such as CD8+ tumor infiltrating lymphocy tes (TILs) and expression of selected immune 
response markers will be used to further support the choice of an active dose of PDR001.
The phase II part of the study  will begin after the recommended phase 2 dose (RP2D) is 
determined. The primary  objecti ve of the phase II part is to evaluate PDR001 antitumor activity , 
in two “benchmark diseases”, NSCL C and melanoma, where response rates to nivolumab and 
pembrolizumab are known, as well as in TNBC in which antitumor activity  was reported for 
pembrolizumab (Nanda 2014, Moreno and Ribas 2015). In response to evidence of clinical 
activity  in a patient during the dose escalation phase of this study , a small group of patients with 
anaplastic thyroid carcinoma will also be enrolled to preliminarily  assess any clinical 
activity 
in this very aggressive disease that lacks effective treatment options. Preliminary data from the 
early clinical studies of nivolumab and pembrolizumab, as well as the anti-PD-L1 antibodies, 
MPDL 3280A and MEDI4736 indicate that PD-L1 protein expression both on tumor cells and 
on tumor -infiltrating immune cells correlates with clinical response to these agents (Topalian 
2012, Weber 2013 , Taube 2014 , Powles 2014, Creelan 2014). PD-L1 expression will be 
measured for all patients enrolled, however, patients will not be selected for PD -L1 expression, 
since the response rates to nivolumab and pembrolizumab available in the literature are based 
on 
unselected populations. In these published studies, patients without PD-L1 expression also 
responded to treatment with anti-PD-1 immunotherap y (Topalian 2012, Hamid 2013b , Robert 
2014, Motzer 2015).
2.3 Rationale for dose and regimen selection
The starting dose and regimen of 1 mg/kg PDR001 administered once every  [ADDRESS_1162216] safet y margin applied in advanced 
oncology  indications, as described in Section 6.2.1 . The dose of PDR001 will be escalated in 
sequential cohorts using a PK-guided approach to achieve an AUC comparable to the active 
range observed with nivolumab and pembrolizumab, as described in Section 2.2and Section 
10.4.2. PDR001 will be administered i.v. every  2  weeks based on an expected half-life of 10-
20 days, and consistent with a schedule commonly used for humanized monoclonal antibodies. 
In order to identify  recommended treatment regimens for future use, alternative regimens (e.g. 
Q3W, Q4W) will also be tested.
3 Objectives and endpoints
Objectives and related endpoints are d
escribed in Table 3-1 below.

[COMPANY_001] Confidential Page 40
Amended Protocol Version 08 (Clean ) Protocol No. CPDR001X2101
Table 3-1 Objectives and related endpoints
Objective Endpoint Anal ysis
Primary Refer to Section 10.4 .
Phase I part:
To estimate the RP2D and/or the MTD for PDR001Phase I part:
● The exposure (AUC (0-336h)) after first dose of treatment at cycle 3
● The incidence of DLTs
Phase II part:
To estimate the anti -tumor activity of PDR001Phase II part:
Overall response rate (ORR) per Response Evaluation Criteria in Solid 
Tumors (RECIST v1.1).
Secondary Refer to Section 10.5.1 .
Phase I/II parts: To characterize the safety and tolerability 
of PDR001Safety: Incidence and severity of adverse events (AEs) and serious adverse 
events (SAEs), including changes in laboratory parameters, vital signs and 
electrocardiograms (ECGs)
Tolerability: Dose interruptions, reductions and dose intensity
Phase I/II parts: To characterize the pharmacokinetic 
profile of PDR001Serum PK parameters (e.g., AUC, Cmax, Tmax, half -life); Serum 
concentration vs. time profiles
To assess emergence of anti -PDR001 antibodies 
following one or more intravenous (i.v.) infusions of 
PDR001Presence and/or concentration of anti -PDR001 antibodies
Phase I part: To evaluate the preliminary anti -tumor 
activity of PDR001ORR, progression free survival (PFS), duration of response (DOR) and 
disease control rate (DCR) , per RECIST 1.1 and irRC
Phase II part: To e valuate the preliminary anti -tumor 
activity of PDR001ORR per immune related Response Criteria (irRC ) and PFS, DOR, DCR per 
RECIST 1.1 and irRC
.

[COMPANY_001] Confidential Page 41
Amended Protocol Version 08 (Clean ) Protocol No. CPDR001X2101

[COMPANY_001] Confidential Page 42
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
4 Study  design
4.1 Description of study  design
This study  is a phase I/II, multi- center, open- label study  starting with a Phase I dose escalation 
part followed b y a Phase II part. PDR001 will be administered i.v. ever y 2 weeks (or ever y 3 or 
4 weeks) until a patient experiences unacceptable toxicity , progressive disease as per irRC 
and/or treatment is discontinued at the discretion of the investigator or the patient. Patients 
should not discontinue treatment based solel y on progressive disease per RECI ST. The study 
design is summarized in Figure 4 -1.
Phase I dose escalation part
During the phase I part of the study , cohorts of patients will be treated with PDR001 until the 
MTD is reached or a lower RP2D is established. It is expected that an RP2D will be established 
before the MTD is reached, as it was observed with other anti -PD-1 antibodies. The RP2D will 
be a dose that results in PDR001 exposure, as measured by [CONTACT_837241]. To assure 
that the 
RP2D does not exceed the MTD, the dose escalation will also be guided by [CONTACT_837242] (BLRM) following the escalation with overdose control 
(EWOC) principle. At least 21 patients are required during dose escalation to define the MTD; 
however, fewer than 21 patients may be t reated if the RP2D is determined prior to reaching the 
MTD (for further details see Section 6.2.3). Data from several PD- [ADDRESS_1162217] demonstrated that inhibitin g the PD-1/PD -L1 interaction can result 
in tumor response across a broad range of solid tumors (Topalian [ADDRESS_1162218] 2014); therefore, the Phase I part of the study  will 
include patients with solid tumors, and is not limited to specific t ypes of tumors.
Potential change to an alternative dosing schedule during the escalation part
If emerging data indicate that a less frequent dosing regimen such as once every  4
 weeks is 
more appropriate, then a new cohort of patients will be enrolled and treated with this schedule, 
and subsequent escalation may proceed using the new regimen. A modification of the dosing 
regimen would be based on emerging PK, PD, and safet y assessments.
Phase II part
Once the MTD and/or RP2D have been declared, additional patients will be enrolled in the 
Phase II part in order to assess the preliminary  anti-tumor activity  of PDR001.
In the phase II part, patients will be assigned to different groups depending on the tumor type 
and dosing regimen as shown in Figure 4 - 1 . Please refer to Section 5.1 for further details.
Groups 1a, 1b and 2 will enroll approximately  60 patients each, group 3 will enroll 
approximately  40 patients, and group 4 will enroll approximately  10 patients. Enrollment to any 
of these groups may  be stopped with fewer patients if achieving these enrollment targets is not 
logistically  feasible. The relativel y small size of the anaplastic thyroid cancer group reflects the 
low prevalence of anaplastic thyroid cancer; this group may be increased in size to 

[COMPANY_001] Confidential Page 43
Amended Protocol Version 08 (Clean ) Protocol No. CPDR001X2101
approximately  40 patients based on feasibility  of enrollment and ifPDR001 appears to be active 
(at least one response or other efficacy data show preliminary anti -tumor activity  in the first 10 
patients) in this disease. A Bay esian design will be used in order to estimate ORR within each 
group. Details of the sample size calculations leading to the patient numbers are provided in 
Section 10.8.
After a preliminary  assessment of the safet y profile in the phase I part, a decision may be made 
to test up to two regimens of PDR001 during the phase II part to better assess the efficacy, 
safet y and benefit -
risk of PDR001. If a second regimen is to be studied, then this would be done 
in one or more disease indications chosen based in part on logistical feasibility . The two 
regime ns would be assigned in an alternating fashion to patients of the same disease group 
across all the sites in this global study .The number of patients tested at this second regimen 
will be similar to the number of patients to be enrolled in this disease setting at the RP2D .
Potential change to flat dosing during the phase II part
If emerging PK data indicate that a flat or fixed dose of PDR001 is appropriate, then a flat 
dosing may be implemented in the phase II part of the study . The data from weight -based dosing 
obtained during the dose escalation part of the study  will be utilized to identify the flat dose to 
be tested in the ph ase II part.
Figure 4-1 Study  design
* In the dose escalation, at least 21 patients are required to define the MTD; however, fewer than [ADDRESS_1162219] 
up to two regimens of PDR001 during the phase II part.

[COMPANY_001] Confidential Page 44
Amended Protocol Version 08 (Clean ) Protocol No. CPDR001X2101
See Section 10Statistical Methods and Data Analy sis for details of timing of the primary 
analysis and final reporting data.
Molecular pre -screening
To enter the screening phase of this study , patients must provide written documentation of 
EGFR (for NSCL C indication), ALK (for NSCLC indication if negative for EGFR mutation) 
or BRAF V600 mutation (for melanoma indication) (see Section 7.1.1 for details) and complete
the molecular pre -screening assessment if needed.
Figure 4-2 Molecular pre -screening
* ALK and EGFR can be tested simultaneously
** Defined as negative for exon 19 deletions and for the L858R mutation in EGFR at a minimum; 
however, if more extensive EGFR mutation testing has been performed, the tumor must not harbor 
any known activating EGFR mutations in Exons 18 -21 in order to be considered EGFR mutation -
negative
*** Patients with ALK translocation -positive NSCLC must have had disease progression following 
treatment with a corresponding inhibitor. Patients with ALK translocation -negative NSCLC must have 
had disease recurrence or progression during or after no more th an one prior s ystemic chemotherapy 
regimen (platinum doublet- based)
**** Patients with V600 mutation positive melanoma must have clinical or radiological evidence of 
disease progression during or after treatment with a BRAF inhibitor alone or in combinatio n with other 
agents. Patients without BRAF mutation are not required to have received a prior therapy

[COMPANY_001] Confidential Page 45
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Screening period
The screening period begins once the patient has signed the study  informed consent. Patients 
will be evaluated against study  inclusion and exclusion criteria (Table 7-1and Section 5.2, 
Section 5.3 and Section 7.1.2).
An archival or newl y obtained tumor biopsy  sample will be required to be submitted to a 
[COMPANY_001] designated central laboratory  for biomarker assessment at baseline. Please refer to 
Section 7.2.[ADDRESS_1162220] of 28 days; for a Q3W 
regimen, a treatment cycle will consist of 21day s.Further details are provided in Table 7 -
1and 
Section 7.1.3.
150-day follow -up (FU) period
For [ADDRESS_1162221] administration of study  treatment, patients will be followed up for 
safet y evaluations ( Table 7 -
1and Section 7.1.6).
Disease progression FU
Patients who discontinue study  treatment for any  reason other than disease progression, lost to 
follow -
up or death will be followed up for progression of disease (Section 7.1.6). The disease 
progression follow -up will be performed until at least 80% of all patients enrolled in each 
disease group of the phase II part of the study  have had progression of disease or discontinued 
the study  for any  reason.
Survival FU
Patients will be followed for survival ( Section 7. 1.6) until the end of the study  is reached.
4.2 Timing of interim analy ses and design adaptations
No formal interim analyses are planned. However, in the phase I part, the dose-escalation design 
foresees that decisions based on the current data are taken befo re the end of the study .
(Section 
10.7)
4.3 Definition of end of the study
The end of the stud y will be when
:
80% of the patients per disease group in the phase II part have completed the follow -up for 
disease progression or discontinued the study  for any reason, and all patients have 
completed treatment and the 150 day  safety  follow -up period, 
or
the study  is terminated early ,
or

[COMPANY_001] Confidential Page 46
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
another clinical study  becomes available that can continue to provide study  treatmen t in this 
patient population, and all patients ongoing are transferred to that clinical study .
At the end of the study , every  effort will be made to continue provis ion of study  treatment 
outside this study  through an alternative treatment option to patients who,in the opi[INVESTIGATOR_1070] ,are still deriving clinical benefit.
See Section 10 Statistical Methods and Data Analy sis for details of timing of the primary 
analysis and final reporti ng of data.
4.4 Early study  termination
The study  can be terminated at any  time for any  reason by  [CONTACT_5343]. Should this be necessary, 
the patient should be seen as soon as possible for End of Treatment (EOT) visit and the 
assessments for EOT should be performe d as described in Section 7.1.[ADDRESS_1162222] ion of the patient’s interests. The 
investigator will be responsible for informing Institutional Review Boards (IRBs) and/or 
independent ethics committees (IECs) of the earl y termination of the trial.
[ADDRESS_1162223] diseases 
(melanoma, NSCL C, TNBC and anaplastic thyroid cancer) as outlined in Figure 4-1and 
Section 5.2.
The investigator or designee must ensure that only patients who meet all the following inclusion 
and none of the exclusion criteria are offered treatme nt in the study .
5.[ADDRESS_1162224] to meet all of the following criteria:
1.Written informed consent must be obtained prior to any  procedures
2.Age ≥ 18 y ears. [For Japan only: written consent is necessary both from the patient 
and his/her legal representative if he/she is under the age of 20 years.]
3.Phase I part: Patients with advanced/metastatic solid tumors, with measurable or non -
measurable disease as determined by  [CONTACT_44993] 1.1 (refer to 
Appendix 1 ), who have 
progressed despi[INVESTIGATOR_837222] y, or for whom no 
standard therap y exists.
4. Phase II part: Patients with advanced/metastatic solid tumors, with at least one measurable 
lesion as determined b y RECI ST version 1.1, who have progressed following their last 
prior therap y, and fit into one of the following groups:
Groups 1a and 1b: NSCLC:

[COMPANY_001] Confidential Page 47
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Patients with NSCL C must have had disease recurrence or progression duri ng or after no 
more than one prior s ystemic chemotherap y regimen (platinum doublet -based) for 
advanced or metastatic disease. Prior maintenance therap y is allowed (e.g. pemetrexed, 
erlotinib, bevacizumab).
Only  patients with EGFR mutation- negative tumor a re eligible (defined as negative for 
exon 19 deletions and for the L 858R mutation in EGFR at a minimum; however, if more 
extensive EGFR mutation testing has been performed, the tumor must not harbor an y 
known activating EGFR mutations in Exons 18 -21 in order to be considered EGFR 
mutation -negative). All patients must be tested for EGFR mutational status and, for ALK 
translocation status if no mutation is detected in EGFR. Patients with ALK translocation -
positive NSCL C must have had disease progression follo wing treatment with a 
corresponding inhibitor and no more than one systemic chemotherapy  regimen (platinum 
doublet -based) , in an y sequence.
Group 2: Melanoma:
All patients must have been tested for BRAF mutations. Patients with V600 mutation 
positive mela noma must have clinical or radiological evidence of disease progression 
during or after treatment with a BRAF inhibitor alone or in combination with other 
agents.
Patients without BRAF mutation are not required to have received a prior therapy .
Group 3: T riple negative breast cancer
Group 4: Anaplastic th yroid cancer
Patients are not required to have received or progressed on a prior therap y.
Patients must not be at short term risk for life threatening complications (such as 
airway  compromise or bleeding from locoregional or metastatic disease,).
Chemoradiation and/or surgery  should be considered prior to study  entry  for 
those patients with locally advanced disease if those therapi[INVESTIGATOR_837223].
5.ECOG Performance Status ≤ 1.
6.Patient must have a site of disease amenable to biopsy , and be a candidate for tumor 
biopsy  according to the treating institution’s guidelines. Patient must be willing to undergo 
a new tumor biops y at bas eline or at molecular pre -screening if applicable, and during 
therap y on this study. For patients in the phase II part of the stud y, exceptions may be 
granted after documented discussion with [COMPANY_001]. After a sufficient number of paired 
biopsies are colle cted, the decision may  be taken to stop the collection of biopsies.
5.[ADDRESS_1162225] not meet anyof the following criteria:
1.Presence of s ymptomatic central nervous s ystem (CNS) metastases, or CNS metastases 
that require local CNS -directed therapy (such as radiotherap y or surgery), or increasing 
doses of corticosteroids within the prior 2 weeks.
2.History  of severe hy persensitivity  reactions to other mAbs
3.Patient having out of range laboratory  values defined as:

[COMPANY_001] Confidential Page 48
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Crea tinine clearance (calculated using Cockcroft- Gault formula, or measured) < 40 
mL/min
Total bilirubin > 1.[ADDRESS_1162226], except for patients with Gilbert’s sy ndrome who are 
excluded if total bilirubin > 3.[ADDRESS_1162227] bilirubin > 1.[ADDRESS_1162228]
Alanine aminotrans ferase (ALT) > [ADDRESS_1162229] tumor 
involvement of the liver, who are excluded if ALT > 5 x UL N
Aspartate aminotransferase (AST) > [ADDRESS_1162230] > 5 x UL N
Absolute neutrophil count < 1.0 x 109/L
Platelet count < 75 x 109/L
Hemoglobin (Hgb) < 8 g/dL
Potassium, magnesium, calcium or phosphate abnormality  > Common Terminology  
Criteria for Adverse Events (CTCAE) grade 2
4.Impaired cardiac function or clinicall y significant cardiac disease, including an y of the 
following:
Clinically  significant and/or uncontrolled heart disease such as congestive heart 
failure requiring treatment (NYHA grade ≥ 2), uncontrolled hy pertension or clinically  
significant arrh ythmia
QTcF >470 msec on screening ECG or congenital long QT s yndrome
Acute m yocardial infarction or unstable angina pectoris < 3 months prior to study 
entry
5.Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, ty pe 
I diabetes mellitus, residual hy pothy roidism due to autoimmune condition only  requiring 
hormone replacement, psoriasis not requiring s ystemic treatment, or conditions not 
expected to recur in the absence of an external trigger are permitted to enroll.
6.History  of drug -induc ed pneumonitis or current pneumonitis.
7.Active infection requiring s ystemic antibiotic therapy .
8.Human Immunodeficiency  Virus (HIV) infection.
9.Active HBV or HCV infection.
10.Malignant disease, other than that being treated in this study . Exceptions to this exclusion 
include the following: malignancies that were treated curativel y and have not recurred 
within 2 y ears prior to study treatment; completely  resected basal cell and squamous cell 
skin cancers; any malignancy considered to be indolent and that has never required 
therap y (e.g. ductal carcinoma in situ, some low grade l ymphomas, high- grade prostatic 
intraepi[INVESTIGATOR_28601], monoclonal gammopathy of undetermined significance) ; and 
completely  resected carcinoma in situ of any  type.
11.Patients with ocular melanoma
12.Any condition that would prevent the patient’s participation in the clinical study  due to 
safet y concerns, compliance with clinical stud y procedures or interpretation of study 
results.
13.Systemic anti -cancer therapy  within [ADDRESS_1162231] major delay ed toxicity , e.g. mitom ycin C and nitrosoureas, 4 

[COMPANY_001] Confidential Page 49
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
weeks is indicated as washout period. For patients receiving anticancer immunotherapi[INVESTIGATOR_837224] -4 antagonists, 6 weeks is indicated as the washout period.
14.Prior PD -1-or PD -L1-directed therapy .
15.Patients requiring chronic treatment with s ystemic steroid therap
y, other than replacement -
dose steroids in the setting of adrenal insufficiency . Topi[INVESTIGATOR_2855], inhaled, nasal and ophthalmic 
steroids are not prohibited.
16.Patients receiving s ystemic treatment with any  immunosuppressive medication (other than 
steroids as described above).
17.Use of an y live vaccines within [ADDRESS_1162232] dose of s tudy treatment (mediastinoscopy , 
insertion of a central venous access device, and insertion of a feeding tube are not 
considered major surgery).
19.Radiotherap y within [ADDRESS_1162233] dose of 
study  treatment.
21.Presence of ≥ CTCAE grade 2 toxicity  (except alopecia, peripheral neuropathy  and 
ototoxicity , which are excluded if ≥ CTCAE grade 3) due to prior cancer therap y.
22.Use of hematopoietic colony -stimulating growth factors (e.g. G -CSF, GMCSF, M -CSF) 
≤[ADDRESS_1162234] dose of PDR001. Highl y effective 
contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
patient. Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post- ovulation 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total h ysterectom y or tubal ligation at least six weeks before taking 
study  treatment. In case of oophorectom y alone, only  when the reproductive status of 
the woman has been confirmed by  [CONTACT_104]
Male sterilization (at least 6 months prior to screening). For female patients on the 
study  the vasectomized male partner should be the sole partner for that patient.
Use of oral, injected or implanted hormonal methods of contraception or placement of 
an intrauterine device (IUD)
or intrauterine s ystem (IUS), or other forms of hormonal 
contraception that have comparable efficacy  (failure rate <1%), for example hormone 
vaginal ring or transdermal hormone contraception.

[COMPANY_001] Confidential Page 50
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_1162235] had over 
12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile age 
appropriate (e.g. generally 40-59 years), history  of vasomotor symptoms (e.g. hot flushes) in 
the absence of other medical justification or have had surgical bilateral oophorectom y (with or 
without hysterectomy ), total hysterectom y or tubal ligation at least six weeks ago. In the case 
of oophorectom y alone, only when the reproductive status of the woman has been confirmed 
by [CONTACT_6592].
6 Treatment
6.1 Stud y treatment
The investigational treatment is PDR001.
6.1.1 Dosing regimen
Table 6
-1 Dose and treatment schedule
Study  
treatmentsPharmaceutical form and route of 
administration Dose Frequency  and/or Regimen
PDR0 01 Powder for solution for infusion 1 mg/kg (starting 
dose)Every 2 weeks (or alternative 
regimens, e.g. Q3W , Q4W)
PDR001 will be administered via i.v. infusion over 30 minutes (up to 2 hour, if clinicall y 
indicated) once every  2 weeks. The next dose may  be delay ed by [CONTACT_8622] 7 day s to recover from 
previous AEs (see Section 6.3.2) before receiving the next dose. If the next dose cannot be 
administered within the above mentioned 7 -day delay, then the dose should be skipped. Dosing 
will resume at the next scheduled dose and assessment schedule will be shifted accordingl y.
Dose modifications should follow Section 6.3.1 and Section 6.3.2.
If a significant number of patients require dose delay s due to PDR001 -
related toxic ities, or if 
the PK data support it, the dosing regimen for the study may be changed to once ever y 28 days. 
This will be discussed in a dose escalation teleconference at the time of the proposed change 
and documented in the meeting minutes accordingl y (see Section 6.2.3). Alternative dosing 
regimens may also be considered based on clinical toxicity  and preliminary  PK/PD and efficac y 
findings.
Once the RP2D dose and schedule are determined, patients from t
he dose escalation who have 
completed 4 cy cles of treatment may  be offered the option of switching to the RP2D (dose and 
schedule). If this change leads to an increase in the dose, then the patient must fulfill the criteria 
outlined in Section [IP_ADDRESS] for intrapatient dose escalation.
6.1.[ADDRESS_1162236] infusion 
of PDR001, in order to determine if pre-medication is necessary. If a patient experiences an 
infusion reaction, he/she may receive pre-medication on subsequent dosing days. The pre-

[COMPANY_001] Confidential Page 51
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
medication should be chosen per institutional standard of care, at the discretion of the treating 
physician.
Acute allergic react ions should be treated as needed per institutional standard of care. In the 
event of anaphy lactic/anaphy lactoid reactions, this includes any therapy  necessary  to restore 
normal cardiopulmonary status. If a patient experiences a severe anaph ylactic/anaph ylactoid 
reaction, the infusion should be discontinued immediatel y. The patient may only  resume study 
treatment following discussion with [COMPANY_001].
Patients should be treated in a facility  equipped for cardiopulmonary resuscitation. Appropriate 
resuscitation equipment should be available at the bedside and a ph ysician readily  available.
Guidelines on management of PDR001 infusion reactions are provided in Section 6.3.2 , Table 
6-4.
The CTCAE category  of “Infusion related reaction” should be used to describe PDR001 
infusion reactions, unless the investigator considers another category , such as “Allergic 
reaction,” “Anaph ylaxis,” or “Cytokine release syndrome” more appropriate in a specific 
situation.
6.1.3 Treatment duration
A patient may continue treatment with PDR001 until the patient experiences unacceptable 
toxicity , confirmed disease progression per irRC and/or treatment is discontinued at the 
discretion of theinvestigator or the patient. Patients will not be withdrawn from the study  due 
to progressive disease per RECI ST. Refer to 
Section 7.1.[ADDRESS_1162237] to be skipped due to PDR001 -related 
toxicities, then the drug should be permanentl y discontinued. If a patient who misses more than 
2 consecutive doses due to a PDR001 -related toxicity  is experiencing clinical benefit, and in 
the opi[INVESTIGATOR_192576]’s best interest to remain on study , then the 
patient may  continue treatment after discussion with [COMPANY_001].
6.2 Dose escalation guidelines
6.2.1 Starting dose rationale
PDR001 cross reacts with monkey  PD-1 but not rodent PD-1; therefore, the starting dose 
selected for this study  is based on 4-week GLP toxicology  studies performed in cynomolgus 
monkey s. PDR001 is a naked monoclonal antibody that does not have agonist activity , and will 
be ad ministered to patients with advanced malignancies; therefore the starting dose is based on 
the ICH S9 guidance. The HNSTD was 100 mg/kg, administered i.v., once weekl y. As PDR001 
will be administered i.v. and it is generall y accepted that antibody  therapeu tics allometricall y 
scale according to body  weight, the human equivalent dose (HED) of the HNSTD is 100 mg/kg. 
The maximum permitted starting dose in patients is 1/6 x 100 mg/kg, or 17 mg/kg administered 
weekl y. Based on the prior clinical experience with nivolumab and pembrolizumab (Topalian 
2012, Topalian 2014, Hamid 2013b, Robert 2014 ), and with the reasonable assumption that 
PDR001 will have similar PK/PD properties as those comparators, PDR001 is expected to 
demonstrate antitumor activity  at doses of 2-3 mg/kg dosed every  2- 3 weeks. In order to 
evaluate the safet y, PK and antitumor activity  of PDR001 across a range of doses, the 

[COMPANY_001] Confidential Page 52
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
recommended starting dose in this study  will be 1 mg/kg, i.v., every  2 weeks, which is well 
below the maximum permitted starting dose.
6.2.2 Provisional dose levels
Table 6 -2describes the starting dose and the dose levels that may be evaluated during this trial.
Table 6-2 Provisional dose levels
Dose level Proposed dose* Increment fr om previous dose
-1** 0.3 mg/kg -70%
1** 1 mg/kg Starting dose
2 3 mg/kg 300%
3 10 mg/kg 333%
*It is possible for additional and/or intermediate dose levels to be added during the course of the study Cohorts 
may be added at any dose level below the MTD in order to better understand safety, PK or PD. Multiple dose 
levels below the MTD may be evaluated simultaneously in order to obtain PK and PD data across a range of 
doses and to establish the RP2D.
**Dose level -[ADDRESS_1162238] cohort will be treated with the 
starting dose of 1 mg/kg.
Patients must complete a minimum of [ADDRESS_1162239] cycle of treatment to be considered 
evaluable for dose escalation decisions (Section 10.1.4 ). Also, for the dose-exposure analysis, 
patients must have re ceived at least one dose of PDR001 during Cycle [ADDRESS_1162240] sufficient PK 
samples in cycle 3 to evaluate the AUC (0-336h) (Section 10.1.5). Dose escalation decisions will 
occur when the cohort of patients has met these criteria. If only 2 patients in a cohort are 
evaluable andneither patient has experienced a treatment -
related toxicity  > CTCAE grade 1, 
dose escalation decisions may  be considered.
Dose escalation decisions will be made by [CONTACT_111847]. 
Decisions will be based on a synthesis of all relevant data available from all dose levels 
evaluated in the ongoing study  including safet y information, DLTs, all CTCAE Grade ≥ 2 
toxicity  data during Cycle 1, and available PK, including Bayesian dose-exposure modeling, 
and PD data from evaluable patients. The recommended dose for the next cohort of patients 
will be 
guided by [CONTACT_837243] (Section 10.4.2).  
 
 
[IP_ADDRESS] Bayesian dose -exposure model
The Ba yesian linear model will estimate the dose -exposure relationship for PDR001 in or der to 
guide the dose recommendation. The pharmacokinetic profiles of pembrolizumab and 

[COMPANY_001] Confidential Page 53
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
nivolumab are similar, as expected considering that both are naked monoclonal antibodies that 
bind to the same target (Patnaik 2012, Robert 2014, Brahmer 2012 ), and the pharmacokinetic 
profile of PDR001 is expected to be similar. Based on the exposure data reported for 
pembrolizumab and nivolumab at their approved doses of 2 mg/kg and 3 mg/kg, respectivel y 
(pembrolizumab US label ; nivolumab US label ), a PDR001 AUC (0-336h) ≥ 1000 µg*day /mL at 
cycle 3 is expected to provide antitumor activity comparable to that of pembrolizumab and 
nivolumab.
A Bayesian linear model will be used to estimate the dose-exposure relationship for PDR001 
in order to guide the dose recomm endation to achieve a PDR001 AUC (0-
336h)≥ 1000 µg*day /mL 
in cycle 3, as described in Section [IP_ADDRESS]. The dose- exposure relationship will be evaluated 
only when sufficient exposure data are available.
[IP_ADDRESS] Bayesian logistic regression model of DLT rate
The adaptive Bayesian methodology  provides an estimate of DLT rate for all dose levels of 
PDR001 that do not exceed the MTD and incorporates all accumulated DLT information from 
all dose cohorts for this estim ation. In general, the next dose will have the highest chance that 
the DLT rate will fall in the target interval [16-33%) and will alway s satisfy  the EWOC principle 
(less than 25% probability that the DLT rate is ≥ 33%). In all cases, the dose for the next cohort 
will not exceed a 334% (1/2 log) increase from the previous dose. Smaller increases in dose 
may be recommended by [CONTACT_837244].
If the first 2 patients in a cohort experience a DLT, further enrollment to that cohort will stop 
and the BLRM will be updated with this new information. Re-evaluation of the available safety, 
PK, and PD data will occur. By  [CONTACT_209173], 
additional patients may be enrolled at this dose level or a lower dose level as agreed by 
[CONTACT_111851] 25% (EWOC).
Dose escalation will continue until identificati on of the RP2D, which is expected to occur before 
the MTD is reached. However, dose escalation will stop when the MTD is reached, even if the 
exposure criteria for the RP2D have not been met.
The MTD is identified when the following 3 conditions are met:
1. at least [ADDRESS_1162241] been treated at this dose
2. this dose satisfies one of the following conditions:
a.the posterior probabilit y of targeted toxicity  at this dose exceeds 25% and is the 
highest among potential doses, or
b.minimum of [ADDRESS_1162242] alread y been treated on the trial to identify  the MTD. 
Recommendation of RP2D may be made with fewer patients, prior to identification of 
MTD.
3.it is the maximum dose recommended for patients, either per the model or by  [CONTACT_837245] b y [COMPANY_001] and I nvestigators in a dose -escalation teleconference see Section 
[IP_ADDRESS].

[COMPANY_001] Confidential Page 54
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
To better understand the safet y, tolerability  and PK of PDR001, additional cohorts of patients 
may be enrolled at preceding dose levels, or to intermediate dose levels before or while 
proceeding with further dose escalation. Multiple dose levels may be evaluated in simultaneous 
cohorts, as long as none exceeds the maximum dose permitted by  [CONTACT_111845], and a maximum 
of [ADDRESS_1162243] dose previously  shown to be 
safe. Depending on the AUC (0-336h) and predicted DLT rate, it is possible that the dose will not 
be escalated above the starting dose of 1 mg/kg, and it is possible that doses greater than 
required to achieve the target exposure will be explored as long as they do not exceed the 
maximum dose permitted by  [CONTACT_111831].
If a decision is made to escalate to a higher dose level but one or more additional patient(s) 
treated at the preceding dose level experiences a DLT during the first cycle of treatment, then 
the BLRM will be updated with this new information before any additional patients are enrolled 
at that higher dose level. Patients ongoing will continue treatment at their assigned dose lev els.
[IP_ADDRESS] Implementation of dose escalation de cisions
To implement dose escalation decisions, the available toxicity  information (including AEs and 
laboratory  abnormalities that are not DLTs), the recommendations from the Bayesian linear 
model and the BLRM, andthe available PK and PD information will all be evaluated by [CONTACT_818428] (including the study  physician and statistician) 
during a dose decision meeting by  [CONTACT_577]. Drug administration at the next higher dose 
level may not proceed until the investigator receives written confirmation from [COMPANY_001] 
indicating that the results of the previous dose level were evaluated and that it is permissible to 
proceed to a higher dose level.
[IP_ADDRESS] Intra -patient dose escalation
For patie nts enrolled in the Phase I part of the study , intra-patient dose escalation is not 
permitted at any time within the first 4 cycles of treatment. After cycle 4 is completed, 
individual patients may be considered for treatment at a dose of PDR001 higher than the dose 
to which they were initially assigned and/or a different dosing regimen. In order for a patient to 
be treated at a higher dose of PDR001, he or she must have tolerated the lower dose for at least 
4 cycles of therap y (i.e. he or she must not have experienced any PDR001 -related toxicity 
CTCAE grade ≥ 2 at the lower dose originall y assigned). Moreover, the new, higher dose with 
which the patient is to be treated must be a dose that has completed evaluation and has not 
exceeded the maximum tolerated dose (MTD). There is no limit to the number of times a patient 
may have his or her dose of PDR001 increased. For any further increase after the initial intra-
patient dose escalation, the following rules apply: the patient must have experienced no CTCAE 
grade ≥ 2, PDR001 -related toxicity  over at least two cycles of therap y at the lower dose, and 
the higher dose being considered must have been fully evaluated and shown not to exceed the 
MTD. Consultation and agreement with [COMPANY_001] must occur prior to any intra-patient dose 
escalation occurring. These changes must be recorded on the Dosage Administration Record 
eCRF. Data from the first cycle of treatment at the new dose level will not be formally included 
in the statistical model describing the relationship between dose and occurrence of DLT. 
However, these data will be incorporated into the clinical assessment of safet y during dose 
escalation teleconferences.

[COMPANY_001] Confidential Page 55
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
For patients enrolled in the phase II part of the study, intra -patient dose escalation or change in 
dosing regimen is not permitted.
6.2.4 Definitions of dose limiting toxicities (DLTs)
A DLT is defined as an AE 
or abnormal laboratory  value of CTCAE grade ≥ [ADDRESS_1162244] cycle of treatment with PDR001 during the dose escalation part of 
the study , with the exceptions described in Table 6 -3.
National Cancer Institute Common Terminology Crite ria for Adverse events (NCI  CTCAE) 
version 4.[ADDRESS_1162245] notify  the Sponsor immediately  of any unexpected CTCAE grade ≥ 3 
AEs or laboratory  abnormalities. Prior to enrolling patients into a higher dose level, CTCAE 
grade ≥ 2 AEs will be reviewed for all patients at the current dose level.
Table 6
-3 Criteria for defining dose limiting toxicities
DLTs include any  AE of CTCAE grade 3 or higher occurring in cy cle 1, during the dose escalation part of 
the study , for which relationship to study  treatment cann ot be ruled out, with the following exceptions:
Hematology Neutropenia is a DLT if it is CTCAE grade 4.
Thrombocytopenia is a DLT if it is CTCAE grade 4.
Anemia is a DLT if it is CTCAE grade 4.
Lymphopenia is a DLT if it is CTCAE grade 4.
Hepatic ≥ CTCAE grade 2 total bilirubin wit h ≥ CTCAE grade 2 ALT is a DLT.
Gastrointestinal Nausea and vomiting are DLTs if they are ≥ CTCAE grade 3 for > 2 days despi[INVESTIGATOR_111764]-emetic therapy.
Diarrhea is a DLT if it is ≥ CTCAE grade 3 for > 2 days despi[INVESTIGATOR_9025] -diarrhea 
treatment.
Pneumonitis CTCAE grade 2 pneumonitis is a DLT if it persists > 7 days despi[INVESTIGATOR_528955]. Grade 3 -4 pneumonitis of any duration is a DLT.
Hypertension CTCAE grade 3 hypertension is a DLT if it persists > [ADDRESS_1162246] > 
[ADDRESS_1162247] > 7 days despi[INVESTIGATOR_837225]. Grade 4 electrolyte abnormality of any duration is a 
DLT.
Rash and/or 
photosensitivity≥ CTCAE grade [ADDRESS_1162248] > 7 days despi[INVESTIGATOR_206800].
Fatigue Fatigue is a DLT if it is ≥ CTCAE grade 3 and lasts > 7 days.
Immune related 
toxicities (except 
pneumonitis)CTCAE grade [ADDRESS_1162249] > 7 days despi[INVESTIGATOR_837226]. Immune related toxicities CTCAE grade 4 of any duration 
are DLTs.
Other AEs Other clinically significant toxicities, including a single event or multiple occurrences of the 
same event that lead to a dosing delay of > 7 days in cy cle 1, may be considered to be 
DLTs by [CONTACT_818429], even if not CTCAE grade 3 or hig her.

[COMPANY_001] Confidential Page 56
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
6.3 Dose modifications
6.3.1 Dose modification and dose delay
For patients who do not tolerate the protocol -specified dosing schedule, dose or schedule 
adjus tments are permitted in order to allow the patient to continue the study  treatment. The 
following guidelines need to be applied:
For clinical management of suspected immune -related events, reference to consensus 
management guidelines is recommended such as those provided in the National 
Comprehensive Ca ncer Network (NCCN) Guidelines for the Management of 
Immunotherap y-Related Toxicities (available at: 
nccn.org/professionals/phy sician_gls/default.aspx#immunotherapy ), the American Societ y 
of Cl inical Oncology  clinical practic e guideline for Management of Immune -Related 
Adverse Events in Patients Treated with Immune Checkpoint I nhibitor Therapy  (Brahmer 
2018) or the European Society  for Me dical Oncology  (ESMO) Clinical Practice 
Guidelines for Management of Toxicities from I mmunotherapy  (Haanen 2017). Note that 
in general, stud y treatment should be interrupted for grade 3 and 4 toxicities an d for a 
subset of lower grade toxicities. 
Consider earl y referral to specialists with expertise in the diagnosis and management of 
immune -related AEs to thoroughl y investigate events of uncertain etiology.
Events not included in the study protocol or the reference guidance documents should be 
managed per institutional preference.
A decision to resume tr eatment following the occurrence of a DLT, grade [ADDRESS_1162250] be discontinued from the study  treatment. If a patient who misses more than 2 
consecutive doses due to a PDR001- related toxicity  is experiencing clinical benefit, and in the 
opi[INVESTIGATOR_192576]’s best interest to remain on study, then the patient 
may continue treatment after discussion with [COMPANY_001].
Patients who discontinue the study  for a study  related AE or a study -related abnormal laboratory 
value must b e followed as described in Section 6.3.[ADDRESS_1162251] once a week (or more frequentl y if 
required by [CONTACT_15931], or if clinically  indicated) for [ADDRESS_1162252]. Appropriate clinical experts should be consulted as deemed necessary . In case of a 
suspected autoimmune disease AE, the relevant immunological assessments (e.g. rheumatoid 
factor, anti -DNA Ab, etc.) should be performed. In case of a toxicity  suspected to be a cytokine 
release syndrome, the assessments outlined in Section [IP_ADDRESS].[ADDRESS_1162253] be performed. All patients 

[COMPANY_001] Confidential Page 57
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
must be followed up for AEs and SAEs for [ADDRESS_1162254] dose of PDR001. Table 
6-4outlines the follow -up evaluation recommended for selected toxicities.
Table 6
-4 Follo w-up evaluations for selected toxicities
TOXICITY FOLLOW -UP EVALUATIO N AND TREATMENT RECOMMENDATIONS
Infusion Reaction or hy persensitivity  reaction
Grade 1 Decrease infusion rate until recovery of the symptoms .
Grade 2 Stop infusion immediately, and keep line open. 
Follow institutional guidelines for the management and follow -up of infusion reaction.
Restart infusion at 50% of previous rate under continuous observation.
Ensure that the re is a minimum observation period of 1 hour prior to restarting the 
infusion.
If the AE recurs at the reinitiated slow rate of infusion, and despi[INVESTIGATOR_217903] -medication, 
then permanently discontinue study treatment .
Grades 3 and 4 Discontinue infusion im mediately , and discontinue study treatment .
Provide supplemental oxygen, fluids, and other resuscitative measures as needed. 
Monitor vital signs (e.g., blood pressure, pulse, respi[INVESTIGATOR_1516], and temperature) every 15 ± 
5 minutes until resolution.
Cytokine Release Sy ndrome (CRS)
Grade 2 See instructions for Grade 2 Infusion Reaction above.
Grade 3 or Grade 4 Discontinue study treatment.
Follow -up CRS as per institutional guidelines.
Take blood for cytokine measurements as specified in Section [IP_ADDRESS] Laboratory 
evaluations
Ocular (uveitis, ey e pain, blurred vision)
Grade 1 Continue study treatment without dose modification.
Ophthalmology consultation.
Grade 2 Hold study treatment.
Urgent ophthalmology consultation.
Upon resolution to ≤ Grade 1 may consider resuming study treatment without dose 
reduction after discussion with the [COMPANY_001] Medical Monitor and in consultation with 
ophthalmology.
Grade 3 or Grade 4 Discontinue study tr eatment.
Urgent ophthalmology consultation.
Pulmonary  (Pneumonitis)
Grade 1 Consider study treatment hold.
Manage per institutional practice.
Consider resuming study treatment upon radiographic evidence of improvement .
Grade 2 Hold study treatment.
Pulmonary and infection workup.
Upon resolution to ≤ Grade 1, may resume study treatment without dose modification.
Grades 3 and 4 Discontinue study treatment . 
Cardiovascular
ECG QTc -Interval prolonged; h ypertension
Grade 3 Hold study treatment.
Upon resolution to Grade ≤ 1 or baseline (hypertension, QTc) or < 30 msec difference 
from baseline (QTc) within ≤ 7 days, may resume study treatment without dose 
modification after discussion with the [COMPANY_001] Medical Monitor. Baseline ECG refers to 
ECG(s) col lected at screening.
Grade 4 Discontinue study treatment.

[COMPANY_001] Confidential Page 58
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
TOXICITY FOLLOW -UP EVALUATIO N AND TREATMENT RECOMMENDATIONS
Other cardiovascular disorders
Grade 2 (except 
myocarditis)Hold study treatment.
Upon resolution to Grade ≤ 1 or baseline, may resume study treatment without dose 
modification after discussion with the [COMPANY_001] Medical Monitor.
Grade 2 myocarditis, 
or Grade ≥ 3 other 
cardiac disorders 
related to study 
treatmentDiscontinue study treatment.
Gastrointestinal
Diarrhea/colitis*
Grade [ADDRESS_1162255] guidelines which could include anti -diarrheal treatment, consideration of 
corticosteroid therapy, and hydration.
Grade 2 Hold study treatment.
GI consultation.
Upon resolution to ≤ Grade 1 and tapering of steroid requirem ent to ≤ 10 mg prednisone 
per day, resume study treatment without dose modification after discussion with the 
[COMPANY_001] Medical Monitor.
Grade3 Hold study treatment.
GI consultation.
Upon resolution to ≤ Grade 1 and tapering of steroid requirement to ≤ [ADDRESS_1162256] and/or ALT elevation
Grade [ADDRESS_1162257] and/or 
ALTHold study treatment.
Manage per institutional practice.
Upon resolution to ≤ Grade 1 or baseline, consider resuming study treatment without 
dose modification.
Grade 2 transaminitis 
with bilirubin > 1.[ADDRESS_1162258] (unless Gilbert’s 
syndrome)Discontinue study treatment.
Grade [ADDRESS_1162259] and/or 
ALTHold study treatment.
Manage per institutional practices.
Upon resolution to ≤ Grade [ADDRESS_1162260] and/or 
ALTDiscontinue study treatment.
Isolated total bilirubin elevation**
Grade 2 Hold study treatment.
Upon resolution to ≤ Grade 1 or baseline, may continue study treatment without dose 
modification.
Grade 3 Hold study treatment.
Upon resolution t o ≤ Grade 1 or baseline, may consider resuming study treatment after 
discussion with the [COMPANY_001] Medical Monitor.
Grade 4 See footnote **. Otherwise, discontinue study treatment.

[COMPANY_001] Confidential Page 59
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
TOXICITY FOLLOW -UP EVALUATIO N AND TREATMENT RECOMMENDATIONS
Asymptomatic amy lase and/or lipase elevation ***
Grade 3 or Grade 4, 
not associated with 
symptoms or clinical 
manifestations of 
pancreatitis***Continue study treatment.
If levels do not resolve to ≤ Grade 2 within ≤ 14 days after the initial report, hold study 
treatment.
Upon resolution to ≤ Grade 2, may resume study treatment without dose modification, 
after discussion with the [COMPANY_001] Medical Monitor.
Pancreatitis
Grade 2/radiologic 
evidenceHold study treatment.
Manage per institutional practice.
Upon resolution to ≤ Grade 1, may resume study treatment without dose modification, if 
no clinical evidence of pancreatitis and after discussion with the [COMPANY_001] Medical 
Monitor.
Grades 3 or Grade 4 Discontinue study treatment.
Renal
Serum creatinine
Grade 2 Hold study treatment.
Manage per institutional practice.
Upon resolution to ≤ Grade 1 , may resume study treatment without dose modification 
after discussion with the [COMPANY_001] Medical Monitor.
Grade 3 or 4 Discontinue study treatment.
Musculoskeletal
Grade 2 or Grade 3 Hold study treatment.
Consider resuming studytreatment without dose modification upon resolution to ≤ Grade 
[ADDRESS_1162261].
Endocrine
Hypoth yroidism or hy perth yroidism
Grade 2 May continue study treatment without dose modification.
Management according to institutional practice.
Grade 3 Hold study treatment. 
Upon resolution to Grade ≤ 1 with appropriate management, may resume study treatment 
without dose modification.
Grade 4 May resume therapy following resolution or control with physiologic hormone 
replacement.
Other endocrine disorders
Grade 2 and Grade 3 Hold study treatment. 
Upon resolution to Grade ≤ 1 with appropriate management, may resume study treatment 
without dose modification.
Grade 4 Hold study treatment.
Grade 4 treatment -related endocrinopathies , such as adrenal insufficiency, 
adrenocorticotropic hormone (ACTH) deficie ncy, hyper- or hypothyroidism, or glucose 
intolerance, which resolve or are adequately controlled with physiologic hormone 
replacement (corticosteroids, thyroid hormones) or glucose -controlling agents, 
respectively, may not require discontinuation after discussion with and approval from the 
[COMPANY_001] Medical Monitor.
Neurology
Grade 1 Consider study treatment hold, particularly for clinical suspi[INVESTIGATOR_217902] -Barre 
syndrome, encephalitis, aseptic meningitis, transverse myelitis, or peripheral neuropathy.
Grade 2 Hold study treatment.
In some cases, resuming study treatment may be considered after discussion with the 
[COMPANY_001] Medical Monitor.

[COMPANY_001] Confidential Page 60
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
TOXICITY FOLLOW -UP EVALUATIO N AND TREATMENT RECOMMENDATIONS
Grade 3 or Grade 4 Discontinue study treatment.
Dermatology  (rash)
Grade 1 Continue study treatment without dose modification . Topi[INVESTIGATOR_8826], antihistamines, 
topi[INVESTIGATOR_39669].
Grade 2 Consider holding study treatment.
Topi[INVESTIGATOR_217901], antihistamines.
If study treatment is held and resolution to ≤ Grade 1, resume study treatment without 
dose modification.
Grade 3 or Grade 4 Hold study treatment.
Manage per institutional practice.
After resolution to ≤ Grade 1, consider resuming study treatment after discussion with the 
[COMPANY_001] Medical Monitor.
Bullous dermatitis Hold study treatment.
Grade 1 -2 bullous dermatitis: discussion with the [COMPANY_001] Medical Monitor is required 
before considering resuming study treatment.  
Grade 3 bullous dermatitis: consider resuming therapy after expert consultation and 
documented discussion with the Novarti s medical monitor.
Grade 4 bullous dermatitis: discontinue study treatment.
Stevens -Johnson 
syndrome (SJS), or 
Lyell syndrome/toxic 
epi[INVESTIGATOR_194] 
(TEN)Permanently discontinue study treatment.
Hematology
Neutropenia (ANC)
Grade 3 or Grade 4 Hold study treatment. 
Upon resolution to ≤ Grade 2 or baseline within ≤ 7 days, resume study treatment without 
dose modification, after discussion with the [COMPANY_001] Medical Monitor.
Febrile neutropenia
Grade 3 or Grade 4 Hold study treatment.
Upon resolution of fever and improvement of neutropenia to ≤ Grade 2 or baseline, 
resume study treatment without dose modification, after discussion with the [COMPANY_001] 
Medical Monitor.
Throm bocy topenia
Grade 3 Hold study treatment.
Upon resolution to ≤ Grade 2 or baseline, resume study treatment without dose 
modification.
For Grade 3 associated with major bleeding, discontinue study treatment.
Grade 4 Discontinue study treatment.
Anemia
Grade 3 or Grade 4
Hold study treatment.
Upon resolution to ≤ Grade 2 o r baseline within 7 days, resume study treatment without 
dose modification.
Lymphopenia
Any grade Treatment -related lymphopenia does not require study treatment hold or discontinuation.
Other laboratory  adverse events, not specified elsewhere in table and not included in the consensus 
guidelines
Grade 3 Hold study treatment.
Upon resolution to ≤ Grade 1, resume study treatment without dose modification.

[COMPANY_001] Confidential Page 61
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
TOXICITY FOLLOW -UP EVALUATIO N AND TREATMENT RECOMMENDATIONS
Grade 4 Isolated Grade 4 electrolyte abnormalities not associated with clinical sequelae and 
corrected after appropriate management within 72 hours of their onset do not require 
discontinuation.
In the case of Grade 4 electrolyte imbalances associated with clinical sequelae, or not 
resolved to ≤ Grade 1 within 72 hours despi[INVESTIGATOR_837227], discontinue 
study treatment.
Other non -laboratory  adverse events, not specified elsewhere in table and not included in the consensus 
guidelines
Grade 2 Consider study treatment hold, at Investigator discretion.
Upon resolution to ≤ Grade 1, resume study treatment without dose modification.
Grade 3 Hold study treatment.
Upon resolution to ≤ Grade 1, resuming study treatment must be discussed with the 
[COMPANY_001] Medical Monitor.
Grade [ADDRESS_1162262] preceding toxicity.
*Note: anti -diarrheal medication is recommended at the first sign of abdominal crampi[INVESTIGATOR_007], loose stools or overt 
diarrhea.
**Note: If Grade [ADDRESS_1162263] (non-conjugated) component only, and hemolysis 
as the etiology has been ruled out as per institutional guidelines (e.g., review of peripheral blood smear and 
haptoglobin determination), then delay study treatment until resolved ≤ Grade 1, and resume study treatment at 
the discretion of the investigator.
***Note: A CT scan or other imaging study to assess the pancreas, liver, and gallbladder must be performed 
within one week of the first occurrence of any ≥ Grade 3 of amylase and/or lipase.
6.3.3 Anticipated risks and safety  concerns of th e study  drug
Appropriate eligibility  criteria and specific DLT definitions, as well as specific dose 
modification and stoppi[INVESTIGATOR_49315]. Recommended guidelines for 
prophy lactic or supportive treatment for expected toxicities, including management of study -
drug induced AEs, i.e. infusion reaction, pneumonitis and other immune related toxicities, are 
provided in Section 6.3.2 . Refer to preclinical toxicity  data provided in the [Investigator’s 
Brochure].
6.4 Concomitant medications
6.4.1 Permitted concomitant therapy
In general, 
concomitant medications and therapi[INVESTIGATOR_632723] 
(e.g. such as anti -emetics, anti -diarrhea) and safety of the patient are allowed.
The patient must be told to notify  the investigational site about any new medications, herbal 
remedies and dietary  supplements he/she takes after the start of the study  treatment. All 
medications (other than study  treatment) and significant non-drug therapi[INVESTIGATOR_014] (including physical 
therap y, herbal/natural medications and blood transfusions) administered during the study  must 
be listed on the Prior and Concomitant Medications or the Surgical and Medical Procedures 
CRF. Prior antineoplastic therapi[INVESTIGATOR_837228], radiotherapy , and surgery  are to be 
recorded on the separate Prior Antineoplastic Therapy  eCRF during screening.
6.4.2 Permitted concomitant therapy  requiring caution and/or action
Treatment with hematopoietic colony -stimulating growth factors (e.g. G
-CSF, GM-CSF, M-
CSF) may not be initiated during the first cy cle in the dose escalation part of the study , unless 

[COMPANY_001] Confidential Page 62
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
the patient has alread y experienced a DLT. Treatment with erythroid stimulating agents (ESAs) 
may not be initiated during the first cycle in the dose escalation part of the study , unless the 
patient has already  experienced a DLT. If a patient is using ESA prior to enrollment (at least 2 
weeks before start of study  treatment), they  may  continue at the same dose.
Anticoagulation is permitted if the patients are already  at stable doses of warfarin or stable doses 
of low molecular weight heparin for >[ADDRESS_1162264] dose and INR should be monitored 
as clinically  indicated per investigator’s discretion. However, ongoing anticoagulant therap y 
sho
uld be temporarily  discontinued to allow tumor biopsy  according to the institutional 
guidelines.
Anti- hypertensives are allowed as concomitant medications; however, because transient 
hypotension has occurred during infusions of monoclonal antibodies, consideration should be 
given to withholding anti-hypertensive medications for [ADDRESS_1162265] cancer. 
However, limited -field palliative radiotherap y to non-target lesion(s) may be allowed as 
concomitant therap y after documented discussion with [COMPANY_001]. For patients with anaplastic 
thyroid cancer, limited -field radiotherap y to a target lesion that is life-threatening may be 
allowed, provided that other measurable disease remains to allow an assessment of response to 
treatment. These cases must be discussed with [COMPANY_001] with written permission. Such local 
therapi[INVESTIGATOR_837229] y –Radiotherap y CRF.
After progression of disease as per RECI ST criteria, radiotherap y and surgery  to select target 
and non-target lesion(s) (such as brain metastases) may be allowed as concomitant therap y after 
documented disc ussion and approval by  [CONTACT_5343] .
Additionally , 
no other therapeutic monoclonal antibodies and no immunosuppressive 
medication may  be administered while on this study .
The use of systemic steroid therap y is not allowed, except for the treatment of the following: 
infusion reactions, immune -mediated toxicities (patients may  resume study treatment while on 
tapering with doses ≤ 10 mg/day  prednisone or equivalent) , COPD exacerbation and 
replacement -dose steroids in the setting of adrenal insufficiency. Additional exceptions may be 
discussed with [COMPANY_001]. Topi[INVESTIGATOR_2855], inhaled, nasal and ophthalmic steroids are not prohibited.
The use of live vaccines is not allowed thr ough the whole duration of the study .
6.[ADDRESS_1162266] Number (Subject 
No.), that is assigned when 
the patient is first pre -screened (if applicable) or when the patient is enrolled for screening. The 
subject number is retained as the primary  identifier for the patient throughout his/her entire 
participation in the trial. The Subject No. consists of the Center Number (Center No.) (as 

[COMPANY_001] Confidential Page 63
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
assigned by [CONTACT_5359]) with a sequential patient number suffixed to it, 
so that each subject is numbered uniquely  across the entire database. Upon signing the informed 
consent form, the patient is assigned to the next sequential Subject No. available to the 
investigator through the Oracle Clinical RDC interface. Once assigned, the Subject No. must 
not be reused for an y other subject and the Subject No. for that individual must not be changed, 
even if the patient is re -screened. If the patient fail s to start treatment for an y reason, the reason 
will be entered into the Screening Disposition page.
6.5.2 Treatment assignment or randomization
The assignment of a patient to a particular cohort will be coordinated by [CONTACT_456]. No 
randomization will be perfo rmed in this study .
6.6 Stud y drug preparation and dispensation
PDR001 (100 mg powder for solution for infusion ) will be administered intravenousl y as a 30 
minute infusion (up to 2 hours, if clinically  indicated). Further instructions for the preparation 
and d ispensation of PDR001 are described in the Pharmacy  Manual.
All dosages prescribed to the patient, all dose interruptions and all dose changes during the 
study  must be recorded on the Dosage Administration Record CRF.
6.6.[ADDRESS_1162267] access. Upon receipt, PDR001 should be stored according to the instructions 
specified on the drug labels.
6.6.3 Study drug compliance and accountability
[IP_ADDRESS] Study drug compliance
Compliance will be assessed by [CONTACT_1755]/or study  personnel at each patient visit and 
information provided by [CONTACT_5363]/or caregiver will be captured in the Drug 
Accountability  Form. This information must be captured in the source document at each patient 
visit.
Study  treatme nt will be administered to the patient by [CONTACT_8887]. Compliance will be 
assured by [CONTACT_837246]/her 
designee.

[COMPANY_001] Confidential Page 64
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
[IP_ADDRESS] Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatment according to local institutional drug accountability  processes. Drug 
accountability  will be noted by  [CONTACT_632759] .
At study close-out, and, as appropriate during the course of the study , the investigator will return 
all used and unused study  treatment, packaging, drug labels, and a copy  of the completed drug 
accountability  logto the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the investigator 
folder at each site.
6.6.[ADDRESS_1162268] party , as appropriate.
7 Visit schedule and assessments
7.1 Stud y flow and visit sch edule
Table 7-1lists all of the assessments and indicates with an “X”, the visits when they are 
performed. All data obtained from these assessments must be sup
ported in the patient’s source 
documentatio n. The table (“Categor y” column) indicates which assessments produce data to be 
entered into the clinical database (D) or remain in source documents only  (S).
No CRF will be used as a source document.
Screening/baseline evaluations must be performed ≤ [ADDRESS_1162269] and/or procedures should occur on schedule whenever 
possible. A visit window of +/- [ADDRESS_1162270] be performed +/-
1 week of the scheduled date of the assessment.

[COMPANY_001] Confidential Page 65
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Table 7-1 Visit evaluation schedule (applicable for all treatment regimens , duration of cy cle is adapted accordingly )
Screening Phase Treatment Phase Follow -up
Visit name
[CONTACT_837267]-
screening
Screening Cycle 1 Cycle 2 Cycle 3
Subsequent 
cycles
EoT
Safety F/U4
Disease 
Progression F/U
Survival F/U
Day of cycle -21 to -1 1 2 3 4 8 11 15 115 1 2 3 4 8 11 15 1
Obtain molecular pre -
screening Informed 
ConsentD7.1.1 . X7
Obtain Informed 
ConsentD7.1.2 . X
Demography D7.1.2.2 . X X
Inclusion/ exclusion 
criteriaD5.2and 
5.3.X
Medical History D7.1.2.2 . X
Diagnosis and extent 
of cancerD7.1.2.2 . X
EBV and MSI status (if 
applicable)D7.1.2.2 . X
EGFR, ALK, BRAF 
V600 status (if 
applicable)D7.1.2.2 . X
Prior antineoplastic 
therapyD7.1.2.2 . X
Prior/concomitant 
medications and non -
drug proceduresD7.1.2.2
and 6.4.X Continuous4

[COMPANY_001] Confidential Page 66
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Screening Phase Treatment Phase Follow -up
Visit name
[CONTACT_837267]-
screening
Screening Cycle 1 Cycle 2 Cycle 3
Subsequent 
cycles
EoT
Safety F/U4
Disease 
Progression F/U
Survival F/U
Day of cycle -21 to -1 1 2 3 4 8 11 15 115 1 2 3 4 8 11 15 1
Concomitant 
antineoplastic 
radiotherapyD6.4.3 . Continuous
Physical examination S7.2.2.1 . X X X X X X X X X
Height D7.2.2.3 . X
Weight D7.2.2.3 . X X X X X X
Vital signs D7.2.2.2 . X X X X X X X X X
Performance status D7.2.2.4 . X
Hematology D7.[IP_ADDRESS] . X X X X X X X X X
Chemistry D7.[IP_ADDRESS] . X X X X X X X X X
Coagulation D7.[IP_ADDRESS] . X
Urinalysis D7.[IP_ADDRESS] . X
Thyroid function D7.[IP_ADDRESS] . X X X X X X
Cytokines
(IFN-γ; IL -6)D7.[IP_ADDRESS] . X In case of a suspected cytokine release syndrome
Pregnancy test D7.[IP_ADDRESS] . X X X X X
S X4
HBV, HCV & HIV D [IP_ADDRESS].8 . X
Antineoplastic 
therapi[INVESTIGATOR_560022]7.1.6 . X X X

[COMPANY_001] Confidential Page 67
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Screening Phase Treatment Phase Follow -up
Visit name
[CONTACT_837267]-
screening
Screening Cycle 1 Cycle 2 Cycle 3
Subsequent 
cycles
EoT
Safety F/U4
Disease 
Progression F/U
Survival F/U
Day of cycle -[ADDRESS_1162271] 1.1 and as 
per irRC.D7.2.1 . X Every 8 weeks ± [ADDRESS_1162272] Cycle 1 Day 1 up to 40 weeks, then every 12 weeks ± 
1 week until progression of disease per irRC or patient withdrawal.
For disease progression f/u, every 8 weeks ± 1 week until 40 weeks, then every 12 weeks± [ADDRESS_1162273] to follow -up.
ECG D7.[IP_ADDRESS] . X As clinically indicated
Adverse events D8. X6Continuous
Collection of archival 
tumor sampleD7.2.4 . X, if 
neededX, if not 
collected 
at 
molecular 
pre-
screening
Collection of newly 
obtained tumor sampleD7.2.4 . X, if 
neededX, if not 
collected 
at 
molecular 
pre-
screeningX2

[COMPANY_001] Confidential Page 68
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Screening Phase Treatment Phase Follow -up
Visit name
[CONTACT_837267]-
screening
Screening Cycle 1 Cycle 2 Cycle 3
Subsequent 
cycles
EoT
Safety F/U4
Disease 
Progression F/U
Survival F/U
Day of cycle -21 to -1 1 2 3 4 8 11 15 115 1 2 3 4 8 11 15 1
Collection of newly 
obtained tumor sampleD7.2.4 . Optional sample collected upon disease progression, for patients who had a response 
to treatment (as determined by [CONTACT_093]).
Study Drug 
administrationD6.1.1 . i.v. every 2 weeks (potential alternative schedule, e.g. every 3 or 4 weeks).
PK sampling D7.2.3 . X X X X X X X X X X X X X X X X1X X8
Immunogenicity (IG) 
samplingD7.2.[ADDRESS_1162274] dose of study treatment with contacts at 30 -, 90-, and 150-day. After initiation of new antineoplastic therapy, only AEs/SAEs 
suspected to be related to study treatment will be collected. Pregnancy tests every month until the 150 -day safety follow -up; can be performed at home or at a local doctor’s 
office if the patient is not coming to the clinic. Concomitant medications collected unti l the [ADDRESS_1162275] only the molecular pre-screening Procedure Related SAEs.
7if written documentation of EGFR (for NSCLC indication), ALK (for NSCLC indication if negative for EGFR mutation) or BRAF V60 0 mutation (for melanoma indication) is 
unavailable.

[COMPANY_001] Confidential Page 69
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
7.1.[ADDRESS_1162276] sign the molecular pre-screening informed consent and provide a new tumor biops y 
sample (or archival biopsy  sample if new biops y is not possible), which will be locall y analyzed 
for mutational status or by a  N ovartis -designated laboratory  if a local laboratory  test is not 
feasible . Once the mutational status is confirmed by [CONTACT_837247], 
the patient may  begin the screening procedures.
The molecular pre-screening informed consent must be signe d prior to any study-related 
molecular pre -screening procedure.
To enter the screening phase of this study , patients must complete the molecular pre -screening 
assessment if written documentation of EGFR (for NSCL C indication), ALK (for NSCL C 
indication if negative for EGFR mutation) or BRAF V600 mutation (for melanoma indication) 
is unavailable. EGFR mutation -negative is defined as negative for exon 19 deletions and for the 
L858R mutation in EGFR at a minimum; however, if more extensive EGFR mutation testin g 
has been performed, the tumor must not harbor any known activating EGFR mutations in Exons 
18-21 in order to be considered EGFR mutation -negative.
7.1.2 Screening
The study  IRB/IEC approved informed consent form must be signed and dated before any 
screening procedures are performed, except for laboratory  and radiological evaluations 
performed as part of standard of care within the screening window.
Patients will be evaluated against study  inclusion and exclusion criteria and safet y assessments. 
For details of assessments, refer to Table 7-1. Screening assessments must be repeated if 
performed outside of the specified screening window ( Section 7.1).
[IP_ADDRESS] Informati on to be collected on screening failures
Patients who sign the molecular pre-screening informed consent and/or the main study  informed 
consent, but fail to be started on study  treatment for any reason will be considered as screen 
failure and data will be h
andled in the same manner.
The screening failure will be entered on the Screening Phase Disposition Page.
The demographic information, informed consent, and Inclusion/Exclusion pages must also be 
completed for Screen Failure patients. No other data will beentered into the clinical database 
for patients who are screen failures, unless the patient experienced a SAE during screening (see 
Section 8.2 for SAE reporting details). For molecular pre-screening failures, only SAEs 
possibly  related to a study  procedure will be reported (i.e., tumor biopsy ).
[IP_ADDRESS] Patient demographics and other baseline characteristics
Data to be collected will include general patient demographics, relevant medical history  and 
current medi cal conditions, diagnosis and extent of tumor, details of prior anti-neoplastic 
treatments, prior medication, procedures, significant non-drug therapi[INVESTIGATOR_632725] .

[COMPANY_001] Confidential Page 70
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
For patients with breast cancer, ER, PR and HER2 status will be collected. For patients with 
Gastric cancer and esophageal adenocarcinoma, the MSI status and the EBV status will be 
collected. For patients with CRC, the MSI status will be collected. If the EBV or the MSI status 
determination is not performed routinel y as part of the patient standard follow -up, they will 
need to be determined locally  during screening. In the phase II part of the study , for patients 
with NSCLC, the EGFR and ALK mutatio n status will be collected; for patients with melanoma, 
the BRAF V600 mutation status will be collected. Patients must not have a tumor with a 
mutation on these markers to be eligible, but the status of these markers must be known to 
determine the eligibil ity of the patient (Section 5.2 ). For patients with anaplastic thyroid cancer, 
BRAF V600 mutation status will be collected but is not required to determine eligibility  to the 
study .
Therefore, if the EGFR, ALK (if applicable) or BRAF V600 status is not known, it will need to 
be determined at molecular pre -screening as applicable at a local laboratory , or by  a [COMPANY_001]
-
designated laboratory  if a local laboratory  test is not feasible.
7.1.3 Treatment period
A treatment cycle is defined as 28 days for the Q2W and Q4W regimens and 21 days for the 
Q3W regimen, for the purposes of scheduling procedures and evaluations. Please refer to Table 
7-1for details of the timing of required assessments and Section 7.1 for visit windows.
Patients will be treated until they experience unacceptable toxicity , progressive disease per irRC 
and/or treatment is
discontinued at the discretion of the investigator or the patient, as described 
in Section 7.1.[ADDRESS_1162277] make every  effort 
(e.g. telephone, e -mail, letter) to determine the primary  reason for this decision and record this 
information in the patient’s chart and on the appropriate CRF pages. They may be considered 
withdrawn if they state an intention to withdra w, fail to return for visits, or become lost to 
follow -up for an y other reason.
The investigator should discontinue study  treatment for a given patient if, on balance, he/she 
believes that continuation would be detrimental to the patient’s well -being.
Study treatment may  be discontinued if any  of the following occur:
Adverse event
Lost to follow -up

[COMPANY_001] Confidential Page 71
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Physician’s decision
Progressive disease per irRC (not per RECI ST)
Study  terminated by  [CONTACT_456]
Subject/guardian decision
Protocol deviation
Technical problem s
Study  treatment must be discontinued if any  of the following occur:
Death
Pregnancy
At the time patients discontinue study  treatment, a visit should be scheduled as soon as possible, 
and within [ADDRESS_1162278] dose of study  drug or within 14 days of the decision to 
permanentl y discontinue study  treatment, at which time all of the assessments listed for the 
EOT visit will be performed (Table 7-1). If the decision to withdraw the patient occurs at a 
regularl y scheduled visit, that visit may become the EOT visit rather than having the patient 
return for an additional visit. An End of Treatment Phase Disposition CRF page should be 
completed, giving the date and reason for stoppi[INVESTIGATOR_5314]. 
End of 
treatment/Premature withdrawal visit is not considered as the end of the study .
Patients who discontinue study  treatment should NOT be considered withdrawn from the study . 
They  should return for the assessments indicated in Section 7.1.6. If the y fail to return for these 
assessments for unknown reasons, every effort (e.g. telephone, email, letter) should be made to 
contact [CONTACT_15026] 
7.1.7. If a patient discontinues study  treatment, but 
continues study  assessments, the patient remains on study  until such time as he/she completes 
protocol criteria for ending stud y assessments.
Patients who transfer into another study  or an alternative treatment option to continue provision 
of study  treatment will perform the end of treatment procedures.
[IP_ADDRESS] Replacement policy
Phase I dose escalation part:
Patients will not be replaced on study . However, if a patient is considered to be non -evaluable 
for the Dose -Determining Safet y Set (DDS), enrollment of a new patient to the current cohort 
will be considered if there is less than the required number of evaluable patients. Enrollment of 
new patients may be considered until at least 
the minimum number or at most the maximum 
number of evaluable patients is achieved within the cohort. Minimum and maximum numbers 
of evaluable patients per cohort are defined in Section 6.2.3 .
Phase II expansion part:
During the phase II expansion part no replacements will be needed.

[COMPANY_001] Confidential Page 72
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
7.1.[ADDRESS_1162279]:
Does not want to participate in the study  anymore, 
Does not allow further collection of personal data.
In this situation , the investigator must make every  effort (e.g. telephone, e-mail, letter) to 
understand the primary  reason for the subject’s decision to withdraw his/her consent and record 
this information.
Study  treatment must be discontinued and no further assessments conducted , and the data that 
would have been collected at subsequent visits will be considered missing .
Further attempts to contact [CONTACT_632761].
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table.
[COMPANY_001] will continue to keep and use collected study  information (including any data resulting 
from the anal ysis of a subject’s samples until their time of withdrawal) according to applicable 
law.
For US and Japan: All b iological samples not yet analyzed at the time of withdrawal may  still 
be used for further testing/analy sis in accordance with the terms of this protocol and of the 
informed consent form.
For EU and RoW: All biological samples not yet anal yzed at the time of the withdrawal will no 
longer be used, unless permitted by  [CONTACT_1289]. They will be stored according to applicable 
legal requirements.
7.1.[ADDRESS_1162280]. If the 150
-
day safety evaluation is conducted by [CONTACT_648], samples do not need to be collected. Data collected 
should be added to the Adverse Events CRF, the antineoplastic therapi[INVESTIGATOR_837230], the Conc omitant Medications CRF, Biomarker blood sample CRF, and 
PK CRFs. For PK samples and Biomarker samples collection schedule is outlined in 
Section 7.2.3 and Section 7.2.4 respectivel y. For female patients of child bearing potential, 
pregnancy  tests will be performed as outlined in Section [IP_ADDRESS].7.
Patients who discontinue study  treatment for any reason other than death, disease progression 
per irRC, clinical progression, lost to follow -
up, consent withdrawal, start of new cancer therap y 
or study  termination, also should return for tumor evaluation assessments and should not be 
considered withdrawn from the study  until 80% of the patients in each disease group of the 

[COMPANY_001] Confidential Page 73
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
phase II part have had progression of disease or discontinued the study  for any reason. If patients 
refuse to return for these visits or are unable to do so, every  effort should be made to contac t 
them or a knowledgeable informant by [CONTACT_837248]. Once the Follow up for Disease progression period ended, the End of Post 
treatment Phase disposition CRF should be completed.
Upon completion of the 150-day  follow up or/and disease progression follow up, patients will 
be followed for survival every 3 months (can be done b y telephone call) until death or until the 
end of the stud y is reached, unless they withdraw consent or are lost to follow -
up.
Antineopla stic therapi[INVESTIGATOR_632727] -up period.
For patients who transfer to another clinical study  or an alternative treatment option to continue 
provision of study  treatment, as described in Section 4.3, the follow - up for 150-day safety, 
disease progression and survival will not be performed.
7.1.[ADDRESS_1162281] to follow -up
For patients whose status is unclear because they  fail to appear for study  visits without stati ng 
an intention to withdraw consent, the investigator should show "due diligence" by [CONTACT_15027], family  or family  physician as agreed in the informed consent and by [CONTACT_15028], e.g. dates of telephone calls, 
registered letters, etc. A patient should not be considered lost to follow -up until due diligence 
has been completed. Patients lost to follow up should be recorded as such on the appropriate 
Disposition CRF.
7.2 Assessment ty pes
7.2.1 Efficac y assessments
Tumor response will be determined locall y according to two sets of criteria:
1.RECI ST v1.1 ( Appendix 1 )
2.irRC ( Appendix 2 )
The local invest igator’s assessment will be used for the analy sis of response according to both 
RECI ST 1.1 and irRC, and for treatment decision making (study  discontinuation due to PD as 
per irRC). During the course of the study , [COMPANY_001] may  decide to have a central revi ew of the 
radiological assessments performed. In such case, the investigator’s staff will be instructed on 
how to send data from these radiological assessments to a Contract Research Organization 
(CRO) for central review when needed.
At screening, all patients will undergo CT with i.v. contrast of the chest, abdomen and pelvis. 
If there is clinical evidence of disease in the neck, a CT with i.v. contrast of the neck will also 
be performed. MRI should only be used to evaluate sites of disease that are not adequatel y 
imaged b y CT. If a patient is intolerant of iodine -based contrast agents, CTs may be performed 
without contrast. MRI may be used to evaluate sites of disease where a CT without i.v. contrast 
is not adequate. Visible skin lesions and easily  palpable subcutaneous tumors may be measured 

[COMPANY_001] Confidential Page 74
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
by [CONTACT_217969] a ruler or calipers. Ultrasound should not be used to measure 
sites of disease. See Table 7 -2for further details.
Tumor assessments will be performed at the following time points:
Screening
Every  8 weeks ± [ADDRESS_1162282] C ycle 1 Day 1 up to 40 weeks, then every 12 
weeks ± 1 week until progression of disease per irRC or patient withdrawal. After EOT, 
during disease progression f/u, every  8 weeks ± 1 week until 40 weeks, then every  12 
weeks ± [ADDRESS_1162283] to 
follow -up.
PR or CR, per both RECIST 1.[ADDRESS_1162284] 4 weeks.
At the End of Treatment, if a scan was not conducted within 30 day s prior to End of 
Treatment
Disease progression follow -up should be performed as described in Section 7.1.6.
Table 7
-2 Disease assessment collection plan
Procedure Screening/Baseline During Treatment/Follow-up
CT or MRI
with contrast 
enhancement
(Chest, Abdomen, Pelvis)Mandated During treatment, before EOT: Every 8 weeks 
± 1 week until completion of 40 weeks, then 
every 12 weeks ± 1 week until progression of 
disease per irRC or patient withdrawal.
After EOT, during disease progression f/u, 
every 8 weeks ± 1 week until 40 weeks, then 
every 12 weeks ± [ADDRESS_1162285]/MRI of chest, abdomen, 
and pelvis
Any other procedure allowed as per RECIST 1.1 guidelines ( Section 14.1)
7.2.2 Safety  and tolerability assessments
Safety  will be monitored by [CONTACT_217970], vital signs, body height and weight, 
performance status, hematology , chemistry , thyroid function, pregnancy , ECG, as well as 
collecting of the AEs at every visit. For details on AE collection and reporting, refer to Section 
8.
[IP_ADDRESS] Physical examination
Physical examination will be performed according to Table 7
-1 .
At Screening and Cycle 1 Day 1, prior to PDR001 infusion, a complete physical examination 
will be performed and will include the examination of general appearance, skin, neck (including 

[COMPANY_001] Confidential Page 75
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities and 
neurologica l. If indicated based on medical history and/or symptoms, rectal, external genitalia, 
breast, and pelvic exams will be performed.
From Cycle 1 Day 8 onwards, a short physical examination will be performed. A short physical 
exam will include the examination of general appearance, vital signs (blood pressure [BP] and 
pulse) and bod y sites as directed b y symptoms.
Significant findings that were present prior to the signature [CONTACT_632789]. Significant new findings that begin or worsen after 
informed consent must be recorded on the Adverse Event CRF page.
[IP_ADDRESS] Vital signs
Vital signs (bod y temperature, pulse rate, blood pressure) must be performed before dosing and 
as indicated in Table [ADDRESS_1162286] ed as unscheduled assessment.
[IP_ADDRESS] Height and weight
Height in centimeters (cm) or inches and body  weight (to the nearest 0.1 kilogram [kg], or to 
the nearest 0.1 
pound, in indoor clothing, but without shoes) will be measured as indicated in 
Table 7-1.
[IP_ADDRESS] Performance status
ECOG performance status will be assessed according to Table 7 -1and Table 7 -3.
Table 7
-3 ECOG performance status
Grade ECOG Status
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature (e.g., light house work, office work)
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more 
than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
[IP_ADDRESS] Laboratory  evaluations
All laboratory  parameters assessed for safety purposes will be evaluated locally . Refer to Table 
7-4for a summary  of the parameters to be evaluated according to Table 7-1. On days of PDR001 
dosing, samples for these parameters will be collected prior to the infusion of PDR001.
More frequent evaluations may be performed at the investigator’s discretion if medicall y 
indicated; results should be recorded as unscheduled laboratory  assessments.
[COMPANY_001] will be provided with a copy of the laboratory  certification and tabulation of the normal 
ranges for each parameter required. In addition, if at any time a patient has laboratory 

[COMPANY_001] Confidential Page 76
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
parameters obtained from a different outside laboratory , [COMPANY_001] must be provided with a copy 
of the certification and a tabulation of the normal ranges for that laboratory .
Table [ADDRESS_1162287] Name
[CONTACT_157131], Hemoglobin, Platelets, W hite blood cells with Differential (Basophils, Eosinophils, 
Lymphocytes, Monocytes, Neutrophils)
Chemistry Albumin, Alkaline phosphatase, ALT (SGPT), AST (SGOT), Bicarbonate, Calcium, Chloride, 
Sodium, Potassium, Creatinine, Glucose
Magnesium, Inorganic Phosphate, Total Bilirubin (also measure direct and indirect bilirubin if 
total bilirubin is > grade 1), Blood Urea Nitrogen (BUN) or Urea
Coagulation Prothrombin time (PT) or International normalized ratio [I NR]), activated partial thromboplastin 
time (APTT)
Urinalysis Macroscopic Panel (Dipstick) (Bilirubin, Blood, Glucose, Ketones, pH, Protein, Specific 
Gravity, W hite Blood Cells)
Thyroid Free T4, TSH
Cytokines IFN-γ; IL -6
Virology HBV, HCV, HIV
[IP_ADDRESS].1 Hematology
Hematology  panel outlined in Table 7-4will be performed as per the assessment schedule in 
Table 7-1.
[IP_ADDRESS].2 Clinical chemistry
Clinical chemistry panel outlined in Table 7-4will be performed as per the assessment schedule 
in Table 7
-1.
[IP_ADDRESS].3 Coagulation
Coagulation panel outlined in Table 7-4will be performed as per the assessment schedule in 
Table 7
-1.
[IP_ADDRESS].4 Urinalysis
Urinaly sis panel outlined in Table 7-4will be performed as per the assessment schedule in Table 
7-1.
[IP_ADDRESS].5 Thyroid function
Thyroid function panel outlined in 
Table 7-4 will be performed as per the assessment schedule 
in Table 7-1.
[IP_ADDRESS].6 Cytokines
Samples for the cytokine panel outlined in Table 7-4will be collected at the following time 
points:
Screening

[COMPANY_001] Confidential Page 77
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
On an ad -hoc basis in case a patient has an adverse event suspected to be a cy tokine 
release sy ndrome ( Table 7 -1). In such case, this assessment should be performed at the 
following time points:
a.within 5 hours (or as soon as possible) after the occurrence of the adverse event
b.
one week after the occurrence of the adverse event.
Samples for cytokine panel at screening will be stored below -70°C. The samples will be 
analyzed retrospectivel y in batches, locall y. The analy sis of the samples will be done only for 
patients who experienced an adverse event suspected to be a cytokine release syndrome and had 
follow -up samples collected.
[IP_ADDRESS].[ADDRESS_1162288] dose. 
During the study  (Day 1 of each cycle starting with Cycle 2) a serum or urine pregnancy  test 
must be performed. At End of Treatment, a serum pregnancy  test must be performed. A urine 
pregnancy  test should be performed every  month during and at the end of the safety  follow -up 
period (i.e. [ADDRESS_1162289] dose of PDR001). If the patient is not coming to the clinic 
during the safet y follow -up, it can be performed at home or at a local doctor’s office, and the 
results will be communicated to the site staff. These follow -up pregnancy tests will be recorded 
only in the source documentation, not in the CRF.
[IP_ADDRESS].8 Virology
Virology  panel outlined in Table 7 -
4will be performed as per the assessment schedule in Table 
7-1.
[IP_ADDRESS] Cardiac as sessments
[IP_ADDRESS].1 Electrocardiogram (ECG)
A standard 12 lead ECG will be performed as per the assessment schedule in Table 7
-1and 
Table 7-5. Blood samples sc heduled at the same time point should be taken after the ECGs are 
completed. For the Screening only one ECG per visit is required. Unscheduled visits can be 
either one ECG or in triplicate based on investigator's choice on which is most appropriate.
Table 7-[ADDRESS_1162290] primary  CSR cut-off date is reached, ECGs will not be reviewed by [CONTACT_11378] .

[COMPANY_001] Confidential Page 78
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Clinically  significant abno rmalities present at screening should be reported on the Medical 
History  CRF page. New or worsened clinicall y significant findings occurring after informed 
consent must be recorded on the Adverse Events CRF page. All eligibility  and patient 
management decisions should be made based on the local reading of the ECG.
7.2.3 Pharmacokinetic and immunogenicity  assessments
The following PK parameters will be determined for PDR001 using non-compartmental 
methods: Cmax, Tmax, AUC0 -tlast (Cycle 1 and Cycle 3), time to last measurable 
concentration (Tlast), t1/2, and the accumulation ratio of PDR001. Possible relationships 
between PK and PD variables, efficacy  and/or selected toxicities may be explored, as 
appropriate.
The data will be analy zed using WinNonlin Phoenix (Phars ight Corporation; Mountain View, 
CA).
PK profiles to assess PK properties of PDR001 will be collected from all enrolled patients. For 
patients enrolled in the phase I dose escalation part and five patients per disease group 1a, 2, 3 
and 4 in the phase II p art and 15 patients in disease group 1b in the phase II, the full PK profile 
will be collected. For all other patients, an alleviated PK sampling schedule is planned. Please 
refer to Table 7
-6and Table 7 -7for details on PK and IG sample collections.
If the dosing of Cycle 3 Day 1 is delay ed, the PK sampling for the full PK profile should be 
delay ed accordingl y to match the scheduled time points for cy cle 3 as outlined in Table 7 -6and 
Table 7-7. PK and IG samples will be collected also at the End of Treatment Visit and in the 
event of a clinically  significant AE (such as infusion reaction/anaph ylaxis) or if IG is suspected. 
After the first primary  CSR data cut -off date is reached, no additional PK and IG samples will 
be collected for the patients still on
-going on the study .
 
 
 
 

[COMPANY_001] Confidential Page 79
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Table 7-6 Pharmacokinetic blood collection log [Dose escalation (all patients) 
and phase II part (5 per dise ase group (1a, 2, 3 and 4) and 15 patients 
in group 1b)]
Cycle Day Scheduled Time Point (h)** Anal ytesPK 
Sample 
NoIG 
Sample 
No*
[ADDRESS_1162291] dose§(± 5 min) mAb [ADDRESS_1162292] dose (± 2h) mAb [ADDRESS_1162293] dose (± 8h) mAb [ADDRESS_1162294] dose (± 8h) mAb [ADDRESS_1162295] dose (± 8h) mAb [ADDRESS_1162296] dose (± 24h) mAb [ADDRESS_1162297] dose (±24h) (Pre -dose of next 
dose for Q2W  schedule)mAb 8
2 1 Predose of cycle 2
(672h ± 48h post dose for Q4W  schedule, 
504h ± 48h post dose for Q3W schedule)mAb and 
IG9 [ADDRESS_1162298] dose§(± 5 min) mAb [ADDRESS_1162299] dose (± 2h) mAb [ADDRESS_1162300] dose (± 8h) mAb [ADDRESS_1162301] dose (± 8h) mAb [ADDRESS_1162302] dose (± 8h) mAb [ADDRESS_1162303] dose (± 24h) mAb [ADDRESS_1162304] dose (± 24h) (Pre -dose of next 
dose for Q2W  schedule)mAb 108
4 1 Predose of Cycle 4
(672h ± 48h post dose for Q4W  schedule, 
504h ± 48h post dose for Q3W  schedule)mAb and 
IG109 [ADDRESS_1162305] dose§(± 5 min) mAb [ADDRESS_1162306] dose§(± 5 min) mAb 302
EOT mAb and 
IG5000 6000
150 days Safety follow -up mAb X
Unscheduled mAb, IG 1001+ 2001+
*IG samples are to be collected together with PK samples at the same time.
§after completion of the infusion.
**PK samples are to be collected from the arm opposite from infusion site, or alternatively, infusion site will need 
to be flushed with 10 mL of saline.

[COMPANY_001] Confidential Page 80
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Table 7-7 Abbreviated pharmacokinetic blood collection log [phase II part (all 
other patients)]
Cycle Day Schedul ed Time Point (h)** Anal ytesPK 
Sample 
NoIG 
Sample 
No*
[ADDRESS_1162307] dose§
(± 5 min)mAb [ADDRESS_1162308] dose (± 2h) mAb [ADDRESS_1162309] dose (± 8h) mAb [ADDRESS_1162310] dose (±24h) (Pre -dose of next dose 
for Q2W  schedule)mAb 8
2 1 Predose of cycle 2
(672h ± 48h post dose for Q4W  schedule, 
504h ± 48h post dose for Q3W schedule)mAb and IG [ADDRESS_1162311] dose§
(± 5 min)mAb [ADDRESS_1162312] dose (± 2h) mAb [ADDRESS_1162313] dose (± 8h) mAb [ADDRESS_1162314] dose (± 24h) (Pre -dose of next dose 
for Q2W  schedule)mAb 108
4 1 Predose of Cycle 4
(672h ± 48h post dose for Q4W  schedule, 
504h ± 48h post dose for Q3W schedule)mAb and IG [ADDRESS_1162315] dose§
(± 5 min)mAb [ADDRESS_1162316] dose§
(± 5 min)mAb 302
EOT mAb and IG 5000 6000
150 days Safety follow -up mAb X
Unscheduled mAb and IG 1001+ 2001+
*IG samples are to be collected together with PK samples at the same time.
§after completion of the infusion.
**PK samples are to be collected from the arm opposite from infusion site, or alternatively, infusion site will need 
to be flushed with 10 mL of saline.
[IP_ADDRESS] Bioanaly tics
Bioanal ysis for pharmacokinetic studies will employ  three validated assays:
1.The assay  to quantify  PDR001 will be a validated LCMS assay .
2.The assay  to quantify  and assess the IG will be a validated homogeneous ELISA.

[COMPANY_001] Confidential Page 81
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
[IP_ADDRESS] PK, IG samples handling, labeling, and shippi[INVESTIGATOR_3931]
A total of 4 mL of blood will be collected at each time point. For time points when PDR001 
(mAb) PK and IG are to be measured, a single blood sample wil l be collected for both IG and 
PDR001 PK.  
Blood samples should be collected from the arm opposite from the investigational drug 
infusion, or from another site. PK and IG sampl eswill be separated in aliquots and will be 
stored frozen until analysis.  
 Please see the CPDR001X2101 Laboratory Manual for detailed instructions about 
collection, handling and shipment of samples. The actual collection date and time of each 
sample will be entered on the Pharmacokinetics/Immunogenicit y  Blood Collection eCRF 
pages.
7.2.[ADDRESS_1162317] of the PDR001 at the molecular and 
cellular level as well as to determine how changes in the markers may relate to exposure and 
clinical outcomes.  
While the goal of the biomarker assessments is to provide supportive data for the clinical study , 
there may be circumstances when a decision is made to stop a collection, or not perform or 
discontinue an analysis due to either practical or strategic reasons (e.g., inadequate sample 
number, issues related to the quality  of the sample or issues related to the assay  that preclude 
analysis, impossibility  to perform correlative analy ses, etc.). Therefore, depending on the 
results obtained during the study , sample collection analysis may be omitted at the discretion 
of [COMPANY_001].
The sample collection information must be entered on the appropriate sample collection log 
eCRF page(s) and requisition form(s). Detailed instructions for the collection, handling, and 
shipment of tumor samples are outlined in the laboratory  manual for the study .
Table 7-8 Biomarker sample collection plan
Sample Ty pe Visit/ Time point Volume Marker Purpose
Tumor
Samples
Archival tumor 
sample
And
newly obtained 
pre-treatment 
tumor biopsyAt molecular pre -
screening (if needed) 
or ScreeningArchival tumor block
or a minimum of 15 
newly cut slides from 
archival paraffin tumor 
tissue
if archival tumor is not 
available, the newly 
obtained formalin fixed 
tumor biopsy in 
ethanol (3 -6 passes) 
as outlined below will 
be used.BRAF V600 
(melanoma and 
anaplastic thyroid 
cancer ), EGFR 
and/or ALK 
(NSCLC)
 
IHC markers as 
required 
(anaplastic thyroid 
cancer patients 
only)Assess molecular 
status (if molecular 
status for the 
indication is unknown 
and local laboratory 
test is not feasible)
 
Confirm diagnosis of 
anaplastic thyroid 
cancer (anaplastic 
thyro id cancer 
patients only)

[COMPANY_001] Confidential Page 82
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Sample Ty pe Visit/ Time point Volume Marker Purpose
Newly obtained 
formalin fixed tumor 
biopsy in ethanol (3 -6 
passes) 
 
 
 Pharmacodynamic 
(Baseline)

[COMPANY_001] Confidential Page 83
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
[IP_ADDRESS] Tumor collection
[IP_ADDRESS].1 Potential predictive markers
The status of several immune checkpoint targets and cell populations may be analyzed in 
archival tumor tissue.  
 
Other related biomarkers may also be analy zed from this sample, depending on sample 
availability , resources, and patient’s outcomes and as new scientific evidence becomes available.
Submission of an archival tumor sample is requested and will be collected from all patients at 
screening if not collected at molec ular pre -screening. A corresponding pathology report should 
be included along with the archival sample. If an archival tumor sample is not available, a newl y 
obtained tumor sample is to be obtained and provided as a formalin- fixed biopsy  in ethanol. An 
additional archival sample may be requested if the original sample provided is of insufficient 
quantity  or qualit y to complete the planned analysis.
[IP_ADDRESS].2 Pharmacodynamic markers
Pharmacody namic assessments in tumor samples
Newl y obtained pre-and on-treatment pairedtumor samples at Screening/baseline if not 
collected at molecular pre-screening and between Cycle [ADDRESS_1162318]+Ki67+ T cells, IFN-, IL-18 and CXCL11 (IFN -induced CCK) 
expressing cells suggests rapid expansion of a pre-existing primed immune response, whilst the 
decrease of IL-6 is indicative of reduced my eloid -derived suppressor cells (MDSC) ( Herbst et 
al 2014 ) (Tumeh et al 2014 ) (Powles et al 2014
).
 
Additional markers or methods may be utilized if indicated by [CONTACT_837249].
After the first primary CSR data cut-off date is reached, no additional samples for 
pharmacod ynamic assessments will be collected.

[COMPANY_001] Confidential Page 84
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
[IP_ADDRESS].3 Assessment of mechanisms of resistance to PDR001
Mechanisms of resistance to PDR001 will be explored with pretreatment, on-treatment and 
disease progression tumor samples (arch ival tumor samples and/or newly  collected tumor 
biopsy  samples, as appropriate). Optimal sample collection for the study  of resistance will 
include a newl y obtained tumor biopsy  taken at screening if not collected at 
molecular pre-
screening , a biops y taken during therapy  (approximately  start of cycle 3, alternative times are 
likely  to be acceptable after discussion with [COMPANY_001]), and a biopsy taken at the time of disease 
progression / resistance, ideally  from a growing lesion if it is safe and feasible forthe patient. 
If a patient has not provided an on therapy  tumor sample, they may still be considered for a 
biopsy  at resistance. Duplicate samples will not be collected: specificall y, any baseline and on 
therap y biopsies provided for pharmacod ynamic assess ments will meet the needs of study ing 
resistance to treatment. The sample at time of disease progression should be collected only from 
patients who have had a response to treatment as defined b y the investigator. This may  include 
a notable period of stable disease and need not require a RECI ST or irRC -defined response. 
The tumor sample at progression of disease should be obtained within [ADDRESS_1162319] be entered on the appropriate CRF page(s).
 
 
 
 
 
 
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 85
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Other assessments
No additional tests will be performed on patients entered into this study .
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and repor ting
An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable 
sign(s), s ymptom(s), or medical condition(s) that occur after patient’s signed informed consent 
has been obtained.
For patients with unknown molecular status and who sign the molecular pre-screening ICF, 
AEs which occur after signature [CONTACT_837268] 8.2 and are reported to be causally  related with study 
procedures (e.g. an invasive procedure such as biopsy ). Once the main study  ICF is signed, all 
AEs per the descriptions below will be captured in the Adverse Event CRF.
Abnormal laboratory  values or test results occurring a fter informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically  significant, 
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Adverse events that begin or worsen after informed consent should be recorded in the Adverse 
Events CRF. Conditions that were alread y present at the time of informed consent should be 
recorded in the Medical History  page of the patient’s CRF. Adverse event monitoring should 
be continued for at least [ADDRESS_1162320] -treatment antineoplastic therapy , only AEs suspected to be related to study  treatment 
will be col lected in the Adverse Events CRF. Adverse events (including lab abnormalities that 
constitute AEs) should be described using a diagnosis whenever possible, rather than individual 
underly ing signs and symptoms. When a clear diagnosis cannot be identified, each sign or 
symptom should be reported as a separate Adverse Event.
Adverse events will be assessed according to the Common Terminology  Criteria for Adverse 
Events (CTCAE) version 4.03. If CTCAE grading does not exist for an adverse event, the 
severit y of mild, moderate, severe, and life -threatening, corresponding toGrades 1 -4, will be 
used. CTCAE Grade 5 (death) will not be used in this study  but is collected as a seriousness 
criterion; information about deaths will be collected through a Death form.
The occurrence of adverse events should be sought by  [CONTACT_105]-directive questioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study . Adverse events also may be detected when they are voluntee red by [CONTACT_102] 
(subject) during the screening process or between visits, or through physical examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be evaluated 
to determine:
1.The severit y grade (CTCAE Grade 1-4)
2.Its duration (Start and end dates)

[COMPANY_001] Confidential Page 86
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
3.Its relationship to the study  treatment (Reasonable possibility  that AE is related: No, Yes)
4.Action taken with respect to study  or investigational treatment (none, dose adjusted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable)
5.Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
6. Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/re solved with sequelae, fatal, unknown)
7.Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.[ADDRESS_1162321] been met
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y is given, this action should be recorded on the Adverse Event CRF.
Once an adverse event is detected, it should be followed until its resolution or until it is judged 
to be permanent, and asses
sment should be made at each visit (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  treatment, the interventions 
required to treat it, and the outcome.
Progression of malignancy  (including fatal outcome s), if documented by [CONTACT_5371] (for example, as per irRC or as per RECI ST), should not be reported as a serious adverse 
event.
Adverse events separate from the progression of malignancy  (example, deep vein thrombosis 
at the time of progress ion or hemopty sis concurrent with finding of disease progression) will 
be reported as per usual guidelines used for such events with proper attribution regarding 
relatedness to the drug.
8.1.[ADDRESS_1162322] abnormalities
[IP_ADDRESS] Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therap y or require 
changes in study  treatment), should be recorded on the Adverse Events CRF. Whe never 
possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low 
hemoglobin). Laboratory 
abnormalities that meet the criteria for Adverse Events should be 
followed until they have returned to normal or an adequate explanati on of the abnormality  is 
found. When an abnormal laboratory or test result corresponds to a sign/s ymptom of an already 
reported adverse event, it is not necessary  to separately  record the lab/test result as an additional 
event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not automatically 
indicate a SAE unless it meets the definition of serious as defined below and/or as per 
investiga tor’s discretion. A dose hold or medication for the lab abnormality  may be required b y 
the protocol in which case the lab abnormality  would still, by [CONTACT_108], be an adverse event 
and must be reported as such.

[COMPANY_001] Confidential Page 87
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
8.2 Serious adverse events
8.2.1 Definitions
Serious a dverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardize s the patient or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Requires inpatient hospi[INVESTIGATOR_1081],
Note that hospi[INVESTIGATOR_837231]:
Routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
Social reasons and respi[INVESTIGATOR_5316]’s 
general condition
Note that treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_15517] a nd involves an event not fulfilling an y of the definitions of a SAE given above 
is not a serious adverse event.
Progression of underly ing malignancy  is not reported as an adverse event if it is clearl y 
consistent with the suspected progression of the under lying cancer as defined by [CONTACT_632763]. Hospi[INVESTIGATOR_632729] a serious adverse event.
Clinical sy mptoms of progression may  be reported as adverse events if the symptom cannot be
determined as exclusively  due to the progression of the underly ing malignancy , or does not fit 
the expected pattern of progression for the disease under study .
Symptomatic deterioration may  occur in some patients. I n this situation, progression is evident
in the patient’s clinical symptoms, but is not supported by [CONTACT_217976]. Or, the 
disease progression is so evident that the investigator may elect not to perform further disease 
assessments. In such cases, the determination of clinical progress ion is based on symptomatic 
deterioration. These determinations should be a rare exception as every  effort should be made 
to document the objective progression of underl ying malignancy .
If there is any  uncertainty  about an adverse event being due only  to the disease under study , it 
should be reported as an AE or SAE.
8.2.2 Reporting
For patients with unknown molecular status and who sign the molecular pre-screening ICF, 
SAE collection will start upon signing the molecular pre-screening ICF. SAEs will only be 
reported if the event is suspected to be causall y related to a study  procedure as assessed by  [CONTACT_121984] 88
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
investigator (e.g. an invasive procedure such as biopsy). SAEs will be followed until resolution 
or until clinically  relevant improvement or stabilization. If themain ICF is not signed 
(molecular pre-screen failure), SAE collection ends [ADDRESS_1162323] be reported as follow -up to the original 
epi[INVESTIGATOR_5319] 24 hours of the investigator receiving the follow -up information. An SAE 
occurring at a different time interval or otherwise considered completely  unrelated to a 
previously  reported one should be reported separately  as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there ismore than one study  treatment), complete the SAE Report 
Form in English [For Japan only: complete the SAE report form in English or Japanese] , 
and submit the completed form within [ADDRESS_1162324] as the original SAE Report. Each re-
occurrence, complication, or progression of the original event should be reported as a follow -
up to that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or withdrew from study  participation.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the [COMPANY_001] study  treatment, an oncology  [COMPANY_001] 
Chief Medical Office and Patient Safety  (CMO & PS)department associate may urgentl y 
require further information from the investigator for Health Authorit y reporting. [COMPANY_001] may 
need to issue an Investigator Notification (I N), to inform all investigators involved in any  study 
with the same drug that this SAE has been reported. Suspected Unexpected Serious Adverse 

[COMPANY_001] Confidential Page 89
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Reactions (S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant 
ethics committees in accordance with Directive 2001/20/EC or as per national regulatory 
requirements in participating countries.
8.[ADDRESS_1162325] 
be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications. After the mother has provided consent, the newborn will be 
followed- up for 12months.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by [CONTACT_15040]  (CMO & PS). 
Pregnancy  follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the investigational treatment and any pregnancy  outcome. Any 
SAE experienced during pregnancy  must be reported on the SAE Report Form.
8.[ADDRESS_1162326] investigator teleconferences on a regular basis during the 
study. Further, during the phase I part of the study  [COMPANY_001] and the investigators will meet 
at 
the end of each treatment cohort to discuss and evaluate all of the gathered safet y data. At the 
dose escalation teleconference the clinical course (safet y info rmation including both DLTs and 
all CTCAE Grade [ADDRESS_1162327] cycle of treatment, and PK data) for 
each patient in the current dose cohort will be described in detail. Updated safet y data on other 
ongoing patients, including da ta in later cy cles, will be discussed as well.
Dose escalation decisions will be based on a clinical synthesis of all relevant available data and 
not solely  on DLT information. Selection of the actual dose for the next cohort of patients will 
be guided by [CONTACT_632765], the Bayesian linear model describing the relationship 
between dose and PDR001 exposure, and a medical review of relevant clinical, PK and 
laboratory  data. [COMPANY_001] and the investigator parties must reach a consensus on whether to 
declar e MTD, escalate the dose any further, or whether to de-escalate and/or recruit an 
additional cohort of patients at the current dose level ( Section 10.4.2 and Section 10.7).
During 
the phase II part of the study  Individual patient data will be reviewed on an ongoing 
basis and aggregate safety  data and the primary  endpoint will be monitored quarterly  by [CONTACT_121984] 90
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
study  team across the duration of the trial. The data review and analysis will be based on the 
available investigator reported data in the clinical database at that time ( Section 10.7 ).
[ADDRESS_1162328] of the following:
What protected health information (PHI) will be collected from subject s in this study
Who will have access to that information and wh y
Who will use or disclose that information
The rights of a research subject to revoke their authorization for use of their PHI .
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability  to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g. has the subject 
experienced an y new or worsened AEs) at the end of their scheduled study period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made available only to authorized personnel who have 
completed prerequisite training.
Prior to entering key sensitive personally  identifiable information (Subject Initials and exact 
Date of Birth), the system will prompt site to verify  that this data is allowed to be collected. If 
the site indicates that country  rules or ethics committee standards do not permit collection of 
these items, the system will not solicit Subject Initials. Year of birth will be solicited (in the 
place of exact date of birth) to establish that the subject satisfies protocol age requirements and 
to enable appropriate age -related normal ranges to be used in assessing laboratory  test results.
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, [COMPANY_001] 
personnel (or designated CRO ) will review the protocol and CRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the CRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on CRFs must be traceable to source documents in the 

[COMPANY_001] Confidential Page 91
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the CRF entries. [COMPANY_001] monitoring standards require full verification for the 
presence of informed consent, adherence to the inclusion/exclusion criteria and doc umentation 
of SAEs. Additional checks of the consistency  of the source data with the CRFs are performed 
according to the stud y-specific monitoring plan.
9.3 Data collection
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter 
the data required by [CONTACT_5374] (eCRF). The eCRFs 
have been built using fully validated secure web-enabled software that conforms to [ADDRESS_1162329] been trained. Automatic validation programs check for data discrepancies in the eCRFs 
and, allow modification or verification of the entered data b y the investigator staff.
The Principal Investigator [INVESTIGATOR_20115], 
accurate, and that entry and updates are performed in a timely  manner.
PK and biomarker (blood, serum, plasma and/or tissue) samples obtained during the course of 
the study  will be collected from the Investigator sites and analyzed by a [COMPANY_001] designated 
laboratory , contracted central laboratories, or local laboratories. ECG data collected during the 
study  until the CSR cut-off date is reached will be reviewed and processed centrall y by a 
specialist CRO . During the course of the study , [COMPANY_001] may decide to have a central review 
of the radiological assessments performed. In such case, the investigator’s staff will be 
instructed on how to send data from these radiological assessments to a Contract Resear ch 
Organization (CRO) for central review when needed. Designated investigational site staff will 
enter the information required by [CONTACT_217981]/or designated 
laboratory  requisition forms. Field monitors will review the eCRFs and laboratory  paper 
requisition forms for accuracy  and completeness and instruct site personnel to make any 
required corrections or additions. One copy of the requisition form will be forwarded to each 
analytical laboratory  with the respective sample(s) by[CONTACT_837250]; and one cop y will be retained at the investigational site.
9.4 Database management and quality  control
For studies using eCRFs, [COMPANY_001] personnel (or designated CRO) will review the data ente red 
by [CONTACT_5375] . Electronic data queries stating the nature 
of the problem and requesting clarification will be created for discrepancies and missing values 
and sent to the investigational site via the EDC system. Designated investigator site staff are 
required to respond promptly  to queries and to make any  necessary  changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification 
system. Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .

[COMPANY_001] Confidential Page 92
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Samples and/or data will be processed centrall y and the results will be sent electronically to 
[COMPANY_001] (or a designated CRO).
For EDC studies, after database lock, the investigator will receive a CD -ROM or paper copi[INVESTIGATOR_5322].
[ADDRESS_1162330] to demographic and baselin e characteristics, 
efficacy  observations and measurements, safety  observations and measurements, and all 
relevant PK and PD measurements.
Categorical data will be presented as contingency  tables (frequencies and percentages). For 
continuous data summary  statistics of mean, standard deviation, median, minimum, and 
maximum will be presented.
The primary  clinical reporting of the dose escalation ,and each of the Phase II indications will 
take place when all patients in the escalation, or relevant indication have discontinued, or 
completed at least six cycles of treatment. This time can be indication specific, therefore a single 
primary  CSR, or several primary  CSRs may be prepared which may include more than one 
indication. Additional data from patients continui ng treatment after the data cutoff for the 
corresponding primary  CSR will be reported in a final CSR once all patients have completed 
study (Section 4.3).
The following rules will be followed for reporting results unless stated otherwise:
For the phase I, cohorts treated with the same dose level and schedule of PDR001 will be 
pooled into a single treatment group. All summaries, listings, figures and analy ses will be 
performed b y treatment group.
For the phase II, all summaries, listings, figures and anal yses will be performed by  [CONTACT_837251]. Patients from the expansion phase will be classified 
according to the group to which they  were assigned at baseline based on the disease type 
and regimen. The different groups are:
Group 1a: NSCL C, RP2D regimen
Group 1b: NSCL C, 300 mg Q3W regimen
Group 2: Melanoma, RP2D regimen
Group 3: Triple negative breast cancer, RP2D regimen
Group 4: Anaplastic th yroid cancer, RP2D regimen
Note: patie nts from the dose escalation and the expansion will not be pooled in any analyses 
unless otherwise specified.
Screen failure 
patients are those who signed the informed consent, but never started the study 
treatment for any reason. For these patients, the eCRF data collected will not be included in 
analyses, but will be reported in the clinical study report (CSR) as separate listings.

[COMPANY_001] Confidential Page 93
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
10.1 Analysis sets
10.1.1 Full A nalysis Set
The Full Anal ysis Set (FAS) includes all patients who received at least one dose of PDR001. 
Patients will be analy zed according to the planned treatment (regimen). The FAS will be used 
for all listings of raw data. Unless otherwise specified, the FAS will be the default analy sis set 
used for all analy ses.
10.1.[ADDRESS_1162331]-baseline safety  assessment. The statement that a patient 
had no AEs (on the AE eCRF) constitutes a valid safet y assessment. Patients will be classified 
accordi ng to treatment received, where treatment received is defined as:
1.The treatment assigned if it was received at least once, or
2.The first treatment received when starting therap y with study  treatment if the assigned 
treatment was never received.
The safet y set will be used for the safet y summary of the study.
10.1.3 Per-Protocol Set
The Per Protocol Set (PPS) consists of a subset of FAS patients in the phase II part who meet 
the following criteria:
Presence of at least one measurable lesion at baseline according to RECI ST 1.1 as per 
Appendix 1 .
At least [ADDRESS_1162332] -baseline tumor assessments (unless disease progression is observed before 
that time)
Have not been previously  treated with PD -1-or PD -L1-directed therapy
Patients will be classified according to treatment received.
The PPS will be used in the phase II part of the study  only  and will define the patients used in 
the sensitivity  anal ysis of the primary  endpoint (see Section 
10.4.4). If the PPS and the FAS are 
identical, then anal yses described b y the PPS below will not be performed.
10.1.[ADDRESS_1162333] met the minimum 
exposure criterio n if he/she received at least 70% of the planned dose of PDR001 at each time 
of dosing during C ycle 1.
Patients who do not experience DLT during the first cycle are considered to have sufficient 
safet y evaluations if they have been observed for ≥ [ADDRESS_1162334] enough safety data to conclude that a 
DLT did not occur.

[COMPANY_001] Confidential Page 94
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Patients who do not meet these minimum safet y evaluation requirements will be regarded as 
ineligible for the DDS and an additional patient may  be recruited (see Section [IP_ADDRESS]).
10.1.5 Dose -determining pharmacokinetic set
The dose-determining pharmacokinetic set (DDP) consists of all patients in the Phase I dose 
escalati on part who have received at least one dose of PDR001 during Cycle [ADDRESS_1162335] 
sufficient PK data in cy cle 3 to evaluate the AUC (0-336h).
10.1.6 Pharmacokinetic analy sis set
The pharmacokinetic analy sis set (PAS) consists of all patients who have at least one blood 
sample providing evaluable PK data. The PAS will be used for summaries of PK concentration 
data, and PK parameters, except that DDP will be used in the dose -exposure analy sis at Phase 
I.
Note: Patients may  be removed from the estimation of certain PK par ameters on an individual 
basis depending on the number of available blood samples. These patients will be identified at 
the time of anal ysis.
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline data will be listed in detail, and summarized descriptively  by 
[CONTACT_837252] I part or b y Group in the phase II part.
10.3 Treatments (study  treatment, concomitant therapi[INVESTIGATOR_014], 
compliance)
The actual dose and duration in day s of PDR001 treatment as well as the dose intensity  (actual 
dose received/actual duration) and relative dose intensity (the ratio of dose intensity to planned 
dose/planned duration) will be listed and summarized by [CONTACT_837253]. Categories for relative dose intensity  of PD R001 will be specified as < 0.5, ≥ 
0.5 - < 0.75, ≥ 0.75 - < 0.9, ≥ 0.9 - < 1.1 and ≥ 1.1. The number and proportion of patients within 
each category  will be presented by  [CONTACT_1570].
These per-patient summaries will, in turn, be summarized using descri ptive statistics by 
[CONTACT_1570].
Concomitant medications and significant non-drug therapi[INVESTIGATOR_837232].
The reason for discontinuation fro
m treatment will be summarized and listed, along with dates 
of first and last study  drug, duration of exposure to PDR001 and date of discontinuation for 
each patient.
Compliance with the protocol will be assessed by [CONTACT_632776]. Protocol deviations will be identified prior to database lock and will be 
listed and summarized.

[COMPANY_001] Confidential Page 95
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
10.4 Primary  objective
Phase I
To estimate the recommended phase 2 dose (RP2D) or the maximum tolerated dose (MTD) for 
PDR001.
Phase II
To estimate the anti -tumor activity  of PDR001.
10.4.1 Variable
Phase I
Dose recommendation and estimation of the RP2D/MTD during the dose -escalation part of the 
study  will be supported by  [CONTACT_235307] -primary  variables:
The AUC (0-336h)after first dose of treatm ent at cy cle 3 for patients in the DDP.
The incidence of DLTs in the first cy cle of treatment for patients in the DDS.
Phase II
The primary  variable is the ORR, defined as the proportion of patients with a best overall 
response of complete response (CR) orpartial response (PR) based on local Investigator 
assessment, as defined in RECI ST 1.1. The true ORR will be estimated upon observed ORR, 
using a Bay esian anal ysis.
10.4.2 Statistical hy pothesis, model, and method of analy sis
Phase I
The dose escalation will be guided by  [CONTACT_837254]001 exposure and the DLT rate. Details of the 
guidelines for dose escalation and determination of the RP2D/MTD are provided in Section 
6.2.3.
Dose -
exposure relationships will be estimat ed for PDR001 via the following dose-exposure 
Bayesian linear model, in order to guide the dose recommendation to targeted exposures of 
PDR001.
log(AUC i) = log(α) + β log(d i/d*) + ε i, α>0, β>0
where i = 1, …, n is the i-th patient in the study , diis the d ose received by [CONTACT_941] i -th patient, AUC i
is the area under the curve of PDR001 concentrations for the i -th patient during the interval of 
0 to 336 hours in cycle 3. The residual error εifollows a Normal distribution with mean of 0 
and variance σ2. Doses arerescaled as di/d* with reference dose d*=3 mg/kg of PDR001. The 
prior distributions for parameters log(α), log(β), and σ are derived based on published summary 
data of Nivolumab and Pembrolizumab ( Rober t 2014 , Deeks 2014 ).
From the estimation of the Bayesian linear model, the following posterior summaries will be 
derived for each dose level of PDR001:

[COMPANY_001] Confidential Page 96
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Mean, median, standard deviation and 95% -credible interval for the exposure of PDR001, 
as measured b y AUC (0-336h)after first dose of treatment at cycle 3.
The probability  that the true AUC (0-336h)after first dose of treatment at cycle 3 achieves the 
target exposure, as measured b y AUC (0-336h)≥ 1000 µg*day/mL.
For further details on the Bay esian linear model including the prior specification for the model 
parameters along with simulation results that show the operating characteristics of the Bayesian 
linear model design, refer to Appendix 3 -Section 14.3.1.
If the dose-
exposure does not follow a linear relationship in the natural log scale, non-linear 
curves will be assessed as detailed in the RAP.
In addition to the Bay esian linear model, an adaptive, 2 parameter Bay esian logistic regression 
model (BLRM) will be used to estimate the probability  of a DLT in the first c ycle of treatment. 
The prior distributions for the BLRM are derived based on available pre-clinical data and 
clinical data for Nivolumab an d Pembrolizumab.
For further details on the BLRM model including the model 
structure, the prior specification 
for the model parameters, and examples of hy pothetical decisions that may  be followed during 
the dose escalation, refer to Appendix 3 -Section 14.3.2 .
After each cohort of patients, the posterior distributions for the probabilities of DLT rates at 
different dose levels are obtained. The results of this analy sis are summarized in terms of the 
probab ility that the true rate of DLT at each dose level lies in each of the following categories:
[0,16%) under -dosing
[16%,33%) targeted toxicity
[33%,100%] excessive toxicity
Dose recommendation will also be guided by [CONTACT_111886], which mandates the dose 
for the next cohort to have less than 25% chance of excessive toxicity . The final estimate of the 
RP2D/MTD will also satisfy  this condition.
In case of changes in dosing schedule during dose -escalation, a BLRM of the same functional 
form described in Appendix 3will be used to estimate the dose-DLT relationship for each 
schedule based on a newly derived prior incorporating the historical trial data and the on -study 
data from previous schedule. At each time the model is updated, all available information on 
the dose -DLT relationship from all explored dosing schedules will be used. In order to account 
for between schedule variability  in the assessment of a given dosing schedule, the DLT data 
obtained from other explored dosing schedules will be down -weighted; details are described in 
the RAP.
Phase II
A Bayesian design will be used in order to estimate ORR within each group (Group 1a: NSCL C 
treated at the RP2D regimen (i.e. Q4W), Group 1b: NSCL C treated at a Q3W regimen, Group 
2: melanoma, Group 3: TNBC, Group 4: anaplastic thyroid 
cancer), and it will be used to 
provide inferential summaries (e.g., mean, median, interval probabilities) in relation to the 
patient population for each of the disease groups (defined in Section 5.2). Sample size for each 

[COMPANY_001] Confidential Page 97
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
treatment group is provided in Section 4.[ADDRESS_1162336] be specified. 
For the current study , the prior clinical assumption for PDR001 in the selected patient 
populations is used in 
order to derive a minimally informative unimodal Beta prior distribution 
that reflects the level of uncertaint y around ORR before starting the current trial 
(Neuenschwander et al 2008 ). The prior mean ORR is set to be equal to 20% and the parameters 
of the minimally  informative Beta prior distribution of ORR have been set up as follows:
a/(a+b) = 0.2
a = 0.25
b = 1.0
At primary  analysis, this prior distribution will be updated with all the data available from the 
patients in the FAS. See sample size estimation in Section 10.8.
Groups 1a, 1b and 2 (NSCLC and melanoma): Estimates of the ORR for each group along 
with mean, median, standard deviation, and 95% credible intervals and the interval probabilities 
for the true ORR lying 
within [0%, 15%), [15%, 20%), [20%, 30%), [30%, 50%) and [50%, 
100%] will be presented.
If the observed ORR is equal to or greater than 20% (i.e. ≥ 12 responses (CR or PR) out of 60
patients) for NSCL C and 30% (i.e. ≥ 18 responses (CR or PR) out of 60 patients) for melanoma, 
then this will be considered as preliminary  evidence of activity  of PDR001 in the respective 
Groups.
Note that for a sample size of n = 60,
for NSCL C (group 1a or 1b), if the observed ORR is 20% then the posterior probability  of 
true ORR greater than 15% is 83.7%.
for melanoma, if the observed ORR is 30% then the posterior probability  of true ORR 
greater than 20% is 96.2%.
Group 3 (TNBC): Estimates of the ORR along with mean, median, standard deviation, and 95% 
credible intervals and the interval probabilities for the true ORR lying within the intervals stated 
below will be presented.
[0, 10%) unacceptable efficacy
[10, 20%) limited efficacy
[20, 30%) moderate effi cacy
[30%, 100%] clinically  relevant efficacy .
Group 4 (Anaplastic thyroid cancer): Estimates of the ORR along with mean, median, 
standard deviation, and 95% credible intervals and the interval probabilities for the true ORR 
lying within the intervals stated below will be presented.
[0, 5%) unacceptable efficacy
[5, 10%) limited efficacy
[10, 20%) moderate efficacy
[20%, 100%] clinically  relevant efficacy .

[COMPANY_001] Confidential Page 98
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
10.4.3 Handling of missing values/censoring/discontinuations
Patients in the dose escalation part who are ineligible for the DDS will be excluded from the 
primary  anal ysis, although their data will be used for all remaining analy ses.
Patients in the phase II part who have Best Overall Response (BOR) of UNK or NA will be 
considered as a treatment failure in the primary  analy sis of ORR. Patients with individual scans 
of UNK or NA will be handled according to RECIST 1.1 as per Appendix 1 .
Other missing data will simply  be noted as missing on appropriate tables/listings.
10.4.4 Supportive analy ses
As a supportive analysis of the primary  endpoint for Phas e II, a Bayesian hierarchical model 
with a flexible exchangeability design will be applied on ORR including data from all 
indications. Exchangeability  of indication parameters will be assessed; for the Bayesian 
methodology  and an application to binary  data see Thall (2003) and Chugh (2009) .
Moreover, the primary  analy sis of the phase II will be repeated using the PPS.
If there is a substantial number ofpatients receiving palliative radiotherap y, sensitivity  analyses 
of ORR will be performed where the tumor response assessments are censored at the time of 
palliative radiotherap y. BOR is determined by [CONTACT_837255]  (including on-treatment palliative radiotherap y of non-target or target 
lesions), whichever occurs first.
Additional supportive  analyseswill be conducted to support the 
primar y 
objective, if appropriate, and the details of these analy ses will be defined in the RAP.
10.5 Secondary  objectives
10.5.1 Key secondary  objective(s)
Not applicable.
10.5.2 Other secondary  efficacy  objectives
Tumor response will be determined per local investigators’ assessment. Secondary  efficacy 
endpoints will include BOR, ORR, PFS, DCR and DOR for Phase I and Phase II. In Phase II, 
BOR and ORR will be defined and analy zed based on tumor assessment by  [CONTACT_837256] 14.[ADDRESS_1162337] of these two assessments is then the date of confirmed progression.  For 

[COMPANY_001] Confidential Page 99
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
patients who have ended treatment without a valid confirmation assessment, for the purposes 
of anal ysis the single asse ssment of PD will be treated as a confirmed PD.  A single assessment 
of PD followed by a subsequent assessment of SD or better will be considered as a pseudo -
progression, and will not be used for anal ysis.
Individual lesion measurements and overall response assessments will be listed by  [CONTACT_632779]. BOR, PFS, DCR and DOR will be listed by  [CONTACT_4676].
The following analyses will be presented b y treatment group for patients treated in the phase II 
part.  
BOR will be summarized
ORR (irRC) 
and DCR will be summarized with an accompan ying [90%] exact binomial 
confidence interval (CI).
For PFS the survival function will be estimated using the Kaplan -
Meier (KM) product 
limit method and display ed graphically . Median duration, with a two- sided 90% CI, and 
25thand 75thpercentiles ( Brookmey er 1982 ,Klein 1997) will be presented.  KM estimates 
of survival proportions at specified time po ints, along wit h corresponding 90% CIs 
(Greenwood’s formula , Kalbfleisch 1980 )will also be provided. 
For DOR, KM estimates may  be provided if sufficient numbers of patients respond.
BOR will be listed and summarized, and ORR and DCR will be summarized with an 
accompan ying 90% exact binomial CI  by [CONTACT_632780] I 
part. 
10.5.3 Safety  objectives
[IP_ADDRESS] Analysis set and groupi[INVESTIGATOR_63964] y analyses, the safet y set will be used. All listings and tables will be presented by 
[CONTACT_1570].
The overall observation period will be divided into three mutually  exclusive segments:
1.pre-treatment period: from day  of patient’s informed consent to the day  before first dose 
of study  medication
2.
on-treatment period: from day  of first dose of study  medication to 30days after last dose 
of study  medication
3.post-treatment period: starting at day  [ADDRESS_1162338] administration of PDR001, adverse events (including serious adverse events), and new 
antineoplastic therapi[INVESTIGATOR_217917] a period of [ADDRESS_1162339] -
treatment periods ( Section [IP_ADDRESS] ).

[COMPANY_001] Confidential Page 100
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
[IP_ADDRESS] Adverse events (A Es)
Primary  summary  tables for AEs will include only  AEs that started or worsened during the on -
treatment period. Additional select summaries will be produced using all relate dAEs that 
started or worsened during the combined on -treatment and post -treatment periods.
The incidence of treatment -emergent AEs (new or worsening from baseline) will be 
summarized by [CONTACT_5379]/or preferred term, severity  (based on CTCAE grades), 
type of AE, relation to study  treatment.
Serious adverse events, non-serious adverse events and adverse events of special interest (AESI) 
will be tabulated. 
All deaths (on- treatment and post -treatment) will be summarized.
All AEs, deaths and serious adverse events (including t hose from the pre and post-treatment 
periods) will be listed and those collected during the pre-treatment and post-treatment period 
will be flagged.
[IP_ADDRESS] Laboratory  abnormalities
For laboratory  tests covered by [CONTACT_15059] (CTCAE) 
version 4.03 the study ’s biostatistical and reporting team will grade laboratory  data accordingl y. 
For laboratory  tests covered by  [CONTACT_3989], a Grade 0 will be assigned for all non -missing values 
not graded as 1 or higher. Grade 5 will not be used.
For laboratory  tests where grades are not defined by [CONTACT_3989], results will be graded by [CONTACT_15060]/normal/high classifications based on laboratory  normal ranges.
The following by-treatment summaries will be generated separatel y for hematology and 
biochemistry  tests:
Shift tables using CTCAE grades to compare baseline to the worst on -treatment value.
Listing of all clinicall y relevant laboratory data with values flagged to show the 
corresponding CTCAE grades and the classifications relative to the laboratory  norma l 
ranges.
 
 
[IP_ADDRESS] Other safety  data
ECG
shift ta ble baseline to worst on- treatment result for overall assessments
listing of ECG evaluations for all patients with at least one abnormality .
Vital signs
Definitions of notably  abnormal results will be specified in the RAP.
shift table baseline to worst on-treatment result

[COMPANY_001] Confidential Page 101
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
[IP_ADDRESS] Supportive analy ses for secondary  objectives
Not applicable.
[IP_ADDRESS] Tolerability
Tolerability  of study  treatment will be assessed by  [CONTACT_217993]. Reasons for dose interruptions anddose reductions will be 
listed by  [CONTACT_111895] (see Section 10.3 ).
10.5.[ADDRESS_1162340] measurable concentration sampling time (tlast) (m ass x 
time x volume -1)
AUCinf The AUC from time zero to infinity (mass x time x volume -1)
AUCtau The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x 
volume -1)
Cmax The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration 
after single dose administration (mass x volume -1)
Tmax The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug 
concentration after single dose administration (time)
T1/2 The elimination half -life associated with the terminal slope ( z) of a semi logarithmic 
concentration -time curve (time). Use qualifier for other half-lives
CL The total body clearance of drug from the plasma (volume x time -1)
Vz The apparent volume of distribution during terminal phase (associated with z) (volume)
PAS will be used in all pharmacokinetic data analy sis and PK summary  statistics, except for 
the dose -exposure analy sis at Phase I.
Pharmacokinetic variables:
The following pharmacokinetic parameters will be determined by [CONTACT_632782]-
compartmental method(s) for PDR001:
AUCinf, AUC0
-336h, Cmax, Tmax, T1/2, CL  and Vz.
Biofluid concentrations will be expressed in mass per volume units. All concentrations below 
the limit of quantitation or missing data will be reported as such in the concentration data listings. 
Concentrations below the limit of quantitation will be treated as zero in summary  statistics.
Descriptive statistics of all pharmacokinetic parameters will include arithmetic and geometric 
mean, media n, SD, and CV, geometric CV, minimum and maximum. Zero concentrations will 
not be included in the geometric mean calculation. Since Tmax is generally evaluated by a 
nonparametric method, median values and ranges will be given for this parameter.
Summary  statistics will be presented for PDR001 serum concentrations at each scheduled time 
point. Descriptive graphical plots of individual serum concentration versus time profiles and 
mean concentration versus time profiles will be generated.

[COMPANY_001] Confidential Page 102
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Missing concentration values will be reported as is in data listings. Concentration values below 
Lower limit of quantitation will be handled as zero in summary  statistics, and reported as is in 
data listings. An y missing pharmacokinetic parameter data will not be imputed.
 
 
 
 
Dose proportionality
The analy sis of dose proportionality  will be conducted for AUC and Cmax of PDR001 using a 
power model on log-transformed scale. The log-transformed PK parameters will each be 
regressed onto a fixed factor for log (dose). The 90% confidence interval (CI) of the slope for 
each PK parameter will be computed from the model and presented in a summary  table.
Immunogenicity  –exposure and/or adverse event relationship
The concentration/adverse event –immunogenicity  relationship will be explored graphicall y, 
tabulated and, if appropriate, characterize a relationship between the changes from screenin g 
immunogenicit y presence and serum concentration of PDR001.
In addition, the potential correlation between immunogenicity  and other endpoints (major safet y, 
efficacy ,  bioma rker parameters) may  be evaluated.

[COMPANY_001] Confidential Page 103
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
10.7 Interim analy sis
No formal interim anal yses are planned.
However, in phase I, the dose-escalation design foresees that decisions based on the current 
data are taken before the end of the study . More precisel y, after each cohort in the dose 
escalation part, the next dose wil l be chosen depending on the observed data (based on safety , 
tolerability , PK, PD and efficacy  data, guided by [CONTACT_632783], the Bayesian linear model of dose-exposure relationship and recommendations 
from participati ng investigators). Details of this procedure and the process for communication 
with I nvestigators are provided in Section 6.2.3.
Data from patients in the phase II part will be reviewed on an ongoing basis to monitor the 
safet y and tolerability of the RP2D in that part of the study.

[COMPANY_001] Confidential Page 104
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
10.[ADDRESS_1162341] 
six patients at the RP2D/MTD level, as described in Section 6.2.3. Multiple cohorts may be 
sequentially  enrolled to the same dose level. Additional cohorts may be opened to enroll patients 
at any previously  tested dose level on or below the estimated RP2D/MTD for further elaboration 
of safet y and pharmacokinetic parameters as required. At least [ADDRESS_1162342] reasonable operating characteristics 
relating to its MTD recommendation. RP2D recommendation may be made with fewer patients.
Phase II
Nivolumab achieved an ORR of 19% in patients with NSCL C based on the Phase III 
CheckMate057 trial with 292 patients treated with Nivolumab ( Paz-Ares 2015). Therefore an 
ORR of 20% will be used as the reference ORR for patients with NSCLC treated with PDR001 
in the Phase II part of the study .
Nivolumab achieved an ORR of 32% in patients with melanoma based on the Phase III 
CheckMate0
37 trial with 120 patients treated with Nivolumab ( Weber 2015). Therefore an 
ORR of 30% will be used as the reference ORR for patients with melanoma treated with 
PDR001 in the Phase II part of the stud y.
There is limited published ORR data for patients with TNBC treated with nivolumab or 
pembrolizumab. Pembrolizumab achieved an ORR of 18.5% in patients with TNBC based on 
a small study (n= 32 patients treated with pembrolizumab (Nanda 2014 ). Therefore, an ORR of 
20% will be used as the reference ORR for patients with TNBC treated with PDR001 in the 
Phase II part of the stud y.
There are no published response data identified at time of this protocol develop
ment for 
anaplastic th yroid cancer patients treated with nivolumab or pembrolizumab.
Approximately  60 patients per disease group will be enrolled to Groups 1a, 1b and 2, which 
include the two “benchmark diseases” NSCLC and melanoma. Approximately  40 patien ts will 
be enrolled to Group 3 (TNBC). Approximately  10 patients will be enrolled to Group 4 
(anaplastic thyroid cancer). The relativel y small size of the anaplastic thyroid cancer group 
reflects the low 
prevalence of this disease; this group may be increa sed in size to approximately  
40 patients based on feasibility  of enrollment and if PDR001 appears to be active in this disease. 
Further details on the patient population are provided in Section 5.2.
It is assumed that efficacy  will be claimed if 
observing an ORR of ≥ 20% (NSCL C), ≥ 30% 
(melanoma) and ≥ 20% (TNBC).The operating characteristics of the design are provided in 
Table 10-2. Specificall y:
If the true ORR is 10% for NSCL C (group 1a or 1b) (i.e. in the unacceptable efficacy  
range), the probability  of observing an ORR ≥ 20% is 1.5% (<5%).
If the true ORR is 15% for melanoma (i.e. in the unacceptable efficacy  range), the 
probability  of observing an ORR ≥30% is 0.2% (< 5%).

[COMPANY_001] Confidential Page 105
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
If the true ORR is 10% for TNBC (i.e. in the unacceptable efficacy  range), the probability  
of observing an ORR ≥ 20% is 4.2% (< 5%).
If the true ORR is 30% for NSCL C (group 1a or 1b) (i.e. in the clinicall y significant 
efficacy  range), the probability  of observing an ORR ≥ 20% is 97.1%.
If the true ORR is 40% for melanoma (i.e. in the clinically  significant efficacy  range), the 
probability  of observing an ORR ≥ 30% is 95.9%.
If the true ORR is 30% for TNBC (i.e. in the clinically  signif icant efficacy  range), the 
probability  of observing an ORR ≥ 20% is 94.5%.
Table 10-2 Operating characteristics of the design (probability  to declare 
efficacy )
Groups 1a and 1b:
NSCLC, n=60 per groupGroup 2:
Melanoma, n=60Group 3:
TNBC, n=40
True 
ORRProbability  to observe an 
ORR ≥ 20%Probability  to observe an ORR 
≥ 30%Probability  to observe an ORR 
≥ 20%
10% 1.5% 0.0% 4.2%
15% 18.1% 0.2% 24.4%
20% 55.1% 4.3% 56.3%
25% 85.2% 22.5% 81.8%
30% 97.1% 54.9% 94.5%
40% 100.0% 95.9% 99.8%
Table 10-3summarizes the 90% Credible Interval for the true ORR at each of the observed 
ORR for the four disease groups. The table shows that with observed ORR of 20% at the 
planned sample size for Group 1a/b, 30% for Group 2, 20% for Group 3, and 20% for Group 4, 
the lower bound of 90% CI is greater than 10% (the threshold of unacceptable efficacy  for 
NSCL C and TNBC), 15% (the thresh old of unacceptable efficacy  for m elanoma) and is around 
5%/11% for anaplastic thy roid cancer (n=10/40) accordingl y.
Table 10-3 Observed ORR and 90% Credible Interval
Groups 1a and 
1b:
NSCLC, n=60 
per groupGroup 2:
Melanoma, n=60Group 3:
TNBC, n=40Group 4:
Anaplastic 
thyroid cancer, 
n=10Group 4:
Anaplastic 
thyroid cancer, 
n=40
Observed 
ORR20% 30% 20% 10% / 20% 10% / 20%
90% CI of 
ORR[12.2%, 28.9%] [20.6%, 39.7%] [10.8%, 30.9%] [1.0%, 29%] / 
[4.7%, 41.5%][3.8%, 19%] / 
[10.8%, 30.9%]
10.9 Power for analy sis of key secondary  variables
Not applicable

[COMPANY_001] Confidential Page 106
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the e thical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigator is required 
to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study  in 
accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, 
[COMPANY_001] Clinical Quality  Assurance representatives, designated agents of [COMPANY_001], 
IRBs/IECs/REBs and regulatory  authorities as required.
11.3 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC/REB -approved informed consent or, if incapable of 
doing so, after such consent has been provided by a legally  acceptable representative of the 
patient. In cases where the patient’s representative gives consent, the patient should be informed 
about the study  to the extent possible given his/her understanding. Ifthe patient is capable of 
doing so, he/she should indicate assent by [CONTACT_18684] a separate assent form.
Informed consent must be obtained before conducting an y stud y-specific procedures (i.e. all of 
the procedures described in the protocol). The process of obtaining informed consent should be 
documented in the patient source documents. The date when a subject’s Informed Consent was 
actuall y obtained will be captured in their CRFs.
[COMPANY_001] will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by [CONTACT_5381]/IEC/REB, and a copy of the 
approved version must be provided to the [COMPANY_001] monitor after IRB/ IEC/REB approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patie nt will not reliably compl y, they 
should not be entered in the study .

[COMPANY_001] Confidential Page 107
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
 
 
 
 
 
11.4 Discontinuation of the study
[COMPANY_001] reserves the right to discontinue this study  under the conditions specified in the clinical 
study  agreement. Specific conditions for terminating the study  are outlined in Section 4.4.
11.5 Publication of study  protocol and results
[COMPANY_001] is committed to following high ethical standards for reporting study  results for its 
innovative medicine, including the timel y communication and publication of clinical trial 
results. [COMPANY_001] assures that the key design elements of this protocol will be posted on the 
publicly  accessible database, e.g. www.clinicaltrials.go v, before study start. I n addition, results 
of interventional clinical trials in adult patients are posted on www.novartisclinicaltrials.com, a 
publicly  accessible database of clinical study  results within 1 year of study  completion (i.e., 
LPLV), those forinterventional clinical trials involving pediatric patients within 6 months of 
study  completion.
[COMPANY_001] follows the ICMJE authorship guidelines (www.icmje.org) and other specific 
guidelines of the journal or congress to which the publication will be sub
mitted.
Authors will not receive remuneration for their writing of a publication, either directl y from 
[COMPANY_001] or through the professional medical writing agency . Author(s) may be requested to 
present poster or oral presentation at scientific congress; ho wever, there will be no honorarium 
provided for such presentations.
As part of its commitment to full transparency in publications, [COMPANY_001] supports the full 
disclosure of all funding sources for the study  and publications, as well as any actual and 
potential conflicts of financial and non-financial nature by [CONTACT_15064], including medical 
writing/editorial support, if applicable.
For the [COMPANY_001] Guidelines for the Publications of Results from [COMPANY_001] -
sponsored Research, 
please refer to www.novartis.com.
11.[ADDRESS_1162343] keepi[INVESTIGATOR_5324], in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional requirements 
for the protection of confidentiality  of subjects. As part of participating in a [COMPANY_001] -sponsored 
study , each site will permit authorized representatives of the sponsor(s) and regulatory agencies 
to examine (and when required by  [CONTACT_1289], to copy ) clinical records for the purposes of 
quality  assurance reviews, audits and evaluation of the study  safet y and progress.

[COMPANY_001] Confidential Page 108
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory  notes, memoranda, subjects’ diaries or evaluation 
checklists, pharmacy  dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_5117], microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, and subject files and records kept 
at the pharmacy , at the laboratories, and medico -technical departments involved in the clinical 
trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Principal I nvestigator. The study  case report form (CRF) is the primary  data collection 
instrument for the stud y. The investigator should ensure the accuracy, completeness, legibility, 
and timeliness of the data reported in the CRFs and all other required reports. Data reported on 
the CRF, that are derived from source documents, should be consistent with the source 
documents or the discrepancies should be explained. All data requested on the CRF must be 
recorded. Any missing data must be explained. Any change or correction to a paper CRF should 
be dated, initialed, and explained (if necessary ) and should not obscure the original entry . For 
electronic CRFs an audit trail will be maintained by  [CONTACT_5382]. The investigator should retain 
records of the changes and corrections to paper CRFs.
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by [CONTACT_5383]/or guidelines. The investigator/institution should take measures to prevent 
accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.
11.[ADDRESS_1162344] ensure anon ymity ofthe patients; patients must not be identified by [CONTACT_5384]. Signed informed consent forms and patient enrollment 
log must be kept strictl y confidential to enable patient identification at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by [CONTACT_5385].
11.9 Financial disclosures
Financial disclosures should be provided by [CONTACT_436702] - prior to study  start.

[COMPANY_001] Confidential Page 109
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
[ADDRESS_1162345] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_5386]/IEC/REB it cannot be implemented. All significant protocol 
deviations will be recorded and reported in the CSR.
12.[ADDRESS_1162346] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC/REB. Only 
amendments that are required for patient safet y may be implemented prior to IRB/IEC/REB 
approval. Notwithstanding the need for approval of formal protocol amendments, the 
investigator is expected to take any immediate action required for the safety  of any patient 
included in this study , even if this action represents a deviation from the protocol. In such cases, 
[COMPANY_001] should be notified of this action and the IRB/IEC at the study  site should be informed 
according to local regulations (e.g. [LOCATION_006] requires the notification of urgent safet y measures 
within 3 day s) but not later than 10 working days.

[COMPANY_001] Confidential Page 110
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
13 References (available upon request)
Bastman JJ, Serracino HS, Zh u Y (2016) Tumor -Infiltrating T Cells and the PD-[ADDRESS_1162347]  in Advanced Differentiated and Anaplastic Thy roid Cancer. J Clin Endocrinol 
Metab; 101(7):2863 -73.
Blank CU (2014) The perspective of immunotherapy : new molecules and new mechanisms of 
action in immune modulation. Curr Opin Oncol; 26:204-14.
Borghaei H , Paz-Ares L, Horn L, et al (2015) Nivolumab versus Docetaxel in Advanced 
Nonsquamous Non- Small -Cell L ung Cancer. N Engl J Med; 373(17):1627-39.
Brahmer JR, Ty kodi SS, Chow L QM, et al (2012) Safety and Activit y of Anti –PD-L1 
Antibody  in Patients with Advanced Cancer. N Engl J Med; 366:2455
-65.
Brahmer JR, L acchetti C, Schneider BJ et al (2018) Management of immune -related adverse 
events in patients treated with immune checkpoint inhibitor therapy : American Society  of 
Clinical Oncology clinical practice guideline. J Clin Onc ol; Epub ahead of print . 
Brookmey er R, Crowley  J (1982) A confidence interval for the median survival time.
Biometrics; 38:29 -41. 
Chugh R, Wathen JK, Maki RG, et al (2009) Phase II multicenter trial of Imatinib in 10 
histologic subty pes of sarcoma using a Bay esian hierarchical statistical model. J Clin Oncol;
27:3148
–53.
Creagan ET, Schaid DJ, Ahmann DL, et al (1990) Disseminated Malignant Melanoma and 
Recombinant Interferon: Analy sis of Seven Consecutive Phase II Investigations. J I nvest 
Dermatol; 95:188S –192S.
Creelan BC (2014) Update on immune checkpoint inhibitors in lung cancer. Cancer Control; 
21:80 -
9.
Deeks ED (2014) Nivolu mab: A review of its use in patients with malignant melanoma. 
Drugs; 74:1233-39.
Freeman G (2008) Structures of PD
-1 with its ligands: Sideway s and dancing cheek to cheek. 
Proc Natl Acad Sci [LOCATION_003]; 105:30.
Fyfe GA, Fisher RI, Rosenberg SA, et al (1996) Long -term response data for 255 patients 
with metastatic renal cell carcinoma treated with high -dose recombinant interleukin- 2 therapy . 
J Clin Oncol; 14:2410 -1.
Garon EB, Rizvi NA, Hui R, et al (2015) Pembrolizumab for the Treatment of Non -Small -
Cell L ung Cance r. N Engl J Med; 372:[ADDRESS_1162348] FA, Antonia SJ, et al (2014) First-line nivolumab (anti -PD-1; BMS -
936558, ONO -4538) monotherapy  in advanced NSCL C: Safety , efficacy , and correlation of 
outcomes with PD -L1 status. J Clin Oncol (Meeting A bstracts); 32(15s):8024.
Guerra A, Di Crescenzo V, Garzi A, et al (2013) Genetic Mutations in the Treatment of 
Anaplastic Th yroid Cancer: A Systematic Review. BMC Surg;13(Suppl 2):S44.
Haanen J BAG , Carbonnel F, Robert C, et al (2017) Management of toxiciti es from 
immunotherapy : ESMO clinical practice guidelines for diagnosis, treatment and follow -up. 
Ann Oncol; 28 :iv119-iv142.

[COMPANY_001] Confidential Page 111
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Hamid O, Carvejal RD (2013a) Anti -programmed death- 1 and anti -programmed death-ligand 
1 antibodies in cancer therap y. Expert Opin Bi ol Ther; 13:847 -61.
Hamid O, Robert C, Daud A, et al (2013b) Safet y and tumor responses with lambrolizumab 
(anti-PD-1) in melanoma. N Engl J Med; 369:134 –44.
Kalbfleisch JD, Prentice RL  (1980) The statistical anal ysis of failure time data. Wiley  series 
in probability  and statistics.
Keir ME, Butte MJ, Freeman GJ, et al (2008) PD- 1 and its ligands in tolerance and immunity . 
Ann Rev I mmunol: 26:677 –704.
Kirkwood JM, Harris JE, Vera R, et al (1985) A randomized study  of low and high doses of 
leukocy te alpha -
interferon in metastatic renal cell carcinoma: the American Cancer Societ y 
collaborative trial. Cancer Res; 45:863-71.
Klein JP, Moeschberger ML  (1997) Techniques for censored and truncated data. Springer 
Verlag.
Kolb HJ, Mittermüller J, Clemm C, et al (1990) Donor leukocy te transfusions for treatment of 
recurrent chronic m yelogenous leukemia in marr ow transplant patients. Blood; 76:2462-5.
Kunstman JW, Juhlin CC, Goh G, et al (2015) Characterization of the mutational landscape of
anaplastic thyroid cancer via whole -exome sequencing. Hum Mol Genet; 24(8):2318-29.
Mangsbo SM, Sandin L C, Anger K, et al (2010) Enhanced tumor eradication by  [CONTACT_632784] A-4 or PD -1 blockade with CpG therap y. J Immunother; 33:225 –35.
Mkrtichy an M , Najjar YG, Raulfs EC, 
et al (2011) Anti- PD-1 synergizes with 
cyclophosphamide to induce potent anti- tumor vaccine effects throug h novel mechanisms. 
Eur J I mmunol; 41:2977 –86.
Moreno HB, Ribas A (2015) 
Anti-programmed cell death protein- 1/ligand -1 therapy  in 
different cancers. Br J Cancer; 112:1421-7.
Motzer RJ, Rini BI , McDermott DF, et al (2015) Nivolumab for metastatic Renal Cell
Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol; 33:1430 -7.
Murphy  K (2011) Janeway ’s Immunobiology . 8thed; [LOCATION_001]: Garland Science.
Nanda R, Chow L, Dees E, et al (2014) A phase Ib study  of pembrolizumab (MK -3475) in 
patients with adva nced triple -negative breast cancer. San Antonio Breast Cancer S ymposium: 
Abstract S1-09.
NCCN Guidelines (version 2.2017): Thy roid Carcinoma .
NCCN Guidelines (version 1.2018): Management of immunotherapy- related toxicities 
(nccn.org/professionals/phy sician_gls/default.aspx#immunotherapy ).
Neff RL , Farrar WB, Kloos RT, et al (2008) Anaplastic thy roid cancer. Endocrinol Metab 
Clin North A m.2008 Jun;37(2):525-38.
Neuenschwander B, Branson M, Gsponer T (2008) Critical aspects of the Bay esian approach 
to phase I cancer trials. Statist Med, 2008; 27: 2420 -
39.

[COMPANY_001] Confidential Page 112
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Nivolumab US label; available at: 
accessdata.fda.gov/drugsatfda_docs/label/2014/125554lbl.pdf
Patnaik A, Kang SP, Tolcher AW, et al (2012) Phase I stud y of MK -3475 (anti- PD-1 
monoclonal antibody ) in patients with advanced solid tumors. J Clin Oncol (Meeting 
Abstracts); 30(15s):2512.
Paz-Ares L, Horn L, Borghaei H, et al (2015) Phase III, randomized trial (CheckMate 057) of 
nivolumab (NIVO) versus docetaxel (DOC) in avanced non -squamous cell (non- SQ) non-
small cell lung cancer (NSCL C). J Clin Oncol (Meeting Abstracts); 33(15s):LBA109.
Pembrolizumab US label; available at: 
accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf
Powles T, Eder JP, Fine GD, et al (2014) MPDL3280A (anti-PD-L1) treatment leads t o
clinical activity  in metastatic bladder cancer . Nature; 515:558-62.
Ribas A, Hodi S, Kefford R, et al (2014) Efficacy  and safet y of the anti -PD-1 monoclonal 
antibody  MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol (Meeting 
Abstracts); 32( 15s):LBA9000.
Riley  JL (2009) PD -1 signaling in primary  T cells. I mmunol Rev; 229:114-25.
Rizvi NA, Garon EB, Patnaik A, et al (2014) Safety  and clinical activit y of MK- 3475 as 
initial therapy  in patients with advanced non- small cell lung cancer (NSCLC). J Clin Oncol 
(Meeting Abstracts); 32(15s):8007.
Rizvi NA, Hellmann MD, Sry der A, et al (2015) Mutational landscape determines sensitivity  
to PD -1 blockade in non -small cell lung cancer. Science; 348:124.8.
Robert C, L ong GV, Brady  B, et al (2015) Nivolumab in Previously  Untreated Melanoma 
without BRAF Mutation. N Engl J Med; 372:320 -30.
Robert C, Ribas A, Wolchok JD, et al (2014) Anti- programmed -death -receptor -1 treatment 
with pembrolizumab in ipi[INVESTIGATOR_125]- refractory  advanced melanoma: a randomised dose -
compar ison cohort of a phase 1 trial. Lancet; 384:1109 -17.
Rosenblatt, J, Glotzbecker B, Mills H, et al (2011) PD -[ADDRESS_1162349] -011, anti -PD-
1 
antibody , enhances ex vivo T -cell responses to autologous dendritic cell/my eloma fusion 
vaccine. J I mmunother; 34:40 9–18.
Segal NH, Antonia SJ, Brahmer JR, et al (2014) Preliminary  data from a multi
-arm expansion 
study  of MEDI4736, an anti -PD-L1 antibody . J Clin Oncol (Meeting Abstracts); 
32(15s):3002.
Seiwert TY, Burtness B, Weiss J, et al (2014) A phase Ib study  of MK-3475 in patients with 
human papi[INVESTIGATOR_28597] (HPV) -associated and non -HPV –associated head and neck (H/N) 
cancer. J Clin Oncol (Meeting Abstracts); 32(15s):6011.
Taube JM, Klein A, Brahmer JR, et al (2014) Association of PD-
1, PD -1 Ligands, and Other 
Featu res of the Tumor Immune Microenvironment with Response to Anti
-PD-1 Therap y. Clin 
Cancer Res; 20:5064 -74.
Thall PF, Wathen JK, Bekele BN, et al (2003) Hierarchical Bay esian approaches to phase II 
trials in diseases with multiple subty pes. Stat Med; 22:763-80.

[COMPANY_001] Confidential Page 113
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Tiedje V, Ting S, Herold T, et al (2017) NGS Based I dentification of Mutational Hotspots for 
Targeted Therapy in Anaplastic Thyroid Carcinoma. Oncotarget; doi: 
10.[ZIP_CODE]/oncotarget.[ZIP_CODE].
Topalian SL , Hodi SF, Brahmer JR, et al (2012) Safet y, Activit y, and Immune Correlates of 
Anti–PD -1 Antibody  in Cancer. N Engl J Med; 366: 2443 - 54.
Topalian SL , Sznol M, McDermott DF (2014) Survival, Durable Tumor Remission, and 
Long -Term Safety  in Patients With Advanced Melanoma Receiving Nivolumab. J Clin Oncol; 
32:1020
-31.
Tumeh PC, Harview CL, Yearley  JH, et al (2014) PD -[ADDRESS_1162350], et al (2011) Natural Innate and Adaptive Immunity 
to Cancer. Ann Rev Immunol; 29:235 -71.
Wang W, Lau R, Yu D, et al (2009) PD -1 blockade reverses the suppression of melanoma 
antigen -specifi c CTL b y CD4+ CD25(Hi) regulatory  T cells. Int. Immunol. 21, 1065–77.
Weber JS, D’Angelo SP, Minor D, et al (2015) Nivolumab versus chemotherap y in patients 
with advanced melanoma who progressed after anti- CTL A-4 treatment (CheckMate 037): a 
randomised, co ntrolled, open -label, phase 3 trial. Lancet Oncol; 16:375-84.
Weber JS, Kudchadkar RR, Yu B, et al (2013) Safety , efficacy , and biomarkers of nivolumab 
with vaccine in ipi[INVESTIGATOR_125]- refractory  or -naive melanoma. J Clin Oncol; 31:4311 -18.

[COMPANY_001] Confidential Page 114
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
14 Appendices
14.1 Appendix 1: Guidelines for Response, Duration of Overall 
Response, TTF, TTP, Progression -Free Survival  
 (based on RECIST 1.1)
Harmonization of Efficacy  Analysis of Solid Tumor Studies
Document type: TA Specific Guideline
Document status: Versio n 3.1: 29-Nov -2011
Version 3:0: 19-Oct -2009
Version 2:0: 18-Jan -2007
Version 1:0: 13-Dec -2002
Release date: 29-Nov -[ADDRESS_1162351] of Contributors
Authors (Version 3.1):
Authors (Version 3):
Authors (Version 2):
Authors (Version 1):
Glossary
CR Complete response
CRF Case Report Form
CSR Clinical Study Report
CT Computed tomography
DFS Disease -free survival
eCRF Electronic Case Report Form
FPFV First patient first visit
MRI Magnetic resonance imaging
LPLV Last patient last visit
PD Progressive disease
PFS Progression -free survival
PR Partial response
RAP Reporting and Analysis Plan
RECIST Response Evaluation Criteria in Solid Tumors
SD Stable disease
SOD Sum of Diameter
TTF Time to treatment failure
TTP Time to progression
UNK Unknown

[COMPANY_001] Confidential Page 115
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
14.1.[ADDRESS_1162352] criteria for tumor responses (Therasse et al 2000 ) and the revised 
RECI ST 1.1 guidelines ( Eisenhauer et al 2009 ).
The efficacy  assessments described in Section 14.1.[ADDRESS_1162353] response in 
Section [IP_ADDRESS] are based on the RECI ST 1.[ADDRESS_1162354] response. Section [IP_ADDRESS] is summarizing the “time to event” 
variables and rules which are mainl y derived from internal discussions and regulatory 
consultations, as the RECI ST criteria do not define these variables in detail. Section 
14.1.4 of 
this guideline describes data handling and programming rules. This section is to be referr ed to 
in the RAP (Reporting and Analysis Plan) to provide further details needed for programming.
14.1.[ADDRESS_1162355] criteria ( Therasse et al 2000 ), New Guide lines 
to Evaluate the Response to Treatment in Solid Tumors, Journal of National Cancer Institute, 
Vol. 92; 205-[ADDRESS_1162356] guidelines (version 1.1) (Eisenhauer et al 2009 ) European 
Journal of Cancer; 45:228 -247.
[IP_ADDRESS] Definitions
[IP_ADDRESS].1 Disease measurability
In order to evaluate tumors throughout a study , definitions of measurability  are required in order 
to classify  lesions appropriately  at baseline. In defining measurability , a distinction also needs 
to be made between nodal lesions (pathological l ymph nodes) and non -nodal lesions.
Measurable disease - the presence of at least one measurable nodal or non-nodal lesion. 
If the measurable disease is restricted to a solitary  lesion, its neoplastic nature should be 
confirmed b y cytology /histology .
For patients without measurable disease see Section [IP_ADDRESS].8 .
Measurable lesions (both nodal and non -nodal)
Measurable non- nodal - As a rule of thumb, the minimum size of a measurable non -nodal 
target lesion at baseline should be no less than double the slice thickness or 10mm 
whichever is greater -e.g. the minimum non -nodal lesion size for CT/MRI  with 5mm cuts 
will be 10 mm, for 8 mm contiguous cuts the minimum size will be 16 mm.
Lytic bone lesions or mixed ly tic-blastic lesions with identifiable soft tissue components, 
that can be evaluated b y CT/MRI , can be considered as measurable lesions, if the soft 
tissue component meets the definition of measurability .
Measurable nodal lesions (i.e. ly mph nodes) - Lymph nodes 15 mm in short axis can be 
considered for selection as target lesions. Ly mph nodes measuring  10 mm and <15 mm 
are considered non -measurable. Ly mph nodes smaller than 10 mm in short axis at 
baseline, regardless of the slice thickness, are normal and not considered indicative of 
disease.

[COMPANY_001] Confidential Page 116
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Cystic lesions:
Lesions that meet the criteria for radiographicall y defined simple cy sts (i.e., spherical 
structure with a thin, non -irregular, non -nodular and non-enhancing wall, no 
septations, and low CT density  [water -like] content) should not be considered as
malignant lesions (neither measurable nor non -measurable) since they  are, by  
[CONTACT_108], simple cy sts.
‘Cystic lesions’ thought to represent cy stic metastases can be considered as 
measurable lesions, if they meet the definition of measurability  described above. 
However, if noncy stic lesions are present in the same patient, these are preferred for 
selection as target lesions.
Non-measurable lesions - all other lesions are considered non -measurable, including small 
lesions (e.g. longest diameter <[ADDRESS_1162357]/MRI  or pathological ly mph nodes with 
10 to < 15 mm short axis), as well as trul y non -measurable lesions e.g., blastic bone 
lesions, leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory  breast 
disease, l ymphangitis cutis/pulmonis , abdominal masses/abdominal organomegaly 
identified by  [CONTACT_15072].
[IP_ADDRESS].2 Eligibility based on measurable disease
If no measurable lesions are identified at baseline, the patient may  be allowed to ente r the study 
in some situations (e.g. in Phase III studies where PFS is the primary  endpoint). However, it is 
recommended that patients be excluded from trials where the main focus is on the Overall 
Response Rate (ORR). Guidance on how patients with just non- measurable disease at baseline 
will be evaluated for response and also handled in the statistical analy ses is given in Section 
[IP_ADDRESS].8.
[IP_ADDRESS] Methods of tumor measurement -general guidelines
In this docu
ment, the term “contrast” refers to intravenous (i.v.) contrast.
The following considerations are to be made when evaluating the tumor:
All measurements should be taken and recorded in metric notation (mm), using a ruler or 
calipers. All baseline evaluatio ns should be performed as closel y as possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the 
treatment.
Imaging- based evaluation is preferred to evaluation by [CONTACT_837257] a ssess the antitumor effect of a treatment.
For optimal evaluation of patients, the same methods of assessment and technique should 
be used to characterize each identified and reported lesion at baseline and during follow-
up. Contrast
-enhanced CT of chest, abdomen and pelvis should preferably  be performed 
using a [ADDRESS_1162358]/MRI  scan 
slice thickness should not exceed [ADDRESS_1162359] or 
develops a contraindication during the trial, the following change in imaging modalit y will 
be accepted for follow up: a non- contrast CT of chest (MRI  not recommended due to 
respi[INVESTIGATOR_14943]) pl us contrast -enhanced MRI of abdomen and pelvis.

[COMPANY_001] Confidential Page 117
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
A change in methodology  can be defined as either a change in contrast use (e.g. keepi[INVESTIGATOR_14967], like CT, but switching from with to without contrast use or vice -versa, 
regardless of the justification for the change) or a change in technique (e.g. from CT to 
MRI , or vice -versa), or a change in an y other imaging modality . A c hange in methodology  
will r esult by [CONTACT_15074] a UNK overall lesion response assessment . However, another 
response assessment t han the [COMPANY_001] calculated UNK response may  be accepted from 
the investigator or the central blinded reviewer if a definitive response assessment can be 
justified, based on the available information.
FDG -PET: can complement CT scans in assessing progression (particularl y possible for 
‘new’ disease). New lesions on the basis of FDG- PET imaging can be identified according 
to the following algorithm:
Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD 
based on a new les ion.
No FDG -PET at baseline with a positive FDG- PET at follow -up:
If the positive FDG -PET at follow -up corresponds to a new site of disease confirmed by  
[CONTACT_4654], this is PD.
If the positive FDG -PET at follow -up is not confirmed as a new site of disease on CT, 
additional follow -up CT are needed to determine if there is trul y progression occurring at 
that Site (if so, the date of PD will be the date of the initial abnormal CT scan).
If the positive FDG -PET at follow -up corresponds to a pre -existing site of disease on CT 
that is not progressing on the basis of the anatomic images, this is not PD.
Chest x -ray: Lesions on chest x -ray are acceptable as measurable lesions when they  are 
clearl y defined and surrounded by [CONTACT_6776]. However, CT is preferable.
Ultrasound: When the primary  endpoint of the study  is objective response evaluation, 
ultrasound (US) should not be used to measure tumor lesions. I t is, however, a possible 
alternative to clinical measurements of superficial palpable l ymph nodes, subcutaneous 
lesion s and thy roid nodules. US might also be useful to confirm the complete 
disappearance of superficial lesions usually  assessed by  [CONTACT_12148].
Endoscopy  and laparoscopy : The utilization of endoscopy  and laparoscopy  for objective 
tumor evaluation has not y et been full y and widely validated. Their uses in this specific 
context require sophisticated equipment and a high level of expertise that may  only be 
available in some centers. Therefore, the utilization of such techniques for objective tumor 
respon se should be restricted to validation purposes in specialized centers. However, such 
techniques can be useful in confirming complete pathological response when biopsies are 
obtained.
Tumor markers: Tumor markers alone cannot be used to assess response. How ever, some 
disease specific and more validated tumor markers (e.g. CA- 125 for ovarian cancer, PSA 
for prostate cancer, alpha-FP, LDH and Beta-hCG for testicular cancer) can be integrated 
as non- target disease. If markers are initially  above the upper norma l limit they must 
normalize for a patient to be considered in complete clinical response when all lesions 
have disappeared.
Cytology and histology: Cytology  and histology  can be used to differentiate between PR 
and CR in rare cases (i.e., after treatment t o differentiate between residual benign lesions 

[COMPANY_001] Confidential Page 118
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
and residual malignant lesions in tumor ty pes such as germ cell tumors). Cytologic 
confirmation of neoplastic nature of an y effusion that appears or worsens during treatment 
is required when the measurable tu mor has met the criteria for response or stable disease. 
Under such circumstances, the cy tologic examination of the fluid collected will permit 
differentiation between response and stable disease (an effusion may  be a side effect of the 
treatment) or progr essive disease (if the neoplastic origin of the fluid is confirmed).
Clinical examination :Clinical lesions will only  be considered measurable when they  are 
superficial (i.e., skin nodules and palpable l ymph nodes). For the case of skin lesions, 
documentat ion by  [CONTACT_6775] , including a ruler to estimate the size of the lesion, is 
recommended.
[IP_ADDRESS] Baseline documentation of target and non -target lesions
For the evaluation of lesions at baseline and throughout the study , the lesions are classified at 
baseli ne as either target or non -target lesions:
Target lesions: All measurable lesions (nodal and non -nodal) up to a maximum of five 
lesions in total (and a maximum of two lesions per organ), representative of all involved 
organs should be identified as target lesions and recorded and measured at baseline. Target 
lesions should be selected on the basis of their size (lesions with the longest diameter) and 
their suitability  for accurate repeated measurements (either by  [CONTACT_15078] ). Each targ et lesion must be uniquely
 and sequentially  numbered on the CRF 
(even if it resides in the same organ).
Minimum target lesion size at baseline
Non-nodal target: Non-nodal target lesions identified by [CONTACT_15079] (e.g . clinical examination, photography ) should be at least [ADDRESS_1162360] diameter. See Section [IP_ADDRESS].1.
Nodal target: See Section [IP_ADDRESS].1 .
A sum o f diameters (long axis for non -nodal lesions, short axis for nodal) for all target lesions 
will be calculated and reported as the baseline sum of diameters (SOD). The baseline sum of 
diameters will be used as reference by [CONTACT_837258] e tumor response. Each 
target lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF.
Non-target lesions: All other lesions are considered non -target lesions, i.e. lesions not 
fulfilling the criteria for target lesions at baseline. Presence or absence or worsening of 
non-target lesions should be assessed throughout the study ; measurements of these lesions 
are not required. Multiple non -target lesions involved in the same organ can be assessed as 
a group and recor ded as a single item (i.e. multiple liver metastases). Each non- target 
lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF.
[IP_ADDRESS] Follow -up evaluation of target and non -target lesions
To assess tumor response, the sum of diameters for all target lesions will be calculated (at 
baseline and throughout the study ). At each assessment response is evaluated first separately 

[COMPANY_001] Confidential Page 119
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
for the target (Table 14-1) and non-target lesions (Table 14 -2) identified at baseline. These 
evaluations are then used to calculate the overall lesion response considering both the target and 
non-target lesions together ( Table 14 - 3) as well as the presence or absence of new lesions.
[IP_ADDRESS].[ADDRESS_1162361] to 
substantial “partial volume” effects (i.e., size may be underestimated because of the distance of 
the cut from the longest diameter; such lesions may appear to have responded or progressed on 
subse quent examinations, when, in fact, they  remain the same size).
If the lesion has completely disappeared, the lesion size should be reported as [ADDRESS_1162362] slice 
thickness (but should not be changed with varying CT slice thickness). Actual measurement 
should be given for all lesions larger than [ADDRESS_1162363] diameter irrespective of slice 
thickness/reconstruction interval.
In other cases where the lesion cannot be reliably measured for reasons other than its size (e.g., 
borders of the lesion are confo unded by [CONTACT_15081]), no measurement 
should be entered and the lesion cannot be evaluated.
Nodal lesions
A nodal lesion less than 10 mm in size by [CONTACT_15082]. Lym ph nodes are not 
expected to disappear completely ,so a “non- zero size” will alway s persist.
Measurements of nodal target lesions that become [ADDRESS_1162364] slice thickness 
(but 
should not be changed with varying CT slice thickness).Actual measurement should be given 
for all lesions larger than 5 mm in short axis irrespective of slice thickness/reconstruction 
interva l.
However, once a target nodal lesion shrinks to less than 10 mm in its short axis, it will be 
considered normal for response purpose determination. The lymph node measurements will 
continue to be recorded to allow the values to be included in the sum of diameters for target 
lesions, which may  be required subsequentl y for response determination.

[COMPANY_001] Confidential Page 120
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
[IP_ADDRESS].2 Determination of target lesion response
Table 14-1 Response criteria for target lesions
Response Criteria Evaluation of target lesions
Complete Response (CR): Disappearance of all non -nodal target lesions. In addition, any pathological lymph 
nodes assigned as target lesions must have a reduction in short axis to < 10 mm .1
Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as 
reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, 
taking as refe rence the smallest sum of diameter of all target lesions recorded at or 
after baseline. In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm.2
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which 
would qualify for PD.
Unknown (UNK) Progression has not been documented and one or more target lesions have not 
been assessed or have been assessed using a different method than baseline.3
1.SOD for CR may not be zero when nodal lesions are part of target lesions
2.Following an initial CR, a PD cannot be assigned if all non -nodal target lesions are still not present and all 
nodal lesions are <10 mm in size. In this case, the target lesion response is CR
3.Methodology change See Section [IP_ADDRESS] .
Notes on target lesion response
Reappearance of lesions: If the lesion appears at the same anatomical location where a target 
lesion had previousl y dis appeared, it is advised that the time point of lesion disappearance (i.e., 
the “0 mm” recording) be re-evaluated to make sure that the lesion was not actually  present 
and/or not visualized for technical reasons in this previous assessment. If it is not possible to 
change the 0 value, then the investigator/radiologist has to decide between the following three 
possibilities:
The lesion is a new lesion, in which case the overall tumor assessment will be considered 
as progressive disease
The lesion is clearl y a reappearance of a previously  disappeared lesion, in which case the 
size of the lesion has to be entered in the CRF and the tumor assessment will remain based 
on the sum of tumor measurements as presented in Table 14-1 above (i.e., a PD will be 
determined if there is at least 20% increase in the sum of diameters of allmeasured target 
lesions, taking as reference the smallest sum of diameters of all target lesions recorded at 
or after baseline with at least 5 mm increase in the absolute sum of the diameters). Proper 
documentation should be available to support this decision. This applies to patients who 
have not achieved target response of CR. For patients who have achieved CR, pl ease refer 
to last bullet in this section.
For those patients who have onl y one target lesion at baseline, the reappearance of the 
target lesion which disappeared previousl y, even if still small, is considered a PD.
Missing measurements: In cases where mea surements are missing for one or more target 
lesions it is sometimes still possible to assign PD based on the measurements of the 
remaining lesions. For example, if the sum of diameters for [ADDRESS_1162365] -baseline visit 
is 140 mm (with data for 2 other lesions missing) then a PD should be assigned. However, 

[COMPANY_001] Confidential Page 121
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
in other cases where a PD cannot definitel y be attributed, the target lesion response would 
be UNK.
Nodal les ion decrease to normal size: When nodal disease is included in the sum of target 
lesions and the nodes decrease to “normal” size they  should still have a measurement 
recorded on scans. This measurement should be reported even when the nodes are normal 
in order not to overstate progression should it be based on increase in the size of nodes.
Lesions split: I n some circumstances, disease that is measurable as a target lesion at 
baseline and appears to be one mass can split to become two or more smaller sub -lesions. 
When this occurs, the diameters (long axis - non- nodal lesion, short axis -nodal lesions) 
of the two split lesions should be added together and the sum recorded in the diameter 
field on the case report form under the original lesion number. This va lue will be included 
in the sum of diameters when deriving target lesion response. The individual split lesions 
will not be considered as new lesions, and will not automatically  trigger a PD designation.
Lesions coalesced: Conversel y, it is also possible t hat two or more lesions which were 
distinctly  separate at baseline become confluent at subsequent visits. When this occurs a 
plane between the original lesions may  be maintained that would aid in obtaining diameter 
measurements of each individual lesion. I f the lesions have trul y coalesced such that they 
are no longer separable, the maximal diameters (long axis - non- nodal lesion, short axis -
nodal lesions) of the “merged lesion” should be used when calculating the sum of 
diameters for target lesions. On t he case report form, the diameter of the “merged lesion” 
should be recorded for the size of one of the original lesions while a size of “0”mm should 
be entered for the remaining lesion numbers which have coalesced.
The measurements for nodal lesions , even if less than [ADDRESS_1162366]  with slight modifications.
Since lesions less than [ADDRESS_1162367] disappeared.
Once a CR target lesion response has been assigned a CR will continue to be appropriate 
(in the absence of missing data) until progression of target lesions.
Following a CR, a PD can subsequently  only be assigned for target lesion response if 
either a non
-nodal target lesion “reappears” or if any  single nodal lesion is at least [ADDRESS_1162368] 20% increase in sum of the diameters of all nodal target lesions 
relative to nadir with at least 5 mm increase in the absolute sum of the diameters.

[COMPANY_001] Confidential Page 122
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
[IP_ADDRESS].3 Determination of non -target lesion response
Table 14-2 Response criteria for non -target lesions
Response Criteria Evaluation of non -target lesions
Complete Response (CR): Disappearance of all non -target lesions. In addition, all lymph nodes assigned a 
non-target lesions must be non -pathological in size (< 10mm short axis)
Progressive Disease (PD): Unequivocal progression of existing non -target lesions.1
Non-CR/Non-PD: Neither CR nor PD
Unknown (UNK) Progression has not been documented and one or more non -target lesions have 
not been assessed or have been assessed using a different method than 
baseline.
1. Although a clear progression of non -target lesions only is exceptional, in such circumstances, the opi[INVESTIGATOR_140943] (or 
study chair).
Notes on non -target lesion response
The response for non- target lesions is CRonly if all non- target non- nodal lesions which 
were evaluated at baseline are now all absent and with all non -target nodal lesions 
returned to normal size (i.e. < 10 mm). If an y of the non -target lesions are still present, or 
there are an y abnormal nodal lesions (i.e. 10 mm) the response can onl y be ‘ Non-
CR/Non -PD’ unless an y of the lesions was not assessed (in which case response is UNK ) 
or there is unequivocal progression of the non -target lesions (in which case response is 
PD).
Unequivocal progression: To achieve “unequivocal progression” on the basis of non -target 
disease there must be an overall level of substantial worsening in non -target disease such 
that, even in presence of CR, PR or SD in target disease, the overall tumor burden has 
increased sufficientl y to merit discontinuation of therap y. A modest “increase” in the size 
of one or more non- target lesions is usually  not sufficient to qualify  for unequivocal 
progression status. The designation of overall progression solely  on the basis of change in 
non-target disease in the face of CR, PR or SD of target disease is therefore expected to be 
rare. In order for a PD to be assigned on the basis of non -
target lesions, the increase in the 
extent of the disease must be substantial even in cases where there is no measurable 
disease at baseline. If there is unequivocal progression of non- target lesion(s), then at least 
one of the non -target lesions must be assigned a status of “Worsened”. Where possible, 
similar rules to those describ ed in Section [IP_ADDRESS].2 for assigning PD following a CR for 
the non- target lesion response in the presence of non- target lesions nodal lesions should be 
applied.
[IP_ADDRESS].[ADDRESS_1162369] s associated with Progressive Disease (PD) and has to 
be recorded as a new lesion in the New Lesion CRF page.
If a new lesion is equivocal , for example because of its small size, continued therap y and 
follow -up evaluation will clarify  if it repr esents truly  new disease. If repeat scans confirm 
there is definitel y a new lesion, then progression should be declared using the date of the 
first observation of the lesion

[COMPANY_001] Confidential Page 123
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
If new disease is observed in a region which was not scanned at baseline or where the 
particular baseline scan is not available for some reason, then this should be considered as 
a PD. The one exception to this is when there are no baseline scans at all available for a 
patient in which case the response should be UNK, as for an y of this patient's assessment 
(see Section [IP_ADDRESS] ).
A lymph node is considered as a “new lesion” and, therefore, indicative of progressive 
disease if the short axis increases in size to [ADDRESS_1162370] t
ime in the study  plus 5 
mm absolute increase.
FDG -PET: can complement CT scans in assessing progression (particularly  possible for 
‘new’ disease). See Section [IP_ADDRESS] .
[IP_ADDRESS] Evaluation of overall lesion respo nse
The evaluation of overall lesion response at each assessment is a composite of the target lesion 
response, non- target lesion response and presence of new lesions as shown below in Table 14 -
3.
Table 14
-3 Overall lesion response at each assessment
Target lesions Non-target lesions New LesionsOverall
lesion response
CR CR No CR1
CR Non-CR/Non-PD3No PR
CR, PR, SD UNK No UNK
PR Non-PD and not UNK No PR1
SD Non-PD and not UNK No SD1, 2
UNK Non-PD or UNK No UNK1
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
1.This overall lesion response also applies when there are no non -target lesions identified at baseline.
2.Once confirmed PR was achieved, all these assessments are considered PR.
3.As defined in Section [IP_ADDRESS] .
If there are no baseline scans available at all, then the overall lesion response at each assessment 
should be considered Unknown (UNK).
If the evaluation of any of the target or non-target lesions identified at baseline could not be 
made during follow -up, the overall status must be ‘unknown’ unless progression was seen.
In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy ) to confirm the CR.
14.1.[ADDRESS_1162371] measurable disease at baseline. 
Section [IP_ADDRESS].[ADDRESS_1162372] y the same concepts.

[COMPANY_001] Confidential Page 124
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
[IP_ADDRESS] Best overall response
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the sma llest measurements recorded 
since the treatment started). In general, the patient's best response assignment will depend on 
the achievement of both measurement and confirmation criteria.
The best overall response will usually  be determined from response assessments undertaken 
while on treatment. However, if an y assessments occur after treatment withdrawal the protocol 
should specificall y describe if these will be included in the determination of best overall 
response and/or whether these additional assessme nts will be required for sensitivity  or 
supportive anal yses. As a default, an y assessments taken more than [ADDRESS_1162373] overall response determination. If response assessments taken after 
withdrawal from study  treatment and/or alternative therap y are to be included in the main 
endpoint determination, then this should be described and justified in the protocol.
Where a study  requires confirmation of response (PR or CR), changes in tumor measurements 
must be confirmed by  [CONTACT_15085] [ADDRESS_1162374] be clearl y stated in the protocol. 
The main goal of confirmation of objective response is to avoid overestimating the response 
rate observed. In cases where confirmation of response is not feasible, it should be made clear 
when reporting the outcome of such studies that the responses are not confirmed.
For non -randomized trials where response is the primary  endpoint, confirmation is needed.
For trials in tended to support accelerated approval, confirmation is needed
For all other trials, confirmation of response may  be considered optional.
The best overall response for each patient is determined from the 
sequence of overall (lesion) 
responses according to the following rules:
CR = at least two determinations of CR at least 4 weeks apart before progression where 
confirmation required or one determination of CR prior to progression where confirmation 
not required
PR = at least two determinations of PR or bett er at least 4 weeks apart before progression 
(and not qualify ing for a CR) where confirmation required or one determination of PR 
prior to progression where confirmation not required
SD = at least one SD assessment (or better) > 6 weeks after randomization /start of 
treatment (and not qualifying for CR or PR).
PD = progression  12 weeks after randomization/ start of treatment (and not qualify ing 
for CR, PR or SD).
UNK = all other cases (i.e. not qualify ing for confirmed CR or PR and without SD after 
more than [ADDRESS_1162375] 12 weeks)
Overall lesion responses of CR must stay the same until progression sets in, with the exception 
of a UNK status. A patient who had a CR cannot subsequently  have a lower status other than a 

[COMPANY_001] Confidential Page 125
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
PD, e.g. PR or SD, as this would imply  a progression based on one or more lesions reappearing, 
in which case the status would become a PD.
Once an overall lesion response of PR is observed (which may have to be a confirmed PR 
depending on the study) this assignm ent must stay the same or improve over time until 
progression sets in, with the exception of an UNK status. However, in studies where 
confirmation of response is required, if a patient has a single PR (30% reduction of tumor 
burden compared to baseline) a t one assessment, followed by  a <30% reduction from baseline 
at the next assessment (but not 20% increase from previous smallest sum), the objective status 
at that assessment should be SD. Once a confirmed PR was seen, the overall lesion response 
should be considered PR (or UNK) until progression is documented or the lesions totally  
disappear in which case a CR assignment is applicable. In studies where confirmation of 
response is not required after a single PR the overall lesion response should still be c onsidered 
PR (or UNK) until progression is documented or the lesion totally  disappears in which case a 
CR assignment is applicable.
Example: In a
 case where confirmation of response is required the sum of lesion diameters is 
200 mm at baseline and then 140mm - 150 mm - 140 mm - 160 mm - 160 mm at the subsequent 
visits. Assuming that non -target lesions did not progress, the overall lesion response would be 
PR -SD - PR -PR -PR. The second assessment with 140 mm confirms the PR for this patient. 
All subsequent assessments are considered PR even if tumor measurements decrease only by 
20% compared to baseline (200 mm to 160 mm) at the following assessments.
If the patient progressed but continues study  treatment, further assessments are not considered 
for the determination of best overall response.
Note: these cases may be described as a separate finding in the CSR but not included in the 
overall response or disease control rates.
The best overall response for a patient is alway s calculated, based on the seque nce of overall 
lesion responses. However, the overall lesion response at a given assessment may  be provided 
from different sources:
Investigator overall lesion response
Central Blinded Review overall lesion response
[COMPANY_001] calculated overall lesion response (based on measurements from either 
Investigator or Central Review)
The primary  anal ysis of the best overall response will be based on the sequence of investigator 
overall lesion responses.
Based on the patients’ best overall response during the study , the following rates are then 
calculated:
Overall response rate (ORR) is the proportion of patients with a best overall response of CR 
or PR. This is also referred to as ‘Objective response rate’ in some protocols or publications.
Disease control rate (DCR) is the proportion of patients with a best overall response of CR or 
PR or SD.

[COMPANY_001] Confidential Page 126
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Another approach is to summarize the progression rate at a certain time point after baseline. In 
this case, the following definition is used:
Early progression rate (EPR) is theproportion of patients with progressive disease within 
8weeks of the start of treatment.
The protocol should define populations for which these will be calculated. The timepoint for 
EPR is study  specific. EPR is used for the multinomial designs of Dent and Zee (2001) and 
counts all patients who at the specified assessment (in this example the assessment would be at 
8 weeks ± window) do not have an overall lesion response of SD, PR or CR. Patients with an 
unknown (UNK) assessment at that time point and no PD before, will not be counted as early 
progressors in the anal ysis but may  be included in the denominator of the EPR rate, depending 
on the analy sis population used. Similarly  when examining overall response and disease control, 
patients with a best overall response assessment of unknown (UNK) will not be regarded as 
“responders” but may be included in the denominator for ORR and DCR calculation depending 
on the anal ysis population (e.g. populations base d on an ITT approach).
[IP_ADDRESS] Time to event variables
[IP_ADDRESS].1 Progression- free survival
Usually  in all Oncology  studies, patients are followed for tumor progression after 
discontinuation of study  medication for reasons other than progression or death. If this is not 
used, e.g. in Phase I or II studies, this should be clearl y stated in the protocol. Note that 
randomized trials (preferably blinded) are recommended where PFS is to be the primary 
endpoint.
Progression -free survival (PFS) is the time from date of randomization/start of treatment to 
the date of event defined as the first documented progression or death due to any cause. If a 
patient has not had an event, progression- free survival is censored at the date of last adequate 
tumor assessment.
 
 
 
 
[IP_ADDRESS].3 Time to progression
Some studies might consider only death related to underly ing cancer as an event which indicates 
progression. In this case the variable “Time to progression” might be used. TTP is defined as
PFS except for death unrelated to underl ying cancer.
Time to progression (TTP) is the time from date of randomization/start of treatment to the 
date of event defined as the first documented progression or death due to underly ing cancer. If 

[COMPANY_001] Confidential Page 127
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
a patient has n ot had an event, time to progression is censored at the date of last adequate tumor 
assessment.
[IP_ADDRESS].[ADDRESS_1162376] of discontinuation 
reasons to be considered or not as treatment failure may be adapted according to the specificities
of the study  or the disease.
Time to treatment failure (TTF) is the time from date of randomization/start of treatment to 
the earliest of date of progression, date of death due to any cause, or date of discontinuation due 
to reasons other than ‘Protocol violation’ or ‘Administrative problems’. The time to treatment 
failure for patients who did 
not experience treatment failure will be censored at last adequate 
tumor assessment.
[IP_ADDRESS].[ADDRESS_1162377] been reports where 
a treatment with a significantly  higher response rate had a significantly shorter duration of 
response but where this probabl y primaril y reflected selection bias which is explained as 
follows: I t is postulated that there are two groups of patients: a good risk group and a poor risk 
group. Good risk patients tend to get into response readily  (and relativel y quickly ) and tend to 
rema in in response after they
 have a response. Poor risk patients tend to be difficult to achieve 
a response, may have a longer time to respond, and tend to relapse quickly  when they do respond. 
Potent agents induce a response in both good risk and poor risk patients. Less potent agents 
induce a response mainly in good risk patients only. This is described in more detail by [CONTACT_15088] 
(1988) .
It is recommended that an analysis of all patients (both 
responders andnon-responders) be 
performed whether or not a “responders onl y” descriptive anal ysis is presented. An analy sis of 
responders should only be performed to provide descriptive statistics and even then interpreted 
with caution by [CONTACT_837259] …If an 
inferential comparison between treatments is required this should only be performed on all 
patients (i.e. not restricting to “responders” only ) using appropriate statistical methods such as 
the techniques desc ribed in Ellis et al (2008) . It should also be stated in the protocol if duration 
of response is to be calculated in addition for unconfirmed response.
For summary  statistics on “responders” only the following definitions are appropriate. (Specific 
definitions for an all-patient analysis of these endpoints are not appropriate since the status of 
patients throughout the study  is usuall y taken into account in the anal ysis).
Duration of overall response (CR or PR):For patients with a CR or PR (which may  have to 
be confirmed the start date is the date of first documented response (CR or PR) and the end date 
and censoring is defined the same as that for time to progression.
The following two durations might becalculated in addition for a large Phase III study  in which 
a reasonable number of responders is seen.

[COMPANY_001] Confidential Page 128
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Duration of overall complete response (CR) :For patients with a CR (which may  have to be 
confirmed) the start date is the date of first documented CR and the end date and censoring is 
defined the same as that for time to progression.
Duration of stable disease (CR/PR/SD) :For patients with a CR or PR (which may have to be 
confirmed) or SD the start and end date as well as censoring is defined the same as that for time 
to progression.
[IP_ADDRESS].6 Time to response
Time to overall response (CR or PR) is the time between date of randomization/start of 
treatment until first documented response (CR or PR). The response may  need to be confirmed 
depending on the ty pe of study and its importance. Where the response needs to be confirmed 
then time to response is the time to the first CR or PR observed.
Although an analysis on the full population is preferred a descriptive analysis may be performed 
on the “responders” subset only, in which case the results should be interpreted with caution 
and in the context of the overall response rates, since the same kind of selection bias may be 
introduced as described for duration of response in Section [IP_ADDRESS].5. It is recommended that 
an anal ysis of all patients (both responders and non -responders) be performed whether or not a 
“responders onl y” descriptive analysis 
is presented. Where an inferential statistical comparison 
is required, then all patients should definitely  be included in the analysis to ensure the statistical 
test is valid. For anal ysis including all patients, patients who did not achieve a response (which 
may have to be a confirmed response) will be censored using one of the following options.
at maximum follow -up (i.e. FPFV to LPLV used for the anal ysis) for patients who had a 
PFS event (i.e. progressed or died due to an y cause). In this case the PFS event is the 
worst possible outcome as it means the patient cannot subseque ntly respond. Since the 
statistical analy sis usually  makes use of the ranking of times to response it is sufficient to 
assign the worst possible censoring time which could be observed in the study  which is 
equal to the maximum follow- up time (i.e. time fro m FPFV to L PLV)
at last adequate tumor assessment date otherwise. In this case patients have not y et 
progressed so they  theoretically  still have a chance of responding
Time to overall complete response (CR) is the time between dates of randomization/start of 
treatment until first documented CR. Similar analy sis considerations including (if appropriate) 
censoring rules apply  for this endpoint described for the time to overall response endpoint.
[IP_ADDRESS].7 Definition of start and end dates for time to event variables
Assessment date
For each assessment (i.e. evaluation number), the assessment date is calculated as the latest of 
all measurement dates (e.g. X -ray, CT-scan) if the overall lesion response at that assessment is 
CR/PR/SD/UNK. Otherwise -if overall lesion resp onse is progression -the assessment date is 
calculated as the earliest date of all measurement dates at that evaluation number.

[COMPANY_001] Confidential Page 129
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Start dates
For all “time to event” variables, other than duration of response, the randomization/ date of 
treatment start will be used as the start date.
For the calculation of duration of response the following start date should be used:
Date of first documented response is the assessment date of the first overall lesion 
response of CR (for duration of overall complete response) or CR / PR (for duration of 
overall response) respectively , when this status is later confirmed.
End dates
The end dates which are used to calculate ‘time to event’ variables are defined as follows:
Date of death (during treatment as recorded on the treatment completion page or during 
follow -up as recorded on the study  evaluation completion page or the survival follow -up 
page).
Date of progression is the first assessment date at which the overall lesion response was 
recorded as progressive disease.
Date of last adequate tumor assessment is the date the last tumor assessment with overall 
lesion response of CR, PR or SD which was made before an event or a censoring reason 
occurred. In this case the last tumor evaluation date at that assessment is used. I f no post -
baseline assessments are available (before an event or a censoring reason occurred) the 
date of randomization/start of treatment is used.
Date of next scheduled assessment is the date of the last adequate tumor assessment plus 
the protocol specif ied time interval for assessments. This date may  be used if back-dating 
is considered when the event occurred bey ond the acceptable time window for the next 
tumor assessment as per protocol (see Section [IP_ADDRESS].8).
Example (if protocol defined 
schedule of assessments is 3 months): tumor assessments at 
baseline - 3 months - 6 months -missing -missing -PD. Date of next scheduled assessment 
would then correspond to 9 months.
Date of discontinuation is the date of the end of treatment visit.
Date of last contact [CONTACT_15090]. This 
corresponds to the latest date for either the visit date, lab sample date or tumor assessment 
date. If available, the last known date patient alive from the survival follow -up page is 
used. If no survival follow- up is available, the date of discontinuation is used as last 
contact [CONTACT_568].
Date of secondary  anti- cancer therap y is defined as the start date of an y additional 
(secondary ) antineoplastic therapy  or surgery .
[IP_ADDRESS].8 Handling of patients with non -measurable disease only at baseline
It is possible that patients with only non- measurable disease present at baseline are entered into 
the study , either because of a protocol violation or by d esign (e.g. in Phase III studies with PFS 
as the primary  endpoint). In such cases the handling of the response data requires special 
consideration with respect to inclusion in any analysis of endpoints based on the overall 
response evaluations.

[COMPANY_001] Confidential Page 130
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
It is recom mended that any patients with only non-measurable disease at baseline should be 
included in the main (ITT) anal ysis of each of these endpoints.
Although the text of the definitions described in the previous sections primarily relates to 
patients with measu rable disease at baseline, patients without measurable disease should also 
be incorporated in an appropriate manner. The overall response for patients with measurable 
disease is derived slightly differentl y according to Table 14
-4 .
Table 14-4 Overall lesion response at each assessment: patients with non -target 
disease only
Non-target lesions New Lesions Overall lesion respon se
CR No CR
Non-CR/Non-PD1No Non-CR/non -PD
UNK No UNK
PD Yes or No PD
Any Yes PD
1As defined in Section [IP_ADDRESS] .
In general, the non-CR/non -PD response for these patients is considered equivalent to an SD 
response in endpoint determination. In summary  tables for best overall response patients with 
only non- measurable disease may  be highlighted in an appropriate fashion e.g. in particular by 
[CONTACT_15093] e specific numbers with the non -CR/non -PD category .
In considering how to incorporate data from these patients into the analy sis the importance to 
each endpoint of being able to identify  a PR and/or to determine the occurrence and timing of 
progression nee ds to be taken into account.
For ORR it is recommended that the main (I TT) analy sis includes data from patients with only 
non-measurable disease at baseline, handling patients with a best response of CR as “responders” 
with respect to ORR and all other pat ients as “non -responders”.
For PFS, it is again recommended that the main ITT analyses on these endpoints include all 
patients with only non -measurable disease at baseline, with possible sensitivity analyses which 
exclude these particular patients. Endpoin ts such as PFS which are reliant on the determination 
and/or timing of progression can incorporate data from patients with only non
-measurable 
disease.
[IP_ADDRESS].9 Sensitivity analyses
This section outlines the possible event and censoring dates for progression, as well as addresses 
the issues of missing tumor assessments during the study . For instance, if one or more 
assessment visits are missed prior to the progression event, to what date should the progression 
event be assigned? And should progression event be ignored if it occurred after a long period 
of a patient being lost to follow -up? It is important that the protocol and RAP specify  the 
primary  analysis in detail with respect to the definition of event and censoring dates and also 
include a description of one or more sensitivity  analy ses to be performed.
Based on definitions outlined in Section [IP_ADDRESS].7 , and using the draft FDA guideline on 
endpoints (Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics- April 2005) 
as a reference, the following analy ses can be considered:

[COMPANY_001] Confidential Page 131
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Table 14-5 Options for event dates used in PFS, TTP, duration of response
Situation Options for end -date (progression or 
censoring)1
(1) = default unless specified differently  in the 
protocol or RAPOutcome
A No baseline assessment (1) Date of randomization/start of treatment3Censored
B Progression at or before next scheduled 
assessment(1) Date of progression
(2) Date of next scheduled assessment2Progressed
Progressed
C1 Progression or death after exactly one 
missing assessment(1) Date of progression (or death)
(2) Date of next scheduled assessment2Progressed
Progressed
C2 Progression or death after two or more 
missing assessments(1) Date of last adequate assessment2
(2) Date of next scheduled assessment2
(3) Date of progression (or death)Censored
Progressed
Progressed
D No progression (1) Date of last adequate assessment Censored
E Treatment discontinuation due to 
‘Disease progression’ without 
documented progression, i.e. clinical 
progression based on investigator claim(1) N/A
(2) Date of discontinuation (visit date at whi ch 
clinical progression was determined)Ignored
Progressed
F New anticancer therapy given (1) Date of last adequate assessment
(2) Date of secondary anti -cancer therapy
(3) Date of secondary anti -cancer therapy
(4) N/ACensored
Censored
Event
Ignored
G Deaths due to reason other than 
deterioration of ‘Study indication’(1) Date of last adequate assessment Censored 
(only TTP 
and duration 
of response)
1=Definitions can be found in Section [IP_ADDRESS].7 .
2=After the last adequate tumor assessment. “Date of next scheduled assessment” is defined in Section 
[IP_ADDRESS].7 .
3=The rare exception to this is if the patient dies no later than the time of the second scheduled assessment as 
defined in the protocol in which case this is a PFS event at the date of death.
The primary  analysis and the sensitivity  analyses must be specified in the protocol. Clearl y 
define if and wh y options (1) are not used for situ ations C, E and (if applicable) F.
Situations C (C1 and C2): Progression or death after one or more missing assessments: The 
primary  anal ysis is usually  using options (1) for situations C1 and C2, i.e.
(C1) taking the actual progression or death date, in t he case of only  one missing 
assessment.
(C2) censoring at the date of the last adequate assessment, in the case of two or more 
consecutive missing assessments.
In the case of two or missing assessments (situation C2), option (3) may  be considered jointly 
with option (1) in situation C1 as sensitivity  analysis. A variant of this sensitivity  analysis 
consists of backdating the date of event to the next scheduled assessment as proposed with 
option (2) in situations C1 and C2.
Situation E: Treatment discontinuation due to ‘Disease progression’ without documented 
progression: By [CONTACT_15094], option (1) is used for situation E as patients without documented PD 
should be followed for progression after discontinuation of treatment. However, option (2) may 
be used as sen sitivity  analy sis. If progression is claimed based on clinical deterioration instead 

[COMPANY_001] Confidential Page 132
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
of tumor assessment by e.g. CT-scan, option (2) may be used for indications with high early 
progression rate or difficulties to assess the tumor due to clinical deteriorat ion.
Situation F: New cancer therapy given :the handling of this situation must be specified in 
detail in the protocol. However, option (1), i.e. censoring at last adequate assessment may be 
used as a default in this case.
Additional suggestions for sensit ivity analyses
Other suggestions for additional sensitivity  analyses may include analy ses to check for potential 
bias in follow -up schedules for tumor assessments, e.g. by [CONTACT_141042]. The latt er could be handled b y replacing in Table 14 -5the 
“Date of last adequate assessment” by [CONTACT_941] “Date of previous scheduled assessment (from 
baseline)”, with the following definition:
Date of previous sched uled assessment (from baseline) is the date when a tumor 
assessment would have taken place, if the protocol assessment scheme was strictly  
followed from baseline, immediately
 before or on the date of the last adequate tumor 
assessment.
In addition, analy ses could be repeated using the Investigators’ assessments of response rather 
than the calculated response. The need for these types of sensitivity  anal yses will depend on the 
individual requirements for the specific study  and disease area and have to be specified in the 
protocol or RAP documentation.
14.1.4 Data handling and programming rules
The following section should be used as guidance for development of the protocol, data 
handling procedures or programming requirements (e.g. on incomplete dates).
[IP_ADDRESS] Study/project specific decisions
For each study  (or project) various issues need to be addressed and specified in the protocol or 
RAP documentation. Any  deviations from protocol must be discussed and defined at the latest 
in the RAP documentation.
The proposed primary  analysis and potential sensitivity  analyses should be discussed and 
agreed with the health authorities and documented in the protocol (or at the latest in the RAP 
documentation before database lock).
[IP_ADDRESS] End of treatment phase completion
Patients may voluntarily withdraw from the study  treatment or may be taken off the study 
treatment at the discretion of the investigator at any time. For patients who are lost to follow -
up, the investigator or designee should show "due diligence" by [CONTACT_5367], e.g., dates of telephone calls, registered letters, etc.
The end of treatment visit and its associated assessments should occur within [ADDRESS_1162378] udy treatment for an y of the following reasons:
Adverse event(s)

[COMPANY_001] Confidential Page 133
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Lost to follow -up
Physician decision
Pregnancy
Protocol deviation
Subject/guardian decision
Death
Progressive disease per irRC (not per RECI ST)
Study  terminated by  [CONTACT_456]
[IP_ADDRESS] End of post -treatment follow -up (study  phase completion)
End of post-treatment follow -up visit will be completed after discontinuation of study  treatment 
and post -treatment evaluations but prior to collecting survival follow-up.
Patients may  provide study  phase completio n information for one of the following reasons:
Adverse event
Lost to follow -up
Physician decision
Pregnancy
Protocol deviation
Technical problems
Subject/guardian decision
Death
New therap y for stud y indication
Progressive disease
Study  terminated by  [CONTACT_456]
[IP_ADDRESS] Medical validation of programmed overall lesion response
As RECI ST is very strict regarding measurement methods (i.e. any assessment with more or 
less sensitive method than the one used to assess the lesion at baseline is considered UNK) and 
not available evaluations (i.e. if any target or non-target lesion was not evaluated the whole 
overall lesion response is UNK unless remaining lesions qualified for PD), these UNK 
assessments may  be re -evaluated by  [CONTACT_111916]. I n addition, data 
review reports will be available to identify  assessments for which the investigators’ or central 
reader’s opi[INVESTIGATOR_140944]. 
This may be queried for clarification. However, theinvestigator or central reader’s response 
assessment will never be overruled.
If [COMPANY_001] elect to invalidate an overall lesion response as evaluated by [CONTACT_15099], the calculated overal l lesion response 
at that specific assessment is to be kept in a dataset. This must be clearl y documented in the 
RAP documentation and agreed before database lock. This dataset should be created and stored 
as part of the ‘raw’ data.

[COMPANY_001] Confidential Page 134
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Any discontinuation dueto ‘Disease progression’ without documentation of progression by 
[CONTACT_15100] y reviewed. Only patients with documented deterioration of 
symptoms indicative of progression of disease should have this reason for discontinuation of 
treatment or study  evaluation.
[IP_ADDRESS] Programming rules
The following should be used for programming of efficacy  results:
[IP_ADDRESS].1 Calculation of ‘time to event’ variables
Time to event = end date -start date + 1 (in day s)
When no post-baseline tumor assessments are availabl e, the date of randomization/start of 
treatment will be used as end date (duration = 1 day ) when time is to be censored at last tumor 
assessment, i.e. time to event variables can never be negative.
[IP_ADDRESS].2 Incomplete assessment dates
All investigation dates (e.g. X-ray, CT scan) must be completed with day , month and y ear.
If one or more investigation dates are incomplete but other investigation dates are available, 
this/these incomplete date(s) are not considered for calculation of the assessment date (and 
assessme nt date is calculated as outlined in Section [IP_ADDRESS].7). If all measurement dates have 
no day  recorded, the 1stof the month is used.
If the month is not completed, for any of the investigations, the respective assessment will be 
considered to be at the date which is exactly  between previous and following assessment. If a 
previous and following assessment is not available, this assessment will not be used for any 
calculation.
[IP_ADDRESS].[ADDRESS_1162379].
[IP_ADDRESS].4 Non-target lesion response
If no 
non-target lesions are identified at baseline (and therefore not followed throughout the 
study ), the non-target lesion response at each assessment will be considered ‘not applicable 
(NA)’.
[IP_ADDRESS].5 Study/project specific programming
The standard anal ysis programs need to be adapted for each study /project.
[IP_ADDRESS].6 Censoring reason
In order to summarize the various reasons for censoring, the following categories will be 
calculated for each time to event variable based on the treatment completion page, the study 
evaluation completion page and the survival page.
For survival the following censoring reasons are possible:

[COMPANY_001] Confidential Page 135
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Alive
Lost to follow -up
For PFS and TTP (and therefore duration of responses) the following censoring reasons are 
possible:
Ongoing without event
Lost to follow -up
Withdrew consent
Adequate assessment no longer available*
Event documented after two or more missing tumor assessments (option
Death due al, see Table 14 -5) to reason other than underly ing cancer (only used for TTP 
and duration of response)
Initiation of new anti
-cancer therapy
*Adequate assessment is defined in Section [IP_ADDRESS].7. This reason is applicable when adequate 
evaluations are missing for a specified period prior to data cut-off 
(or prior to any other 
censoring reason) corresponding to the unavailability  of two or more planned tumor 
assessments prior to the cut-off date. The following clarifications concerning this reason should 
also be noted:
This may  be when there has been a definite decision to stop evaluation (e.g. 
reason=“Sponsor decision” on study  evaluation completion page), when patients are not 
followed for progression after treatment completion or when onl y UNK assessments are 
available just prior to d ata cut -off).
The reason "Adequate assessment no longer available" also prevails in situations when 
another censoring reason (e.g. withdrawal of consent, loss to follow -up or alternative anti -
cancer therap y) has occurred more than the specified period foll
owing the last adequate 
assessment.
This reason will also be used to censor in case of no baseline assessment.
14.1.5 References (available upon request)
Dent S, Zee (2001) application of a new multinomial phase II stoppi[INVESTIGATOR_14974] y progression, J Clin Oncol; 19: 785
-791.
Eisenhauer E, et al (2009) New response evaluation criteria in solid tumors: revised RECI ST 
guideline (version 1.1). European J ournal of Cancer, Vol.45: 228 -47.
Ellis S, et al (2008) Analysis of duration of response in oncology  trials. Contemp Clin Trials 
2008; 29: 456-465.
FDA Guidelines: 2005 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, April 2005.
FDA Guidelines: 2007 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, May  2007.
Morgan TM (1988) Analy sis of duration of response: a problem of oncology  trials. Cont Clin 
Trials; 9: 11-18.

[COMPANY_001] Confidential Page 136
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Therasse P, Arbuck S, Eisenhauer E, et al (20 00) New Guidelines to Evaluate the Response to 
Treatment in Solid Tumors, Journal of National Cancer Institute, Vol. 92; 205 -16.

[COMPANY_001] Confidential Page 137
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
14.2 Appendix 2: Guidelines for immune -related Response Criteria 
(irRC) using one -dimensional measurements (simulating RECIST 
1.1)
14.2.1 Introduction
The purpose of this document is to summarize the immune -related Response Criteria (irRC) 
(Wolchol et al 2009) using one-dimensional measurements (Nishino et al 2013) that will be 
used to assess tumor response.
The definition of target/non target lesions, the criteria for lesion measurement, number of 
lesions that can be assessed and method of evalua tion are the same 
for irRC and RECI ST 1.[ADDRESS_1162380] 1.1 guidelines ( Appendix 1 ).
This appendix outlines the specificities for irRC evaluation.
14.2.[ADDRESS_1162381] 
lesions shall be selected as new measurable lesions. Up to five new measurable lesions (and a 
maximum of two per organ) are allowed in total and will be included in the overall tumor 
assessment .
Non-target lesions (baseline and new non-measurable lesions) are used primarily  for 
determination of Complete Response (CR). A CR requires that all non- target lesions disappear 
(both those present at baseline and any  new non -measurable lesions that have appeared during 
the study ). If after worsening a non-target lesion becomes measurable, it should still be followed 
as a non-target lesion. Worsen ing of non-target lesions and new non-measurable lesions only 
indicate disease progression if there is unequivocal evidence o
f disease progression ( Table 14 -
6).
14.2.3 Follow -up evaluation of target and non -target lesions
To assess tumor response, the sum of diameters for all target lesions is calculated (at baseline 
and throughout the study). The diameters of any new measurable lesions are included in the 
sum of diameters at each assessment to provide the total tumor burden. At each 
assessment, 
percent change in the sum of diameters is calculated and compared to baseline or to nadir in 
order to evaluate the target lesion response (including new measurable lesions) (Section 14.2.4). 
This evaluation combined with the status of non-target lesions (baseline and new non-
measurable lesions) is then used to determinate the overall les
ion response ( Table 14-6 ).

[COMPANY_001] Confidential Page 138
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
14.2.4 Defin itions of response categories and evaluation of overall lesion 
response
In irRC, the overall response is primarily based on target lesions (baseline and new measurable 
lesions). The non-target lesions only contribute to define irCR, and irPD in the case of
unequivocal progression, as shown below in Table [ADDRESS_1162382] 
4 weeks.
The response categories are defined as follows:
Immune related Complete Response (irCR): Disappearance of all non -nodal target lesions 
and non
-target lesions in two consecutive observations not less than [ADDRESS_1162383] a reduction in 
short axis to < 10 mm. (Sum of diameters may  be greater than zero at the time of CR, if 
nodal lesions are included as target lesions).
Immune related Partial Response (irPR): At least a 30% decrease in the sum of diameters 
of all target lesions including new target lesions in two consecutive observations not less 
than 4 weeks apart, taking as reference the baseline sum of diameters.
Immune related Progressive Disease (irPD): At least a 20% increase in the sum of 
diameters of all measured target lesions including new measurable lesions. The irPD must 
be confirmed in a second evaluation not less than [ADDRESS_1162384] sum of diameter of all target lesions recorded at or after baseline (nadir). In 
addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5 mm. Worsening of non -target lesions (existing or new) only  indicate 
PD when there is unequivocal evidence of progression, confirmed in a second evaluation 
not less than 4 weeks later.
Immune related Stable Disease (irSD): Neither a sufficient shrinkage to qualify  for irPR or 
irCR, nor an increase in lesions which would qualify for irPD.
Unknown (UNK): Progression has not been documented and one or more target lesions or 
new measurable lesions observed at earlier assessment have not been
/could not be
assessed ,or have been assessed using a method significantly  different from baseline
(target lesions) or assessment of first occurrence (for new measurable lesions) that 
prevents reasonable comparison to the prior assessments.

[COMPANY_001] Confidential Page 139
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Table 14-6 Overall response at each assessment
Target and new measurable lesions 
(Tumor burden), * (% )Non-target lesions
(both baseline and new non- measurable)Overall
lesion response
-100 Absent irCRa
-100 Stable/not evaluated irPRa
≤-30bAbsent/Stable/not evaluated irPRa
>-30band<+20cAbsent/Stable/not evaluated irSD
≥+20cAny irPDa
Any Unequivocal progression irPDa
*the diameter of new measurable lesions is included in the calculation of the sum of diameters.
ato be confirmed after at least [ADDRESS_1162385] be ‘unknown’ unless progression was documented.
If the evaluation of any  non-target lesions is not made, and all target lesions disappeared, irCR 
cannot be determined and overall response must be “irPR”.
In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy ) to confirm the irCR.
14.2.5 Only  non -measurable disease at baseline
For patients with only non-measurable disease at baseline, unequivocal progression of non-
target lesions will constitute an irPD (i.e. worsening of the overall tumor burden which is 
substantial enough to lead to discontinuation or change of therap y). In addition, the appearance 
of new lesions (measurable or non
-measurable) consistent with unequivocal progression taking 
intoaccount the overall disease burden will constitute an irPD. The absence of all non-target 
lesions and no new lesions will qualify  for irCR. Otherwise the overall response will be 
considered as irNon -CR/Non -PD (irNCRNPD) similar to RECI ST 1.1. Confirmation of irPD 
and irCR is required, as specified above in Section 
14.2.4. If any baseline non-target lesion or 
a new lesion observed at an earlier post -baseline evaluation was not/could not be assessed at a 
later post -baseline tumor evaluation, then the overall response will be irUNK. No confirmation 
is required for irNCRNPD.
14.2.6 References (available upon request)
Bohnsack O, Ludajic K, Hoos A (2014) 
Adaptation of the immune -related response criteria: 
irRECI ST. ESMO 2014; Abstract 4958 visible at: 
https://www.webges.com/cslide/library /esmo/browse/search/eTT#9faE02tu.
Nishino M, Giobbie -Hurder A, Gargano M, et al (2013) Developi[INVESTIGATOR_007] a Common L anguage for 
Tumor Response to I mmunotherapy : Immune -Related Response Crite ria Using 
Unidimensional Measurements. Clin Cancer Res; 19:3936 -3943.
Wolchok JD, Hoos A, O'Day  S, et al (2009) Guidelines for the Evaluation of I mmune 
Therap y Activity  in Solid Tumors: I mmune -Related Response Criteria. Clin Cancer Res; 
15:7412-20.

[COMPANY_001] Confidential Page 140
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
14.3 Appendi x 3: Statistical details of Bay esian regression models, 
priors, design operating characteristics and hy pothetical dose 
escalation scenarios
The dose recommendations and estimation of the RP2D/MTD during the escalation part of the 
study  will be guided by [CONTACT_837254]001 exposure and the DLT rate. The dose-exposure 
relationship will be estimated for PDR001 via a Bayesian linear regression model. 
An adaptive, 
2 parameter Bayesian logistic regression model (BLRM) will be used to estimate the probability 
of a DLT inthe first cycle of treatment. Dose recommendation based on DLT rate will be guided 
by [CONTACT_111814] (EWOC) principle. The use of Bayesian response 
adaptive models for Phase I studies has been advocated by [CONTACT_837260] (2006) and by [CONTACT_540896] (2007) and is one of the key elements of the FDA’s Critical 
Path I nitiative.
14.3.1 Bayesian linear regression model
[IP_ADDRESS] Intro duction
The dose-exposure relationship in the escalation part of the study  will be described by [CONTACT_837261]:
log(AUC i) = log(α) + β log(d i/d*) + ε i, α>0, β>0 (1)
where i = 1, 
…, n is the i-th subject in the study , diis the dose received by [CONTACT_941] i-th subject, AUC i
is the area under curve of PDR001 concentrations for the i -th subject during the interval of 0 to 
336 hours in cycle 3. The residual error εifollows a Normal distribution with mean of 0 and 
variance σ2.
Doses are rescaled as di/d* with reference dose d*=3 mg/kg of PDR001. As a consequence log(α) 
is equal to the predicted mean of log(AUC) at d*. Since a Bayesian approach is used, prior 
distributions need to be specified for parameters log(α), log(β), and σ.
[IP_ADDRESS] Prior specificat ions
The meta -analytic-predictive (MAP) approach was used to derive an informative prior for 
log(α), log(β), and σ from published AUC data on Nivolumab and Pembrolizumab . For details 
on the MAP approach see Neuenschwander et al (2010) , Schmidli et al (2014) .
MAP priors assume similarity (exchangeabilit y) of model parameters among trials for the three 
molecules: Nivolumab, Pembrolizumab and PDR001. Assum ing log(α h), log(β h) and σ hare the 
parameters for the hthprevious study , a MAP prior distribution for the parameters in the new 
study  is given b y the predictive distribution of log(α*), log(β*), and σ* in the following model:
(log(α h), log(β h)) ~ BVNormal ((µ a, µb), Ψ), σ h~ LN(µ s, τs2), h = 1, 2, 3
(log(α*), log(β*)) ~ BVNormal ((µ a, µb), Ψ), σ* ~ L N(µ s, τs2)
where Ψis the between -trial variance -
covariance matrix for (log(α), log(β)), with standard 
deviations τ a, τband correlation coefficient ρ. BVNormal refers to the bivariate normal 
distribution; LN refers to the log -normal distribution.
1.The priors for h yper-parameters in the model were set as follows:

[COMPANY_001] Confidential Page 141
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Table 14-7 Prior distributions of model hy per-parameters (N=Normal, LN= Log -
Normal)
Parameter Prior Median (95%  interval)
µa N(6, 102) “flat”
τa LN(-0.693, 0.7072) 0.5 (0.125, 2)
µb N(0, 0.3542) 0 (-0.693, 0.693)
τb LN(-2.079, 0.3542) 0.125 (0.063, 0.25)
ρ Uniform( -1, 1)
µs N(-1.386, 0.7072) -1.386 (-2.772, 0)
τs LN(-1.386, 0.7072) 0.25 (0.063, 1)
The parameters τ a, τband τ squantify  the degree of between trial heterogeneity  on the intercept, 
log(slope) and error standard deviation of the dose-exposure regression model, respectively. 
The choices of prior for those parameters reflect the assumption that the exposure at d*may 
vary considerably between the different compounds but the slope may be similar.
2.Published summary  data on Nivolumab and Pembrolizumab from three studies are 
available (see Section [IP_ADDRESS] ) and summarize d in Table 14-8 after unit conversion is 
applied on source data.
Table 14
-8 Geometric mean (micro gram day /mL) and geometric CV% of A UC 
data from three Nivolumab or Pembrolizumab studies
Dose (mg/kg) Study  1 Study  2 Study  3
N G. Mean (CV% ) N G. Mean (CV% ) N G. Mean (CV% )
1 3 160 (20) 37 92 (34)
2 89 643 (37)
3 3 975 (24) 42 323 (46.5)
10 8 2282 (31) 83 2770 (33) 52 1526 (59)
The geometric mean and CV% of AUC data can be converted to the sample mean (SM) and 
sample variance (SV) of log(AUC) through the equations:
SM in log scale = log(geometric mean)
SV in log scale = log(1+(CV%/100)2)
The distribution s of aggregate data were then used to capture the data likelihood as follows:
SM h,d~ N((log(α h) + β hlog(d/d*)), σ h2/nh,d)
SV h,d~ Gamma ((n h,d-1)/2, (n h,d-1)/(2 σh2))
where n h,d, SM h,dand SV h,dare the sample size, sample mean and sample variance of 
log(AUC) for the dose group d and trial h, respectively .
3. The MAP distributions were derived based on the priors in step 1 and available previous 
study  result summary  in step 2. A Normal distribution was used to approximate the MAP 
distribution for log(σ). For the regression coefficients (log(α), log(β)), a three -component 
multivariate normal mixture distribution was used to approximate the derived MAP 
distribution. To allow for more robust inference i n case of the discrepancy  between MAP 
information and the trial data, a non -informative prior component was added as the 4th

[COMPANY_001] Confidential Page 142
Amended Protocol Version 08 (Clean ) Protocol No. CPDR001X2101
component. The respective distribution for each component and its weight is provided in 
Table 14-9
.
Table 14-9 Prior distribution of (log(A lpha), log(Beta)) and sigma for the ne w trial
Parameter Means Standard deviations Correlation Weight
Component 1:
log(α), log(β) (6.40, 0.05) (0.683, 0.180) -0.463 0.480
Component 2:
log(α), log(β) (6.38, 0.05) (0.403, 0.118) -0.773 0.425
Component 3:
log(α), log(β) (6.42, 0.05) (1.410, 0.257) - 0.217 0.095
Prior for σ: LN(-0.97, 0.3172)
Figure 14-1 shows a visualization of the geometric mean AUC at each interested dose level 
together with a 95% interval, predicted b y the priors in Table 14-9.
Figure 14-
1 V isualization of the mean A UC
[IP_ADDRESS] AUC data on Nivolumab and Pembrolizumab
Study 1 (Pembrolizumab, Patna ik et al 2012 )
Table 14-10 Area under the pembrolizumab concentration versus time curve by  
[CONTACT_837262] (mg/kg) N AUC 0-28day (CV % )*
1 3 160 (20)
3 3 975 (24)
10 8 2282 (31)
* Numbers presented are assumed to be geometric mean in µg·day/mL and geometric CV %.
Profile supports dosing every 2 or 3 weeks.

[COMPANY_001] Confidential Page 143
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Study 2 (Pembrolizumab, Robert et al 2014 )
Table 14-11 Area under the pembrolizumab concentration versus time curve at 
steady  state by  [CONTACT_2939]
2 mg/kg Q3W
n=8910 mg/kg Q3W
n=83
Median, g•day/L 0.654 3.76
Geometric mean, g•day/L 0.643 3.77
Geometric CV, % 37 33
5th and 95th percentiles, g•day/L 0.345 –1.12 2.13–5.99
Range, g•day/L 0.254 –1.27 1.85–7.00
Study 3 (Nivolumab, Brahmer et al 2012 )
“Serum levels of anti–PD-L1 antibod y increased in a dose -dependent manner from 1 to 10 mg 
per kilogram in 131 patients who were evaluated. The geometric mean area under the curve (0 
to 14 day s) for doses of 1 mg, 3 mg, and 10 mg per kilogram were 2210, 7750, and 36,620 µg 
per milliliter per hour, respectively  (coefficient of variation, 34 to 59%).”
This information is summarized in Table 14-12:
Table 14-12 Area under the nivolumab concentration versus time curve by  [CONTACT_837263] (mg/kg) N*AUC 0-14day Geometric Mean 
(µg•hour/mL) AUC 0-14day Geometric CV %
1 37 2210 34
3 42 7750 46.5**
10 52 36,620 59
* Numbers of treated patients are 37, 42, and 125 for 1 mg, 3 mg, and 10 mg per kilogram, respectively. Total 
number of patients evaluated in this summary is 131 across three dose groups. Assuming only part of the 125 
patients in the 10 mg/kg dose group had AUC assessments, the distribution of the 131 patients are assumed to 
be 37, 42, and 52 for 1 mg, 3 mg, and 10 mg per kg.
** The CV% for 3 mg/kg is assumed to be the average of CV % of 1 mg/kg and 10 mg/kg.
[IP_ADDRESS] Operating characteristics of Bay esian dose -exposu re design
Scenarios of dose -exposure relationship
In order to show how the BLM design performs, 5 hypothetical profiles of dose-exposure 
relationship were investigated using simulations:
Profile 1: exposure increases with dose following the same trend as Nivolumab and 
Pembrolizumab; 3 mg/kg and higher doses meet the target exposure
Profile 2: exposure increases with dose following the same trend as Nivolumab and 
Pembrolizumab; only  10 mg/kg meets the target exposure
Profile 3: exposure increases with dose following the same trend as Nivolumab and 
Pembrolizumab; all doses at 1 mg/kg and higher meet the target exposure
Profile 4: exposure increases slowly  with dose increasing; 3 mg/kg and higher doses meet 
the target exposure

[COMPANY_001] Confidential Page 144
Amended Protocol Version 08 (Clean ) Protocol No. CPDR001X2101
Profile 5: exposure increases rap idly with dose increasing; 3 mg/kg and higher doses meet 
the target exposure
Table 14-13 Hypothetical profiles of dose -exposure relationship used in 
simulations
Profile BLM intercept -log(alpha) BLM slope -betaAUC (µg•da y/mL)
1 mg/kg 3 mg/kg 10 mg/kg
1 7 1 366 1097 3655
2 6 [PHONE_17439]
3 8 1 994 2981
9937
4 7 0.5 633 1097 2002
5 7 2 122 1097 [ZIP_CODE]
Figure 14-2 Visualization of five hypothetical p rofiles
Simulation parameters
To examine the data sufficiency , four sample set with various sample sizes ranging from 18 to 
24 were considered for each dose-exposure 
profile:
1.6 patients at each dose level (1 mg/kg, 3mg/kg, and 10 mg/kg); total N = 18
2.3, 9, 6 patients at 1 mg/kg, 3mg/kg, and 10 mg/kg, respectivel y; total N = 18
3.3, 12, 6 patients at 1 mg/kg, 3mg/kg, and 10 mg/kg, respectivel y; total N = 21
4. 3, 12, 9 patients at 1 mg/kg, 3mg/kg, and 10 mg/kg, respectivel y; total N = 24

[COMPANY_001] Confidential Page 145
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
There are total 20 scenarios to be simulated combining 5 dose- exposure profiles and 4 sample 
set considerations. 500 trials were used to simulate each of the 20 scenarios. For each trial, the
AUC data for individual patients were randoml y generated from a Log-Normal distribution 
where
log(AUC) ~ Normal(log(mean as specified in Table 14 -13), standard deviation =0.4).
For each simulated trial, the Bayesian Linear Regression Model was implemented using the 
simulated AUC data with the priors specified in Section [IP_ADDRESS] .
Metrics
There are a set of operating characteristics and metrics evaluated based on the simulations to 
compare the relative performance under each true scenario. The metrics reviewed include:
1.Average posterior mean exposure at 1 mg/kg, 3mg/kg, and 10 mg/kg
2.Average posterior probability  of exposure greater than 1000 µg•day /mL at 1 mg/kg, 
3mg/kg, and 10 mg/kg
3.Average posterior probability  of exposure ly ing in the interval of 800 -1200 µg•day /mL at 
1 mg/kg, 3mg/kg, and 10 mg/kg
4.
Percentage of trials where the posterior mean exposure is at least 1000 µg•day /mL at 1 
mg/kg, 3mg/kg, and 10 mg/kg
5. Percentage of trials where the posterior probability  of exposure greater than 1000 
µg•day /mL is at least 50% at 1 mg/kg, 3mg/kg, and 10 mg/kg
6. Percentage of trials where the posterior probability  of exposure ly ing in the interval of 800 
-1200 µg•d ay/mL at 1 mg/kg is the highest among 3 doses; similar percentage will be 
calculated for 3 mg/kg and 10 mg/kg
The evaluation indicated that the model is performing appropriatel y under the 20 scenarios.
Results
Table 14-14 summarizes the probabilities of the dose recommended from the model for the five 
different profiles and four sample sets studied. Based on the dose-exposure analysis, a dose is 
recommended for a trial if this dose meets the following cri teria:
(1) posterior mean exposure at this dose ≥ 1000 µg•day /mL, and
(2) posterior probability  of exposure greater than 1000 µg•day /mL > 50%.

[COMPANY_001] Confidential Page 146
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Table 14-14 Summary  of recommendation rate for all profiles and sample sets at 
various doses based on the dose recommendation criteria (1) and (2)
ProfileSample 
SetProbability  (%) that a dose level is recommended
0.3 
mg/kg1 
mg/kg2 
mg/kg3 
mg/kg5
mg/kg7 
mg/kg9 
mg/kg10 
mg/kg
1 1 0 0 0 76 100 100 100 100
2 0 0 0 77 100 100 100 100
3 0 0 0 79 100 100 100 100
4 0 0 0 82 100 100 100 100
2 1 0 0 0 0 0 49 99 100
2 0 0 0 0 0 48 99 100
3 0 0 0 0 0 48 99 100
4 0 0 0 0 0 42 99 100
3 1 0 47 100 100 100 100 100 100
2 0 50 100 100 100 100 100 100
3 0 51 100 100 100 100 100 100
4 0 52 100 100 100 100 100 100
4 1 0 0 3 83 100 100 100 100
2 0 0 1 63 100 100 100 100
3 0 0 0 70 100 100 100 100
4 0 0 0 61 100 100 100 100
5 1 0 0 0 81 100 100 100 100
2 0 0 0 84 100 100 100 100
3 0 0 0 86 100 100 100 100
4 0 0 0 87 100 100 100 100
Table 14 -15below summarizes the percentages of the recommended dose of the model for the 
five different profiles and four sample set studied. Based on the dose -exposure anal ysis, a dose 
is recommended for a trial if this dose meets the criteria (1) and (2) and the following added 
criteria (3):
(3) Highest posterior probability  of exposure l ying in the interval of 800 - 1200 µg•day /mL 
among all provisional doses (e.g. 0.3, 1, 2, 3, 5, 7, 9 and 10 mg/kg).

[COMPANY_001] Confidential Page 147
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Table 14-15 Summary  of recommendation rate for all profiles and samples set at 
various doses based on the dose recommendation criteria (1), (2), and 
(3)
ProfileSample 
SetProbability  (%) that a dose is recommended
1 mg/kg 3 mg/kg 10mg/kgOther doses 
recommendedNo dose 
recommended
1 1 0 65 0 0 35
2 0 64 0 0 36
3 0 68 0 0 32
4 0 71 0 0 29
2 1 0 0 0 51 49
2 0 0 0 53 47
3 0 0 0 50 50
4 0 0 0 50 50
3 1 47 0 0 0 53
2 49 0 0 0 50
3 51 0 0 0 49
4 52 0 0 0 48
4 1 0 54 0 3 44
2 0 49 0 1 50
3 0 56 0 1 43
4 0 51 0 0 49
5 1 0 81 0 0 19
2 0 83 0 0 17
3 0 86 0 0 14
4 0 87 0 0 13
The simulated operating characteristics presented show that the Baye sian Linear Model 
performs well under the hypothetical profiles investigated. In conclusion, the simulations 
performed illustrate that the model has reasonable operating characteristics.
14.3.2 Bayesian logistic regression model (BLRM)
[IP_ADDRESS] Introduction
The dose-toxicity  relationship in the dose escalation part of the study  will be described by [CONTACT_685460]:
logit(π (d)) = log(α) + β log(d/d*), α>0, β>0
where logit(π (d)) = log((d)/(1
-(d))), and π(d)is the probability  of a DLT at dose d. Doses are 
rescaled as d/d* with reference dose d*=3 mg/kg of PDR001. As a consequence α is equal to 
the odds of DLT rate at d*. Note that for a dose equal to zero, the probability of toxicity  is zero.

[COMPANY_001] Confidential Page 148
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
[IP_ADDRESS] Prior specifications
Prior for (log(α), log(β)):
This study  uses a mixture prior consisting of two components. Compo nent 1 is the distribution 
derived based on PDR001 preclinical data and data on Nivolumab and Pembrolizumab, and is 
also the component to allow for a less dose toxicity case. The assigned weight for component 1 
is 80%. Component 2 allows for a more dose to xicity  case. The assigned weight for mixture for 
component 2 is 20%.
Component 1:
A weakl y informative bivariate normal prior for the model parameters (log(), log()) is 
assumed based on prior information (medians) for the probabilities of DL T at each dos e, from 
PDR001 preclinical data and data on Nivolumab and Pembrolizumab, and considering wide 
confidence intervals. The priors are obtained as follows:
For the purposes of tuning the prior for the BLRM model, the median DLT rate at 1 mg/kg 
Q2W is assumed t o be at 5%, and the median DLT rate at 10 mg/kg Q2W is assumed to 
be at 10%. For the remaining doses, median DLT rates a priori are assumed linear in the 
logit-scale as a function of log -dose.
Based on the above specified medians for the DLT rate at certai n dose and wide prior 
confidence intervals, the optimal parameters of the bivariate normal distribution can be 
obtained following the procedure described b y (Neuenschwander et al 2008). Based on 
Neuenschwander’s procedure, the initial set of prior (-2.692, - 1.26, 2.484, 0.745, -0.765) 
is derived.
The initial set of prior is then fine -tuned in combination with the component 2 prior, by  
[CONTACT_837264](α) and log(β) as well as setting the correlation between log(α) and 
log(β) = 0, to achieve reasonable performance for the hy pothetical dose -escalation 
scenarios in Section [IP_ADDRESS] .
The Component 1 is set to be (-2.692, - 1.26, 1.0, 1.0, 0)
Component 2:
This high
-toxicity  component is a vague bivariate normal prior derived by  [CONTACT_837265] 1, 3, 10 mg/kg are 3%, 9%, 25%, respectively , as well as a 
log-linear relationship between dose strength and the odds of DLT as def ined in Section 
[IP_ADDRESS]. By  [CONTACT_837266](β) at 0, the log(α) value is adjusted to achieve estimated 
probability  of DLT (using the equation logit(π(d)) = log(α) + β log(d/d*)) at 1, 3, 10 
mg/kg being 3%, 9%, 25% respectively , which results in log(α) being -2.3. At the 
meanwhile, setting SD of log(α) = 2 and log(β) = 1, and setting the correlation between 
log(α) and log(β) = 0 to complete the determination of the component 2.
The component 2 is set to be ( -
2.3, 0, 2, 1, 0)
All the information to derive the prior distributions for the model parameters is provided in 
Table 14-16.

[COMPANY_001] Confidential Page 149
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Table 14-[ADDRESS_1162386] deviations Correlation Weight
Component 1: weakly  informative priors
log(α), log(β) -2.692, -1.26 1.0, 1.0 0 0.8
Component 2: priors for a more toxicity  sensitive population
log(α), log(β) -2.3, 0 2, 1 0 0.2
Table 14-17, Table 14-18and Table 14 -19summarize the DLT rates of the associated prior 
distribution. The doses not meeting the overdose criteria are bold in the table, i.e. it is not 
eligible at the start of the study  (under the prior).
Table 14-17 Summary  of prior distribution of DLT rates (derived from the mixture 
prior in Table 14 -16)
(Table 14-
16)
PDR001 dose 
(mg/kg Q2W)Prior probabilities that Pr(DLT) is i n 
interval:
Mean SDQuantiles
[0, 0.16) [0.16,0.33) [0.33, 1] 2.50% 50.00% 97.50%
0.3 0.939 0.047 0.014 0.049 0.076 0 0.024 0.252
1 (starting dose) 0.9 0.075 0.026 0.069 0.095 0.001 0.039 0.334
3 0.805 0.134 0.061 0.11 0.133 0.006 0.066 0.518
10 0.615 0.2 0.185 0.205 0.233 0.012 0.114 0.946
Note: bold values indicate doses not meeting the overdose criterion (more than 25% chance of excessive toxicity) 
with the prior information only.
Table 14-18 Summary  of prior distribution of DLT rates (derived from the 
Component 1 prior in Table 14 -16)
(Table 14-16 )
PDR001 dose 
(mg/kg Q2W)Prior probabilities t hat Pr(DLT) is in 
interval:
Mean SDQuantiles
[0, 0.16) [0.16,0.33) [0.33, 1] 2.50% 50.00% 97.50%
0.3 0.948 0.046 0.006 0.048 0.059 0 0.028 0.216
1 (starting dose) 0.918 0.071 0.011 0.064 0.069 0.004 0.041 0.257
3 0.849 0.127 0.024 0.09 0.084 0.009 0.064 0.327
10 0.683 0.211 0.106 0.151 0.154 0.013 0.1 0.603
Note: bold values indicate doses not meeting the overdose criterion (less than 25% chance of excessive toxicity) 
with the prior information only.

[COMPANY_001] Confidential Page 150
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Table 14-19 Summary  of prior distribution of DLT rates (derived from the 
Component 2 prior in Table 14 -16)
(Table 14-16 )
PDR001 dose 
(mg/kg Q2W)Prior probabilities t hat Pr(DLT) is in 
interval:
Mean SDQuantiles
[0, 0.16) [0.16,0.33) [0.33, 1] 2.50% 50.00% 97.50%
0.3 0.898 0.053 0.048 0.056 0.129 0 0.006 0.496
1 (starting dose) 0.821 0.09 0.089 0.095 0.167 0 0.022 0.653
3 0.624 0.162 0.214 0.193 0.231 0.002 0.092 0.838
10 0.345 0.154 0.501 0.42 0.346 0.006 0.332 0.999
Note: bold values indicate doses not meeting the overdose criterion (less than 25% chance of excessive toxicity) 
with the prior information only.
To check the performance of the model, the document summarizes some hypothetical dose 
escalation scenarios. Details regarding dose recommendation are described in Section 10.4.2 of 
the protocol.
[IP_ADDRESS] Hypothet ical dose escalation scenarios based on DLT data alone
In order to show how the Bayesian model performs, different hypothetical dose escalation 
scenarios were investigated. The design should make reasonable dose-recommendations during 
the clinical trial based on the observed DLTs for hypothetical dose escalation scenarios. During 
the study , the decision to dose escalate after completion of a given cohort and the actual dose 
chosen for the subsequent cohort will depend on the recommendation of the BLRM per E WOC 
principle, estimated/predicted exposure at each dose level, and medical review of available 
clinical and laboratory  data.
Some hypothetical dose escalation scenarios to illustrate the dose escalation up to the fourth 
dose 
cohort are listed in Table 14-20. The maximum dose increment allowed in the scenarios 
did 
not exceed 334% as per escalation rules defined in Section 6.2.3. The recommended next 
dos
e level satisfied the EWOC principle.
Table 14-20 Hypothetical dose escalation scenarios for on -study  decisions
Scenario CohortPDR001 
Dose level 
(mg/kg)N 
patN 
toxNext Dose 
Level (NDL)P(Target) 
NDLP(Over) 
NDLMedian DLT 
rate (NDL)
1 1A 1 4 0
3 0.104 0.025 0.054
2 1A 1 4 1
3 0.26 0.114 0.121
3 1A 1 4 2
1 0.37 0.21 0.186
4 1A 1 4 0
2A 3 3 0
10 0.156 0.106 0.079
5 1A 1 4 0
2A 3 3 1
3 0.2 0.055 0.097

[COMPANY_001] Confidential Page 151
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Scenario CohortPDR001 
Dose level 
(mg/kg)N 
patN 
toxNext Dose 
Level (NDL)P(Target) 
NDLP(Over) 
NDLMedian DLT 
rate (NDL)
6 1A 1 4 0
2A 3 3 2
1 0.201 0.031 0.087
7 1A 1 4 0
2A 3 3 0
3A 3 3 0
10 0.122 0.094 0.07
8 1A 1 4 0
2A 3 3 0
3A 3 3 1
10 0.243 0.187 0.138
9 1A 1 4 0
2A 3 3 0
3A 3 3 2
3 0.334 0.084 0.141
10 1A 1 4 0
2A 3 3 1
3A 3 3 0
10 0.243 0.187 0.138
11 1A 1 4 0
2A 3 3 1
3A 3 3 1
3 0.334 0.084 0.141
12 1A 1 4 0
2A 3 3 1
3A 3 3 2
1 0.233 0.034 0.1
13 1A 1 4 0
2A 3 3 2
3A 1 3 0
3 0.321 0.241 0.181
14 1A 1 4 0
2A 3 3 2
3A 1 3 1
1 0.352 0.07 0.142
15 1A 1 4 0
2A 3 3 2
3A 1 3 2
1 0.505 0.208 0.222
16 1A 1 4 1
2A 1 3 0
3 0.217 0.065 0.103

[COMPANY_001] Confidential Page 152
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Scenario CohortPDR001 
Dose level 
(mg/kg)N 
patN 
toxNext Dose 
Level (NDL)P(Target) 
NDLP(Over) 
NDLMedian DLT 
rate (NDL)
17 1A 1 4 1
2A 1 3 1
3 0.384 0.171 0.175
18 1A 1 4 1
2A 1 3 2
1 0.456 0.247 0.225
19 1A 1 4 1
2A 1 3 0
3A 3 3 0
10 0.243 0.099 0.117
20 1A 1 4 1
2A 1 3 0
3A 3 3 1
10 0.373 0.248 0.198
21 1A 1 4 1
2A 1 3 0
3A 3 3 2
1 0.352 0.07 0.142
22 1A 1 4 1
2A 1 3 0
3A 3 3 0
4A 3 3 0
10 0.2 0.061 0.1
23 1A 1 4 1
2A 1 3 0
3A 3 3 0
4A 3 3 1
10 0.367 0.164 0.168
24 1A 1 4 1
2A 3 3 1
2B 1 3 0
3A 3 5 1
3 0.423 0.06 0.155
25 1A 1 4 0
2A 3 5 1
2B 1 3 0
10 0.232 0.208 0.138
26 1A 1 4 0
2A 3 5 1
2B 1 3 0
3A 10 6 1
3B 3 4 0
30 0.322 0.223 0.175

[COMPANY_001] Confidential Page 153
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
Scenario CohortPDR001 
Dose level 
(mg/kg)N 
patN 
toxNext Dose 
Level (NDL)P(Target) 
NDLP(Over) 
NDLMedian DLT 
rate (NDL)
27 1A 1 3 0
2A 3 4 0
2B 1 3 0
10 0.124 0.107 0.073
28 1A 1 3 0
2A 3 4 0
2B 1 3 0
3A 10 6 1
3B 3 6 1
30 0.32 0.212 0.171
29 1A 1 3 0
2A 3 5 2
3A 1 3 1
3 0.461 0.178 0.198
30 1A 1 3 0
2A 3 5 2
3A 1 3 1
4A 1 4 0
3 0.427 0.125 0.173
Cohort naming convention: the number identifies the cohort number, the letter “A” indicates escalation cohort, the 
letter “B” indicates concurrent expansion at lower dose level to obtain additional PK data.
Within Table 14 -20, P(Target) NDL represents the probability that the true DLT rate for the dose lies in the ta rget 
interval (16%, 33%) while P(Over) NDL represents the probability that the true DLT rate for the dose exceeds 
33%.
Overall, the model is showing appropriate behaviors, in agreement with clinical sense and 
decision making process. The dose levels inves tigated correspond to the provisional dose levels 
specified in Section 6.2.2 .

[COMPANY_001] Confidential Page 154
Amended Protocol Version 08 ( Clean ) Protocol No. CPDR001X2101
14.3.3 References (available upon request)
Brahmer JR, Ty kodi SS, Chow L QM, et al (2012) Safety and Activit y of Anti –PD-L1 
Antibody  in Patients with Advanced Cancer. N Engl J Med
; 366: 2455 -65.
EMEA (2007) Guideline on Clinical Trials in Small Populations. Committee for Medicinal 
Products for Human Use (CHMP).
Neuenschwander B, Branson M, Gsponer T (2008) Critical aspects of the Bay esian approach 
to phase I cancer trials. Statist. Med, 2008; 27:2420 -39.
Neuenschwander B, Capkun -Niggli G, Branson M, et al (2010) Summarizing historical 
information on controls in clinical trials. Clin Trials; 7:5-18.
Patnaik A, Kang SP, Tolcher AW, et al (2012) Phase 1 Study  of MK -3475 (Anti -PD-1 
Monoclonal Antibody ) in Patients With Advanced Solid Tumors. J Clin Oncol (Meeting 
Abstracts); 30( 15s):2512 .
Robert C, Ribas A, Wolchok JD, et al (2014) Anti- programmed -death -receptor -1 treatment 
with pembrolizumab in ipi[INVESTIGATOR_125]- refractory  advanced melanoma: a randomised dose -
comparison cohort of a phase 1 trial. Lancet; 384:1109-17.
Rogatko A, Schoeneck D, Jonas W, et al (2007) Translation of innovative designs into phase I 
trials. J Clin Oncol; 25:4982
-6.
Schmidli H, Gsteiger S, Roy choudhury  S, et al (2014) Robust meta -analytic-predictive priors 
in clinical trials with historical control information. Biometrics: Epub ahead of p rint.
